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ABSTRACT
Many real applications require decision-making under uncertainty. These deci-
sions occur at discrete points in time, influence future decisions, and have uncer-
tainties that evolve over time. Mean-risk stochastic integer programming (SIP) is
one optimization tool for decision problems involving uncertainty. However, it may
be challenging to develop a closed-form objective for some problems. Consequently,
simulation of the system performance under a combination of conditions becomes
necessary. Discrete event system specification (DEVS) is a useful tool for simulation
and evaluation, but simulation models do not naturally include a decision-making
component. This dissertation develops a novel approach whereby simulation and op-
timization models interact and exchange information leading to solutions that adapt
to changes in system data.
The integrated simulation and optimization approach was applied to the schedul-
ing of chemotherapy appointments in an outpatient oncology clinic. First, a simula-
tion of oncology clinic operations, DEVS-CHEMO, was developed to evaluate system
performance from the patient and managements perspectives. Four scheduling al-
gorithms were developed for DEVS-CHEMO. Computational results showed that
assigning patients to both chairs and nurses improved system performance by reduc-
ing appointment duration by 3%, reducing waiting time by 34%, and reducing nurse
overtime by 4%.
Second, a set of mean-risk SIP models, SIP-CHEMO, was developed to deter-
mine the start date and resource assignments for each new patients appointment
schedule. SIP-CHEMO considers uncertainty in appointment duration, acuity lev-
els, and resource availability. The SIP-CHEMO models utilize the expected excess
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and absolute semideviation mean-risk measures. The SIP-CHEMO models increased
throughput by 1%, decreased waiting time by 41%, and decreased nurse overtime by
25% when compared to DEVS-CHEMOs scheduling algorithms.
Finally, a new framework integrating DEVS and SIP, DEVS-SIP, was developed.
The DEVS-CHEMO and SIP-CHEMO models were combined using the DEVS-SIP
framework to create DEVS-SIP-CHEMO. Appointment schedules were determined
using SIP-CHEMO and implemented in DEVS-CHEMO. If the system performance
failed to meet predetermined stopping criteria, DEVS-CHEMO revised SIP-CHEMO
and determined a new appointment schedule. Computational results showed that
DEVS-SIP-CHEMO is preferred to using simulation or optimization alone. DEVS-
SIP-CHEMO held throughput within 1% and improved nurse overtime by 90% and
waiting time by 36% when compared to SIP-CHEMO alone.
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1. INTRODUCTION
1.1 Motivation and Problem Statement
Simulation and mathematical optimization are useful modeling tools for many
decision-making problems in science and engineering. In real complex systems, data
uncertainties often evolve over time. Decision makers are sometimes required to
make important system decisions prior to observing uncertain events. Often the
decisions epochs occur during discrete times periods and influence future decisions.
Consequently, modeling the system using an explicit mathematical formulation can
be impossible, and simulation of the system performance under a combination of
conditions becomes necessary in order to model uncertain events and evaluate possi-
ble decision options. Due to data uncertainties in the system, decision-making is not
trivial and requires stochastic optimization to determine a combination of stochastic
conditions that would result in best system performance.
This dissertation concerns such challenging decision-making problems under un-
certainty. Motivation for this work stems from the lack of solution methods for
the class of decision-making problems described above, which have many real life
applications. For example, problems arising in healthcare regarding patient service
management under limited resources (e.g. nurses, medical equipment, etc.) call for
system simulation and stochastic optimization due to there complexity. These prob-
lems have uncertainty in several aspects of the decision problem such as the arrival
of appointment scheduling requests, treatment duration, and resource availability.
Stochastic optimization has evolved into a viable approach for decision-making
under uncertainty, much of the progress has been made under simplifying assump-
tions such as closed-form objective functions, precise knowledge of a static under-
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lying probability distribution, and decisions do not influence future decisions. In
many practical applications, however, these simplifying assumptions are not appro-
priate. For example, in oncology clinic operations performance measures such as
throughput or overtime cannot be captured by a closed-form mathematical expres-
sion and the probability distribution of an appointment duration can change over
time. Scheduling decisions made in one time period will impact future decisions and
outcomes. Also, scheduling oncology clinic patients later than the oncologist’s pre-
scribed treatment start date can pose risk to the patient in terms how they respond
to treatment. Therefore, simulation of the underlying system is necessary in order to
make any data-driven decisions. Consequently, SIP alone is not adequate for optimal
decision-making in this case.
Discrete event simulation has been shown to be a useful tool for evaluating com-
plex systems under a given combination of conditions. However, simulation models
are traditionally designed without knowledge of possible mathematical decision mod-
els. Therefore, simulation alone is generally not sufficient when it comes to making
optimal decisions under uncertainty. A new framework for combining stochastic opti-
mization with simulation is needed, whereby the stochastic optimization and system
simulation models interact and exchange information leading to solutions that adapt
to changes in system data.
The objective of this dissertation is to develop and implement theory, models, and
algorithms for integrated discrete event simulation and stochastic optimization with
application to healthcare. Specifically, this dissertation integrates discrete event sys-
tem specification (DEVS) simulation and mean-risk stochastic integer programming
(mean-risk SIP) under a new paradigm termed, DEVS-SIP.
2
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Figure 1.1: DEVS-SIP Framework for Decision-Making Under Uncertainty
In the DEVS-SIP framework (Figure 1.1), a decision maker (DM) of a real system
uses simulation and optimization to make decisions. The simulation and optimization
models are both abstractions of the real system and have access to system data,
including uncertain system parameters. The DM uses a SIP model to make a decision
when there is uncertainty in the problem’s parameters. The SIP model decisions
are only optimal for the current state of the system and the limited information
used to formulate the model. By using SIP, the decisions should perform “good”
under any realization of future uncertainty. However, a tractable formulation of the
SIP model will not consider all problem parameters with as much granularity as a
simulation model can. Furthermore, the future decisions and their impact on the
current decision are difficult to incorporate into a SIP model.
The optimization decisions from the SIP model are implemented and evaluated
using a DEVS simulation model that also simulates future decisions and outcomes.
The DM determines practical levels of system performance which are then used
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to established stopping criteria for the solution search process. If the performance
measures from the DEVS simulation satisfy the stopping criteria established by the
DM, then the SIP model’s most recent optimization decision is provided to the DM.
Otherwise, the performance measures that failed to meet the stopping criteria are
used to modify the SIP model’s parameters and constraints. The modifications (e.g.,
changing objective function coefficients, adding constraints, etc.) depend on the
specific application and the targeted performance measures.
The revised SIP model is then solved to determine a new optimization decision
for evaluation in the DEVS simulation model. This process is repeated until the
stopping criteria are satisfied and the results are reported to the DM. The DM
then determines an implementable decision for the real system. An implementable
decision is a course of action that can be put into effect after careful consideration.
The DM may implement the decision provided by DEVS-SIP, modify the decision,
or even choose an alternative course of action.
In this dissertation, the integrated DEVS-SIP methodology is applied to the
healthcare setting of oncology clinic operations management. Oncology clinics deal
with scheduling patients and allocating limited resources such as treatment chairs
and nurses. The decision-making process in this setting involves scheduling a series
of appointments for each new cancer patient based on the oncologist’s prescrip-
tion. A scheduler is tasked with the responsibility of determining the appointment
schedule for the patient and the resource assignments for each appointment in the
patient’s treatment regimen. The scheduler knows the new patient’s treatment regi-
men, the clinic’s resource characteristics, requirements for resource assignment, and
past scheduling decisions.
Complicating the decision is the uncertainty in appointment duration, patient
acuity levels and nurse availability. The realization of uncertain parameters and the
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number and type of future appointment requests that will also compete for clinic
resources are unknown. A simulation model of the oncology clinic can evaluate
possible decisions under the realization of uncertainty. The performance measures
from the simulation model can then be used to update the optimization model. This
process will continue until a decision is identified that best satisfies the performance
measure expectations determined by the DM. The nature of the oncology clinic
setting is suitable for decision-making under uncertainty (mean-risk SIP) and system
simulation (DEVS).
1.2 Research Tasks
Three research tasks were completed to achieve the objective of integrating dis-
crete event simulation and stochastic optimization with application to healthcare.
First, a simulation model of the underlying healthcare problem was designed and
implemented. Next, the chemotherapy appointment scheduling decision was mod-
eled using an optimization model. Finally, the simulation and optimization models
were integrated using the DEVS-SIP framework. Next is an overview of each research
task.
1.2.1 Simulation Model for Oncology Clinic Operations
In the first task (Chapter 3), a DEVS model of a real oncology clinic called DEVS-
CHEMO was developed. The DEVS-CHEMO simulation model allows for modeling
and simulating the arrival of appointment requests, the arrival process of the patients
to the clinic on the day of their appointment, and the activities of clinic resources.
DEVS-CHEMO was also designed to allow for assessing and evaluating different
patient scheduling rules using performance measures from both the patient’s and
management’s perspectives. DEVS-CHEMO was verified using a real oncology clinic
setting through collaboration with the Scott & White Oncology Clinic in Temple,
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Texas. Four scheduling algorithms were developed and implemented to determine
which resources were important for chemotherapy appointment scheduling. Exper-
iments were also conducted to demonstrate the effectiveness of DEVS-CHEMO in
determining staffing levels for the oncology clinic.
1.2.2 Mean-Risk Stochastic Integer Programming Model for Oncology Clinic
Appointment Scheduling
The second task (Chapter 4) was to develop mean-risk SIP models for the prob-
lem of scheduling patients, chairs, and nurses in an outpatient oncology clinic. The
models produced in this task are the first optimization models for oncology clinic
appointment scheduling that incorporate uncertainty in the problem parameters and
addresses the concept of risk-averse decision-making. In the mean-risk SIP models,
called SIP-CHEMO, appointments are scheduled for a patient based on recommen-
dations from an oncologist. The models determine the appointment dates, start
times, and resource assignments. Mean-risk SIP allows for modeling different levels
of risk using mean-risk measures such as expected excess and absolute semidevia-
tion. Risk in this problem is associated with how likely an appointment schedule will
cause scheduling conflicts such as overlapping appointments or overtime. Three SIP-
CHEMO models were developed, implemented, and compared to current scheduling
methods in a real oncology clinic.
1.2.3 Integrated Simulation and Optimization for Oncology Clinic Operations
The final task (Chapter 5) required the development of a new framework, termed
DEVS-SIP, which enables interaction between simulation (DEVS) and optimization
(mean-risk SIP). The real system is simulated using DEVS. In each decision period,
the parameters for the mean-risk SIP model are computed via DEVS. The mean-risk
SIP model is then solved to determine an optimal decision for the current state of
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the system. The decisions are implemented in a second DEVS simulation model
which incorporates future uncertainty for system performance evaluation. If the
stopping criteria are satisfied, then the best decision is implemented in the original
DEVS simulation model. Else, the mean-risk SIP model is updated to obtain a new
decision that is also evaluated in the second DEVS simulation model. DEVS-SIP is
a general framework designed to be tailored to different applications.
To demonstrate the DEVS-SIP framework, the mean-risk SIP-CHEMO optimiza-
tion model and the DEVS-CHEMO simulation model were combined. This disser-
tation then applied DEVS-SIP to decision-making under uncertainty for oncology
clinic operations management. This new methodology, called DEVS-SIP-CHEMO,
enables data-driven decision-making for both strategic and operational planning in
oncology clinics. Four stopping criteria and four modifications were developed for
DEVS-SIP-CHEMO. The stopping criteria and modifications were implemented in
different combinations to determine which was most effective in improving system
performance.
1.3 Research Contributions
This dissertation advances the state-of-the-art in stochastic programming with
simulation by contributing new concepts, models, and algorithms, for a variety of
applications. Specific contributions are as follows:
• DEVS simulation model of oncology clinic operations. The DEVS-CHEMO
simulation model allows for modeling and simulating the arrival of appointment
requests, the arrival process of the patients to the clinic on the day of their
appointment, and the activities of oncology clinic resources. DEVS-CHEMO
provides managers with a tool for analyzing decision-making and operational
policies within the oncology clinic.
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• Mean-Risk SIP model of oncology clinic decisions. The mean-risk SIP-CHEMO
optimization model is the first optimization model for the decision problem of
scheduling oncology clinic patients, chairs, and nurses under uncertainty and
considering risk. The inclusion of a suitable mean-risk measure in the objective
function enables DMs to consider risk preferences in their scheduling decisions.
• New simulation and optimization framework for many applications. This con-
tribution provides a new paradigm, DEVS-SIP, for decision-making under un-
certainty for complex problem settings. DEVS and SIP are extended to a new
level beyond some of the traditional impractical assumptions. The extensions
include, 1) formal coupling between DEVS and SIP, 2) decision-making avail-
able in DEVS using an SIP model, 3) non-static probability distributions for
SIP (generated via DEVS), and 4) non-closed-form objective functions for SIP
(modeled, evaluated, and revised via DEVS). An important feature of DEVS-
SIP is that it allows for automated online (or real-time) system data update for
both DEVS and SIP models, thus enabling decision-making over time adapting
to dynamic changes in the problem data. This kind of decision-making frame-
work is necessary in many practical applications where a decisions have to be
made at discrete time periods over a rolling horizon.
• Integrated solution method for decision-making of oncology clinic operations
management. The integrated DEVS-SIP-CHEMO simulation and optimiza-
tion model is a practical tool for decision-making of oncology clinic operations
under uncertainty. DEVS-SIP-CHEMO enables data-driven decision-making
for both strategic and operational planning in oncology clinics. Furthermore,
the computational results for the DEVS-SIP-CHEMO show that integrating
simulation and optimization yields better overall system performance results
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that either method alone. Results also provide insight into the practicality and
use of the DEVS-SIP framework in a real setting and for other applications.
DEVS-SIP has the potential to address many important decision problems in a
variety of applications, such as extended attack response planning for large-scale es-
caped wildfires. Optimal decision-making for such a problem has the potential to save
lives as well as billions of dollars in property damage and natural resources. For the
case of oncology clinic appointment scheduling, optimal decisions under uncertainty
provide an improved patient-centered experience and reduce clinic overtime.
1.4 Dissertation Organization
The rest of this dissertation is organized as follows: Chapter 2 reviews closely
related work in simulation and optimization, oncology clinic operations, mean-risk
SIP, and discrete event simulation. The DEVS-CHEMO simulation model for oncol-
ogy clinic operations is developed, verified, and analyzed in Chapter 3. Mean-risk
SIP-CHEMO models for scheduling oncology clinic appointments are developed and
analyzed in Chapter 4. Chapter 5 develops an integrated simulation and optimiza-
tion framework that combines the SIP-CHEMO optimization model and the DEVS-
CHEMO simulation model and provides computational results. Finally, concluding
remarks and future research directions are discussed in Chapter 6.
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2. LITERATURE REVIEW
This chapter provides a literature review of simulation and optimization method-
ology, oncology clinic operations management, DEVS, and mean-risk SIP. Each sec-
tion identifies gaps in the existing literature and further motivates the need for
the proposed research. The first section discusses how simulation and optimization
have been previously combined and describes specific applications in the healthcare
setting. The second section discusses existing classification-based and optimization-
based approaches for chemotherapy appointment scheduling problems. The third
section examines the history of discrete event simulation, the development of DEVS,
and the use of simulation in healthcare. Finally, a review of the development of
mean-risk SIP is provided in the fourth section.
2.1 Simulation and Optimization Methodology
Simulation and optimization have been integrated to solve problems from various
applications, including the healthcare setting. Table 2.1 summarizes three papers
from other application areas and six papers from the healthcare setting. Although
simulation and optimization in healthcare and other areas have shown promising
results, the general methodology has never been formally developed. Additionally,
most other works use the simulation model to evaluate the optimization decisions,
generate scenarios for the optimization model, or compute parameters or objectives
for the optimization model. None of these works have used the simulation model to
revise the optimization model to improve the scheduling decisions for oncology clinic
operations management.
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Table 2.1: Simulation and Optimization Literature Review
Paper Brief Description Application
Cheung et al.
[9]
Simulation and optimization applied to network
service planning.
Ko et al. [21] Hybrid simulation and optimization approach
for a distribution network design.
Other Appli-
cations
Acar et al. [1] Simulation and optimization for combinatorial
problems applied to a facility location problem.
Kropp et al.
[23]
Recursive simulation and optimization approach
for staffing and facility plans.
Butler et al. [6] Linkage of a simulation and optimization model
for facilities strategic hospital planning.
Baesler and
Sepulveda [5]
Combine simulation, goal programming, and a
genetic algorithm to examine the impact of re-
source capacities at an oncology clinic.
Pe´rez et al. [29] Stochastic online scheduling for appointments in
nuclear medicine.
Healthcare
Woodall et al.
[48]
Simulation-optimization for daily nurse sched-
ules at an outpatient oncology clinic.
Gocgun and
Puterman [13]
Use Markov decision processes and approximate
dynamic programming to schedule chemother-
apy patient appointments and evaluate the deci-
sions with simulation.
This work Develops a general discrete event simulation and
stochastic optimization framework applied to
oncology clinic operations management.
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Simulation and optimization have been used for network service planning [9]. In
a two-stage methodology, the optimization model determined the network configu-
ration at the macro-planning level, then the simulation model verified and evaluated
the performance at the operational level before sending feedback to the optimization
model. Ko et al. [21] also used a “hybrid” simulation and optimization approach for
the distribution network design of third-party logistics to evaluate the performance
for warehouses. The framework of the “hybrid” model was such that the optimiza-
tion model generated a network, then the simulation was used to evaluate warehouse
capacities. If the simulation outputs satisfied the performances, then the procedure
terminated. Otherwise, the design parameters and constraints were modified in the
optimization model. The work by Cheung et al. [9] and Ko et al. [21] are different
from this dissertation in that this work formally defines a DEVS and SIP framework
for how the simulation and optimization models interact for multiple decisions over a
planning horizon instead of only one decision period. Additionally, this dissertation
is applied to a different application area.
Acar et al. [1] used an integer optimization model and a simulation to solve
combinatorial problems. In their iterative approach, the optimization model was
used to generate a solution. If the solution had already been simulated, then the
iteration stopped. If not, then the simulation was used to evaluate the solution.
The difference between the deterministic cost function and the average simulation
cost was used to update the optimization formulation. The work by Acar et al.
[1] differs from DEVS-SIP in that the DEVS-SIP optimization model also considers
uncertainty from the decision problem and the system performance motivates the
stopping criterion.
Early research using simulation and optimization for healthcare problems focused
on facilities planning [6, 23]. Kropp et al. [23] used a mixed-integer program (op-
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timization model) to generate staffing and facility plans and a simulation model to
evaluate their day-to-day acceptability. The optimization model provided a decision-
making component and reduced the number of alternatives for the simulation model
to examine. The simulation model was designed to handle the system’s complex rela-
tionships that were too cumbersome for the optimization model. A linear regression
used the simulation results to add non-cost constraints to the optimization model.
In the work by Butler et al. [6], simulation and optimization were used for multi-
level strategic evaluation of hospital plans and decisions. The optimization model
dealt with the facility layout and capacity allocation while the simulation model was
used to capture the complexities of the hospital operations. Both works [6, 23] uti-
lized simulation and optimization for a different type of healthcare problem than the
research in this dissertation and both used deterministic optimization models.
Multi-objective simulation optimization was developed by Baesler and Sepulveda
[5] for a cancer treatment center. Their work combined simulation, goal program-
ming, and genetic algorithms. The goal was to find the optimal number of clinic
resources that best improved a multi-objective formulation. The simulation model
was a black box representing the objective functions for the problem and the genetic
algorithm performed the search for improved solutions.
Both simulation and optimization have been used to address stochastic online
appointment scheduling in nuclear medicine [29]. A stochastic online scheduling
algorithm used an optimization model to determine patient and resource schedules.
The simulation model obtained scenarios for the stochastic programming models and
tested the performance. The computational study by Pe´rez et al. [29] considered
both patient and clinic performance measures. They concluded that the stochastic
online scheduling algorithm allowed more patients per year on average and decreased
patient waiting time for an appointment by an average of two days. The research
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in this dissertation is different because the simulation model is used to update the
optimization models to find decisions that improve system performance.
A discrete event simulation model was used to predict patient waiting time and
resource utilization at the Duke Cancer Institute [48]. A simulation analysis revealed
that nurses are the limiting resource in the clinic. A mixed-integer programming
model was used to optimize the nurse schedules on a weekly and monthly basis.
Then a simulation-optimization approach optimized the daily schedule for the nurse
shifts. The optimization model’s objective was intractable so simulation was used to
sample expected patient waiting times. Tabu search and other heuristics were used
to find a near-optimal schedule. The work by Woodall et al. [48] is important because
it analyzed the benefits of using detailed nurse schedules, included a combination of
full-time and part-time nurses from different cancer disease groups, and incorporated
varying start time shifts for nurses.
Finally, simulation and Markov decision processes (MDP) have been used together
to dynamically schedule chemotherapy patient appointments [13]. Each appointment
in the treatment regimen was assumed to have a time window, within a few days, of a
target appointment date. A MDP and an approximate dynamic programming (ADP)
model was developed to determine the date for each appointment. The simulation
was used to evaluate the scheduling decisions of the ADP as compared to several
heuristics. The research in this dissertation focuses on a different set of decisions
and uses simulation to update the optimization model’s decisions.
2.2 Oncology Clinic Operations Management
In the last decade research has developed in the area of scheduling of chemother-
apy appointments. Hospital and clinic staff were the first approached the problem
using various classification-based approaches. Classification-based approaches used
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acuity levels [18, 24], next-day scheduling [12, 33], or patient classification systems [7].
It was not until the last two to three years that operations researchers began utilizing
optimization-based techniques to schedule chemotherapy appointments [8, 36, 46].
None of the optimization-based techniques included uncertain problem parameters
in the optimization model.
2.2.1 Classification-Based Chemotherapy Scheduling
Table 2.2 contains a summary of the literature on the chemotherapy appointment
scheduling problem using classification-based approaches. A number of oncology
clinics have tried to improve the scheduling of chemotherapy appointments using
various classification approaches. Some clinics created schedules by classifying nurse
tasks [24] or acuity levels [18] while others have used drug [12] or patient types [7].
Although none of these classification techniques used optimization or uncertainty,
they were simple methods that were successfully implemented in practice. These
works provide guidance on the key aspects of the decision problem (acuity levels,
resource availability, treatment duration, etc.). In addition, many clinics [12, 24, 33]
have noted considerable success using next-day scheduling. A next-day, or split-
scheduling, method implies that patient arrives one day for blood work and returns
the next day to receive their chemotherapy treatment.
One next-day scheduling system used nurse task classification based on the time
required to complete the tasks [24]. The three-step process of (1) lab and x-ray,
(2) oncologist visit, and (3) chemotherapy administration was scheduled over two or
three days. This system assumed that the time between appointments was “free”
and thus patients spent less time waiting. After implementation, the laboratory
observed fewer inquiry calls, more balanced nursing workloads, and more time for
preparation and assessment. Rosenburg [33] also used a split-scheduling system for
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three out-patient chemotherapy centers. The new system allowed the clinic to order
the chemotherapy drugs overnight. Analysis revealed more chair space, more efficient
use of nurses, reduced inventory, and increased patient satisfaction.
Table 2.2: Literature Review on Classification-based Techniques for Chemotherapy
Appointment Scheduling
Paper Brief Description
Langhorn and Morrison
[24]
Patient appointment scheduling using nine acuity levels.
Doblish [12] Next-day scheduling system in an oncology center using
a drug classification system.
Gruber et al. [14] Identified a “perfect day” for cancer patients and oncol-
ogy clinic staff.
Chabot and Fox [7] Patient classification system in an outpatient infusion
center.
Hawley and Carter [18] Development of a scheduling system based on an acuity
rating system.
Rosenburg [33] Split-scheduling system for three out-patient chemother-
apy centers.
Ahmed et al. [3] Developed a scheduling template based on a best-scenario
performance using a simulation model.
Kallen et al. [20] Identified and prioritized four items (IV assessment,
quick treatments, completion of chemotherapy orders,
and pharmacy notification) to improve patient waiting
times.
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One next-day chemotherapy scheduling system used drug classification based on
infusion times [12]. Rising demand for treatment caused overtime, long patient
wait times, and high resource utilization. Patients were arriving early for their
appointments hoping to get through the system faster, but this only led to congestion
in the clinic. The next-day system allowed the pharmacy adequate preparation time
before administration. After implementation, the quality of work-life improved for
the clinic staff and patients accepted the changes. The repeated success of next-day
scheduling systems motivated the decision to limit the scope of the chemotherapy
scheduling problem to only the drug infusion appointment.
In one study, the “perfect day” for cancer patients and oncology clinic staff was
developed at the Roswell Park Cancer Institute in Buffalo, NY [14]. The common
goal was for patient appointments to begin on time. A series of improvements were
implemented to achieve this goal. Some of the improvements included changing staff
start times, cross-training nurses, revising the patient appointment schedule, and
modifying prescribing practices. Prior to implementing the changes, only 11% of
appointments began on time as compared to 94% afterwards.
A two-patient classification system (those with pre-medications and those with-
out) was developed by Chabot and Fox [7]. Prior to this classification system, pa-
tients were often double-booked and had long waiting times, appointments rarely
began on the recommended start date, and nurses had inadequate breaks. The new
scheduling system required a minimum break time between appointments. After
three years of implementation, the clinic observed an increase of 10% throughput,
longer lunch breaks for the nurses, a decrease in late arrivals, increased job satis-
faction, and increased patient satisfaction. An acuity rating system was developed
at a Cleveland cancer center to address scheduling problems [18]. They developed
a medical oncology five-level acuity rating system. After treatment lengths were
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also incorporated in the scheduling template, the new system resulted in improved
patient satisfaction scores.
One study aimed to increase throughput and reduce patient waiting time in the
chemotherapy treatment unit at CancerCare Manitoba [3]. Several scenarios were
created that matched resource schedules with the clinics arrival pattern of patients.
A simulation model analyzed each scenario’s performance. The scenario with the
best performance was used to create a scheduling template. The new template
increased throughput by 22.5% and increased resource utilization without requiring
more resources.
At the Ambulatory Treatment Center of the MD Anderson Cancer Center in
Houston, TX, researchers implemented four new policies to improve patient wait
time [20]. First, they began performing earlier evaluations on the appropriateness and
accessibility of IV lines. Second, short-duration appointments were streamlined to a
specific unit. The third modification began directly paging oncologists to complete
drug orders. Finally, the fourth change notified the pharmacy earlier in the treatment
process that a patient was ready for medication. In combination, the four changes
showed a 25% improvement in the time patients waited on the day of treatment.
2.2.2 Optimization-Based Chemotherapy Scheduling
Table 2.3 contains a summary of the literature on the chemotherapy appointment
scheduling problem using optimization-based approaches. In the past three years,
researchers started using optimization models to address the chemotherapy schedul-
ing problem. One model producing near optimal solutions was implemented in a
real clinic setting [46], but the results are not necessarily applicable to other clinics.
Although one study did consider uncertainty in real time decision requests [17], none
of the works incorporated uncertainty in the problem parameters.
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Table 2.3: Literature Review on Optimization-based Techniques for Chemotherapy
Appointment Scheduling
Paper Brief Description
Santiba´n˜ez
et al. [36]
Developed chemotherapy appointment scheduling software
(Chemo Smartbook) to determine near-optimal schedules.
Chan [8] Used an inverse optimization model to determine nurses’ pref-
erences in the Chemo Smartbook.
Sadki et al. [35] Oncology appointment scheduling with oncology and bed re-
sources using lagrangian-based heuristic and local optimization
heuristics.
Turkcan et al.
[46]
Multi-period time horizon chemotherapy schedule with rolling
horizon methodology.
Sevinc et al.
[42]
Negative feed-back algorithm for laboratory scheduling and
heuristic for multiple knapsack problem of scheduling infusion
appointments.
Woodall et al.
[48]
Mixed-integer programming model for nurse weekly and
monthly scheduling and simulation-optimization model for
daily nurse shifts.
Hahn-Goldberg
et al. [17]
Dynamic template scheduling to accommodate online appoint-
ment requests and cancellations.
Gocgun and
Puterman [13]
Used Markov decision processes and approximate dynamic pro-
gramming to schedule patient appointments within specific
time windows.
This work Uses stochastic optimization and simulation to account for
uncertainty in three problem parameters when scheduling
chemotherapy appointments and clinic resources.
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The paper-based scheduling system at the British Columbia Cancer Agency’s
(BCCA) Vancouver Cancer Centre was insufficient to handle increased demand and
more complex treatments. A Chemo Smartbook [36] scheduling system was devel-
oped as an innovative software approach that offered customized, flexible scheduling
and considered patient time preferences, appointments from different departments,
system capacity, nurse workload, and staff schedules. The implementation of the
Chemo Smartbook led to 58% reduction in late patient appointment confirmations
and a wait list reduction of 84%. Overall patient satisfaction increased, staff workload
became more balanced, and stress levels were reduced. Furthermore, the wait-list size
decreased by 84% and the number of days to first appointment decreased from eleven
days to five days. Later, Chan [8] used an inverse optimization model to determine
nurses’ preferences in order to create better schedules in the Chemo Smartbook.
Another study also addressed the appointment scheduling problem in an outpa-
tient oncology clinic [35]. Their work is one of the few that consider the oncologist
consultation in the problem setting. After mathematically modeling this problem,
two solution methods were considered: a Lagrangian relaxation-based heuristic and
local optimization heuristic. Numerical tests showed the Lagrangian relaxation-based
heuristic to be best.
A multi-period time horizon approach to address the problem of scheduling pa-
tients and resources for an oncology outpatient clinic was developed by Turkcan et al.
[46]. The objectives were to minimize the treatment delay, patient waiting times,
and staff overtime while simultaneously maximizing the staff utilization. In this two-
stage problem, the first stage determined the treatment start day for the patients. In
the second stage of the problem, the daily schedule was determined for all patients.
Turkcan et al. [46] proposed an algorithm for solving their two-stage problem and
used a rolling horizon methodology. The optimization model is closely related to
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the one presented in this dissertation, but it did not include mean-risk measures or
uncertain problem parameters.
Algorithms for scheduling chemotherapy regimens were developed by Sevinc et al.
[42] with the goal of maintaining the treatment regimen specifications, minimizing
patient waiting time, and optimizing chair utilization. This was one of the few
papers to consider lab appointments along with infusion appointments. The plan for
laboratory tests used an adaptive negative-feedback algorithm and target infusion
chair utilization to control the load on the system. If the laboratory test results were
approved by the oncologist, the second-phase determined infusion seat allocation.
The second-phase was modeled using a multiple knapsack problem and solved using
on-line heuristics. A simulation model was used to evaluate the scheduling methods.
The main contribution of [42] was that this work addressed infusion appointment
cancellations and delays due to poor laboratory test results.
Recall that Woodall et al. [48] used a mixed-integer programming model to op-
timize nurse schedules on a weekly and monthly basis. The problem considered a
combination of full-time and part-time nurses from different cancer disease groups.
A simulation-optimization model determined a near-optimal daily schedule for the
nurse shifts with the objective of minimizing the expected patient wait time. Because
the model’s objective was intractable, a simulation was used to sample expected pa-
tient waiting times.
Recently, a dynamic optimization model was developed by Hahn-Goldberg et al.
[17] to schedule chemotherapy appointments. Their work considered uncertainty
through real-time requests for appointments and uncertainty due to last-minute
scheduling changes. This work used a scheduling template and online optimiza-
tion in a novel technique they refer to as dynamic template scheduling. A sample of
appointments were used in a deterministic optimization model to create a schedul-
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ing template for the day. As appointment requests arrived, the appointments were
allocated to available slots in the template. When a request arrived that did not fit
the template, a new, smaller sample of appointments were generated and the open
time slots were once again optimized to include the latest scheduling request. To
accommodate last minute cancellations and requests, a shuﬄing algorithm moved
appointment start times within a predefined time limit. Results show that their
approach improved the makespan by 20% compared to the current practice.
Finally, recall that Gocgun and Puterman [13] used simulation and Markov deci-
sion processes (MDP) to dynamically schedule chemotherapy patient appointments.
In their problem, each appointment in the treatment regimen was assumed to have
a time window, within a few days, of a target appointment date. The schedul-
ing problem determined the date for each appointment using a MDP. The MDP
was intractable so a linear-programming approximate dynamic programming (ADP)
model was used to obtain an approximate solution. The simulation was implemented
in GAMS and used to evaluate the scheduling decisions of the ADP as compared to
several heuristics. Although the ADP solution approach was valid, the earliest policy
heuristic, which schedules patients on the earliest available day within each appoint-
ment’s respective time window, also worked well and was faster computationally.
2.3 Discrete Event Simulation
Discrete event simulation first emerged in the 1950s and is now a well-known
tool for operations research analysts in various applications such as manufacturing,
finance, and healthcare. Tocher and Owen [45] is generally credited with creating
the first simulator called the general simulation program. Over time, simulation
has become popular in computational techniques such as Monte Carlo methods and
random number generation. Additionally, discrete event simulation has been used
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in various modeling approaches such as queuing theory, stochastic processes, and
DEVS. This section discusses the history of the DEVS formalism and the use of
discrete event simulation in healthcare.
The DEVS formalism was developed by Zeigler et al. [51]. Many DEVS extended
formalisms have been introduced with their own purposes such as P-DEVS for paral-
lel discrete event simulation [11] and RT-DEVS for realtime discrete event simulation
[10]. The DEVS formalism and its variations have been used to simulate fire spread,
nuclear medicine departments, and manufacturing systems. The text by Zeigler et al.
[52] provides theory and modeling for the integration of discrete event simulation and
continuous complex dynamic systems. For an introduction to DEVS modeling and
simulation methodology, see Zeigler and Sarjoughian [50], which defines the concepts
of experimental frame, models, state transitions, etc. used in the DEVS formalism
and provides minimal working examples.
In the past several decades, discrete event simulations have been used as a tool
for analyzing healthcare problems. Many of the contributions in this area are sum-
marized in Jun et al. [19]’s extensive taxonomy of research using discrete-event sim-
ulations in healthcare clinics between 1978-1997. The taxonomy identified a void
in research on complex integrated systems, such as multi-facility healthcare delivery
systems. Additionally, Jun et al. [19] specified the combination of simulation and
optimization as a future research direction. The taxonomy identified five papers that
used optimization to arrive at parameters for a simulation model, but none of them
used the simulation to improve decision making criteria for the optimization model.
At the time of the taxonomy’s publication, many simulation software packages were
just beginning to provide an optimization add-on to the software to provide special
search algorithms to guide a simulation model to an optimal or near-optimal solution.
A survey by Gu¨nal and Pidd [15] indicated that there has been a notable in-
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crease in the number of papers published on discrete event simulation in healthcare
since 2004. They concluded that few simulation papers propose or illustrate general
approaches, but instead focus on specific healthcare applications such as an inten-
sive care unit or emergency room. There have been several authors who have used
discrete event simulations in outpatient clinics. Guo et al. [16] presented a discrete
event simulation framework for the evaluation and optimization of outpatient clinic
scheduling rules. Takakuwa and Katagiri [43] used simulation for the modeling of pa-
tient flows in a large-scale outpatient hospital ward using electronic medical records.
More recently, Weerawat et al. [47] modeled the orthopedic outpatient department
in a large public hospital.
A DEVS simulation model for multi-step sequential nuclear medicine procedures
was developed in Pe´rez et al. [28], Pe´rez-Roman [30]. This work also included stochas-
tic online scheduling algorithms where the appointment requests were revealed one
at a time. The characteristics of the nuclear medicine problem differs from the
chemotherapy scheduling problem. For example, the nuclear medicine requires strict
time windows due to the short half-life of radio-pharmaceuticals and resources are
not shared among multiple patients.
A number of simulation models have been used for oncology clinics (Table 2.4).
The first simulation model identified in the literature for an outpatient oncology clinic
was developed by Sepulveda and Cahoon [41]. The simulation model analyzed the
impact of alternate floor layouts on resource and patient flow. The results indicated
that a relocation of the clinic’s pharmacy and laboratory, along with scheduling
changes, would allow an increase of 30% in patient throughput using the same number
of clinic resources. The performance measures in their study were patient waiting
times and clinic closing time.
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Table 2.4: Literature Review on Oncology Clinic Simulations
Paper Brief Description
Sepulveda and
Cahoon [41]
Developed an ARENA simulation model to analyze the layout
of an outpatient oncology clinic.
Ahmed et al. [3] Used an ARENA simulation model to analyze the performance
of a scheduling template in an outpatient oncology clinic.
Yokouchi et al.
[49]
Developed an ARENA simulation model of blood exams, on-
cologist visits, and chemotherapy infusions at an outpatient
oncology clinic.
Sevinc et al.
[42]
Used Micorsoft SQL to simulate the scheduling and postpone-
ment of lab tests and infusion appointments.
Woodall et al.
[48]
Used an ARENA simulation model to sample expected patient
waiting times for the objective of an optimization model.
Gocgun and
Puterman [13]
Used a GAMS simulation to evaluate the proposed scheduling
policies for chemotherapy patient appointments.
This work Uses simulation to generate requests for appointments by can-
cer patients, to evaluate the scheduling decisions made by a
mean-risk SIP optimization model, and to update the opti-
mization model for improved decisions.
A simulation model developed by Ahmed et al. [3] was used to analyze the per-
formance of a scheduling template in an oncology clinic. Using ARENA Rockwell
Simulation Software, the simulation modeled five stations in the chemotherapy unit
and two main resources, chairs and nurses. The oncologist visit and laboratory tests
were excluded from the simulation model. Yokouchi et al. [49] developed a simulation
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model of an outpatient oncology clinic to explore appointment scheduling based on
properties of the treatments. The ARENA simulation model included blood exams,
oncologist visit, and chemotherapy infusion. The results indicated that a scheduling
method based on infusion time was necessary.
Recall that some simulation models of the oncology clinics have been used as anal-
ysis tools for scheduling methods [42]. Other simulation models of oncology clinics
have been previously discussed in combination with simulation-optimization [13, 48].
This dissertation uses DEVS integrated with mean-risk SIP to generate requests for
appointments, evaluate the scheduling decisions, and update the optimization model
for improved decisions.
2.4 Mean-Risk Stochastic Integer Programming
This research uses mean-risk SIP for optimal decision-making under uncertainty.
Mean-risk stochastic programming [34] was first developed for financial risk analysis
and began with the axiomatic principles of stochastic dominance, a form of stochastic
ordering. In a two-stage mean-risk SIP, the first-stage decision variables represent the
“here and now” decisions while the second-stage decisions represent the “recourse”
decisions made after uncertainty is realized. Historically, SIP used the expected value
of the first-stage objective function, which is appropriate for the risk-neutral case or
when the law of large number can be applied. But in certain applications it may
be more appropriate to explicitly model risk within its objective. Mean-Risk SIP
models represent risk using both the expected value and a mean-risk measure in the
objective function to more accurately reflect the inherent uncertainty in a problem.
Early risk measures such as variance and value-at-risk (VaR) did not provide
suitable properties for analysis. Artzner et al. [4] defined four properties of coherent
risk measures: translation invariance, subadditivity, monotonicity, and positive ho-
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mogeneity. Ogryczak and Ruszczynski [27] discussed the transition from stochastic
dominance to mean-risk as a means of quantifying risk-aversion using both the mean
and a measure of risk. Pflug [31] presented some properties and comparisons of VaR
and conditional value-at-risk (CVaR). The analysis concluded that CVaR is a co-
herent risk measure. Pflug [31] also defined the VaR optimization problem and the
CVaR optimization problem for portfolio optimization. The VaR optimization prob-
lem is nonconvex in general, but the CVaR risk measure provides either a singleton
or a convex polyhedron solution.
The structural properties of the expectation in the objective function such as real
valuedness and lower semicontinuity are derived in Schultz [37]. Relatively recently,
Ma¨rkert and Schultz [26] and Schultz [38] obtained similar results for the mean-risk
measures based on either quantiles or deviations from some target. The quantile
measures include excess probability and CVaR, while the deviation measures include
expected excess and absolute semideviation.
Structural and algorithmic properties of two-stage stochastic linear programs
(SLP) with deviation measures were derived in Kristoffersen [22]. Similar results
for excess probability were obtained in Riis and Schultz [32]. Risk aversion for SLP
was addressed in Ahmed [2] with a focus on convexity properties and subgradient
decomposition. Stochastic mixed-integer programs with risk functionals based on
the semideviation and value-at-risk (VaR) were studied in Ma¨rkert and Schultz [26]
and in a thesis by Tiedmann [44]. Schultz and Tiedemann [39] studied SIP based on
excess probabilities, while Schultz and Tiedemann [40] studied SIP2 based on condi-
tional value-at-risk (CVaR). Although SIP has been used to schedule appointments
in nuclear medicine [29], the complexities and constraints were quite different than
those seen in oncology clinics. To the best of our knowledge, this dissertation is the
first to use mean-risk SIP for oncology clinic appointment scheduling.
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3. SIMULATION MODEL FOR ONCOLOGY CLINIC OPERATIONS
Chemotherapy is a common treatment method for cancer patients. Chemother-
apy treatments are administered orally or intravenously at outpatient oncology clin-
ics. Reports have shown that cancer costs in the U.S. exceeded $124 billion in 2010
and are expected to increase 27% by 2020 [25], while the demand for oncology ser-
vices is projected to increase by 48% between 2005 and 2020 [46]. Cancer patients
receiving chemotherapy treatment require a series of appointments over several weeks
or months and the timing of these appointments is critical to the treatment’s effec-
tiveness. Oncology clinics deal with the problem of scheduling the cancer patients’
appointments using limited clinic resources. The timing sensitivity as well as the
rising costs and demand motivate the need for efficient chemotherapy appointment
schedules.
This chapter describes the design, verification, and testing of a simulation model
for an outpatient oncology clinic using DEVS. The simulation, termed DEVS-CHEMO,
models the scheduling process of clinic resources (chairs and nurses) and chemother-
apy patients, the arrival process of the patients to the clinic for each appointment, and
the oncology clinic operations as patients receive chemotherapy treatment. DEVS-
CHEMO was also designed to enable oncology clinic managers to evaluate different
patient scheduling algorithms and operations planning decisions using performance
measures from the patient and management perspectives.
Chemotherapy appointment scheduling decisions involve a complex problem set-
ting due to high level of interaction among patients, nurses, and other resources in
the system. Because of this complexity, oncology clinic managers find it challenging
to assess the impact of their scheduling decisions on overall clinic operations and per-
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formance. Modeling and simulation is a viable approach to addressing this aspect of
the chemotherapy appointment scheduling problem. In this chapter, modeling and
simulation are used to develop a discrete event simulation model, DEVS-CHEMO,
using the DEVS formalism. The DEVS formalism allows for hierarchical and modular
construction and uses well-defined concepts for coupling components. The modular
construction allows the user to design and construct models independently. By cou-
pling components, the individual models can interact with one another and even
combine to create a hierarchy of models.
DEVS-CHEMO is a useful tool that allows the oncology clinic managers to ad-
dress the chemotherapy scheduling problem by evaluating different appointment
scheduling algorithms and implementation policies. The testing of DEVS-CHEMO
in this chapter focuses on how patients should be scheduled and the impact of the
number of nurse resources in the clinic. DEVS-CHEMO has been designed to cap-
ture performance measures from both the patient and management perspectives in
order to identify scheduling policies that achieve high levels of patient service and
satisfy the clinic’s business objectives.
The contributions of this dissertation include a discrete event simulation of out-
patient oncology clinic operations, an innovative tool that can assist oncology clinic
managers in determining appointment scheduling and operational policies. Addition-
ally, DEVS-CHEMO not only allows assessment from the management perspective,
but the patient perspective as well. Thus DEVS-CHEMO provides an advance to-
ward higher levels of patient service in healthcare. The DEVS-CHEMO simulation
results provide insight for oncology clinic managers on how to schedule chemotherapy
appointments and determine staffing needs.
The rest of the chapter is organized as follows: section 3.1 provides background
information on outpatient oncology clinic scheduling. The DEVS formalism is first
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reviewed in section 3.2, then the DEVS-CHEMO simulation model is presented in-
cluding the system objects, model abstraction, performance measures, hierarchical
design, and implementation. Simulation results are reported in section 3.3 while
section 3.4 summarizes the chapter.
3.1 Background on Outpatient Oncology Clinics
In an oncology clinic, once a patient is diagnosed with cancer, an oncologist
prescribes a unique treatment regimen, or series of chemotherapy appointments, to
each cancer patient based on the patient’s current state of health. A treatment
regimen (Table 3.1) consists of a prescribed start date for the patient, frequency
of appointments (treatment days), the suggested duration (in minutes), acuity level
(values of 1, 2, or 3), and drug name for each appointment. The start date is the
number of days into the future that the patient’s oncologist recommends for the first
treatment to begin. Treatment days specifies the spacing between each appointment.
In the example in Table 3.1, the patient has three treatments spaced two days apart.
Duration is the total time that the appointment is expected to take from the time
the patient arrives to the clinic until they are discharged from the clinic. The acuity
level is a relative measure of the nurse’s attention required by a patient during an
appointment. Finally, the drug name is a list of the chemotherapy drugs the patient
will receive during the appointment. Treatment regimens depend on the patient’s
type of cancer, stage of the cancer growth, and current health. Therefore treatment
regimens are unique to each individual patient.
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Table 3.1: Example Treatment Regimen
Start Treatment Duration Acuity Drug
Date Days∗ (mins.) Level Name
1 1 118 1 Alimta, Carboplatin
3 540 3 Carboplatin, Taxol
5 320 2 Carboplatin, Taxol
∗Oncologist specifies start date
Figure 3.1 illustrates the chemotherapy scheduling process. The treatment regi-
men prescribed by the oncologist is sent to a scheduler to determine the appointment
schedule and to allocate clinic resources for each appointment in the treatment reg-
imen. All appointments in the treatment regimen need be scheduled at this time
to guarantee the availability of the later appointments. To maximize treatment
effectiveness, these appointments should be scheduled as close to the state date rec-
ommended by the oncologist as possible. Delay from the prescribed start date is
referred to as type I delay. Delays patients experience in the waiting room is re-
ferred to as type II delay. The time elapsed between the patient being seated in their
chemotherapy chair until the infusion begins is referred to as the type III delay. The
scheduler uses a model or algorithm to make a chemotherapy scheduling decision,
which allocates a specific date, time, and set of clinic resources (chair and nurse)
to each appointment in the patient’s treatment regimen. Then the scheduler sends
the patient appointment schedule to the patient and the chair and nurse resource
schedules to the oncology clinic.
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Figure 3.1: Chemotherapy Scheduling Process
Before a chemotherapy treatment is given, a cancer patient sometimes has an
appointment for laboratory blood work. Afterward, the patient then meets with
their oncologist to discuss their lab results and whether to proceed with the sched-
uled chemotherapy treatment. Although this is common practice, many oncology
clinics have a separate laboratory for blood work or use next-day scheduling (dis-
cussed in the literature review Section 2.2.1), which allows the appointment for the
chemotherapy treatment to be considered independent of the laboratory blood work
appointment. The oncology clinic that contributed to this dissertation uses an an
external laboratory for blood work. Because of this and considering the repeated
success of next-day scheduling systems, the scope of the oncology clinic operations
management problem examined in this dissertation excludes blood work and lab re-
sults. Instead, this dissertation focuses on the oncology clinic operations that occur
during the chemotherapy appointment and the patient appointment flow depicted in
Figure 3.2.
Chemotherapy scheduling decisions are also challenging because of the nature of
the patient appointment flow (Figure 3.2) in the oncology clinic. When a patient
arrives for a chemotherapy appointment, the patient first checks-in with a receptionist
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and then waits in the waiting room for an available nurse and chair. Once both a
chair and a nurse are available, the available nurse escorts the patient to the available
chair, orders the patient’s chemotherapy drug from the pharmacy, and checks the
patient’s vital signs. While waiting for the drug to be prepared in the pharmacy, the
nurse starts the patient’s intravenous (IV) drug infusion. When the chemotherapy
drug is ready at the pharmacy, the patient’s identity is verified and the nurse starts
the patient’s chemotherapy drug infusion. The entire process (escorting the patient
to starting the infusion) takes around 15 minutes and the nurse is fully dedicated to
a single patient during this time. Therefore, nurses can only start one patient during
this 15 minute time period. Afterwards, the nurse is free to continue monitoring
all patients as the chemotherapy infusion can take anywhere from one-half to eight
hours. Stopping an infusion and discharging a patient generally takes a few minutes.
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Figure 3.2: Oncology Clinic Patient Appointment Flow
Chemotherapy treatments are well-known for causing nausea and the cancer
weakens the immune system, both of which can severely deteriorate a patient’s state
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of health. The side-affects can occur suddenly during the chemotherapy adminis-
tration. Depending on the type and intensity of the treatment, nurses must pay
close attention to patients in order to monitor the patient’s condition and reactions
to these side-affects. It is possible for each nurse to simultaneously monitor the
chemotherapy treatments of several patients at the same time. However, it is crucial
that the nurses are not over-utilized since they must be available to assist patients
experiencing adverse reactions to the chemotherapy drugs. To account for this, the
concept of acuity levels is used. An acuity level is a relative measure of the nurse’s
attention required by a patient during an appointment. Acuity levels are assigned
a value of 1, 2, or 3, where an acuity level of 3 represents the maximum attention
required by the patient from the nurse. Each nurse can monitor several patients at
once, provided that the sum of the acuity levels for all patients is less than or equal
to a pre-determined maximum acuity level for that nurse.
Figure 3.3 provides an example of limitations associated with scheduling a patient
appointment using acuity levels and patient starts when scheduling a nurse. A patient
start is the process a nurse completes to start a new patient’s infusion. A patient
start includes the steps shown in Figure 3.2 from seating a patient in a chemotherapy
chair to starting the infusion. This example assumes one nurse and 15 minute time
slots. Patient 1 begins treatment during time slot 1 and continues for 60 minutes
(4 time slots). Patient 2 begins treatment during time slot 2 and continues for 60
minutes (4 time slots). Therefore, the nurse has a patient start during time slots
1 and 2. This single nurse could not have started both patients in the same time
slot. The acuity levels of each patient are summed to compute the total acuity. The
nurse can handle multiple patients as long as the total acuity does not exceed a
pre-determined maximum acuity level.
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Time Slots 1 2 3 4 5 
Patient 1 Acuity 
Level: 2 
Acuity 
Level: 2 
Acuity 
Level: 2 
Acuity 
Level: 2 
 
Patient 2  Acuity 
Level: 1 
Acuity 
Level: 1 
Acuity 
Level: 1 
Acuity 
Level: 1 
      
Patient Starts (1) 1 1 - - - 
Total Acuity (2) 2 3 3 3 1 
(1) Each nurse can only start one patient in each time slot 
(2) Each nurse’s total acuity for all patients cannot exceed a  
    pre-determined maximum acuity level (e.g., 4). 
Figure 3.3: Example Acuity Level and Patient Start Limitations for a Nurse Schedule
Using 15 Minute Time Slots
In chemotherapy appointment scheduling, no-shows and cancellations are not a
problem because the cancer patients rarely miss appointments. However, reschedul-
ing of appointments is one issue that does pose a challenge for the scheduler. When
the patient’s health status deteriorates or the results of the blood test are not within
the normal range, the oncologist may delay or modify the remaining appointments
in the patient’s treatment regimen. When such circumstances arise, the scheduler
most cancel some or all of the remaining appointments and schedule the new treat-
ment regimen. Although rescheduling is important in oncology clinic operations, it
is beyond of the scope of work presented in this dissertation.
3.2 DEVS-CHEMO Simulation Model
This section describes the DEVS formalism, objects in the oncology clinic, dis-
cusses performance measures of interest, and then derives the corresponding models
for the DEVS-CHEMO simulation model. The hierarchical organization of the mod-
els are also described using a system entity structure and the end of the section
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discusses software implementation.
3.2.1 Overview of the DEVS Formalism
DEVS-CHEMO is modeled using the DEVS formalism. The DEVS formalism
allows for hierarchical and modular construction and uses well-defined concepts for
coupling components. The modular construction allows the user to design and con-
struct models independently. By coupling components, the individual models can
interact with one another and even combine to create a hierarchy of models. There
are three objects in the conceptual framework of the DEVS formalism: model, simu-
lator, and experimental frame [50]. The model is a set of instructions for generating
data comparable to the real system. The simulator exercises the model’s instructions
to actually generate behavior. The experimental frame captures how the modeler’s
objectives impact the model construction, experimentation, and validation.
The DEVS formalism consists of two model types: atomic and coupled. An
atomic model is the simplest class and forms the building block for the simulation
model. Atomic models contain a set of input and output ports, state variables and
parameters, a time advance function, transition functions, and output function. The
internal transition function specifies which state the system will transition to after
the time given by the time advance function has elapsed. The external transition
function specifies how the system will change state when an input is received. The
confluent transition function is used when an input is received at the same time an
internal transition is to occur. The output function generates an external output just
before an internal transition takes place.
The coupled model links other component models and specifies how to couple
(connect) the component models together. A coupled model can be used as a com-
ponent of a larger coupled model, thus giving rise to hierarchical construction. Cou-
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pled models specify the set of component models, set of input and output ports,
and coupling specifications. A coupling specification consists of 1) external input
coupling (EIC ) which connects the input port of the coupled model to an input port
of a component model 2) internal coupling (IC ) of the output port of a component
model to the input port of another component model and 3) external output coupling
(EOC ) which connects the output port of a component model to the output port of
the coupled model.
3.2.2 Objects in the Real System
The oncology clinic setting involves human resources, patients, clinic stations,
and performance measures. There are ten types of objects in the real oncology clinic
setting (Table 3.2). An object is a material thing that can be seen and touched.
In DEVS, objects can be modeled as atomic models, coupled models, or entities.
Atomic and coupled models are used when the behavior, or current state and reaction
to events in the system, of the object is needed in the simulation. The atomic models
are used for simple objects with behavioral properties and coupled models are used
when the object has behavior properties and is composed of other objects. An entity
is used when the behavior of the object is not relevant to the simulation. Because
entities has attributes and methods, then properties of the entity objects can still be
modeled.
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Table 3.2: Objects in the Real Oncology Clinic Setting
Human Resources
Oncologist
Scheduler
Receptionist
Registered Nurse
Charge Nurse
Patients Chemotherapy Patients
Clinic Stations
Waiting Room
Pharmacy
Chemotherapy Chairs
Oncology Clinic
A human resource is an individual who makes up part of the workforce at an
organization. There are five types of human resource objects in an oncology clinic:
oncologist, scheduler, receptionist, charge nurse, and registered nurse. The oncol-
ogist is the doctor who treats cancer patients and prescribes a treatment regimen
and start date for the cancer patient. Because the oncologist is not present during
the chemotherapy treatment, the behavior of the oncologist is not explicitly mod-
eled. However, the behavior of the remaining four human resources is important
and therefore they are represented using atomic models. The scheduler receives an
appointment request for a patient and works to schedule the patient’s treatment reg-
imen based on the availability of clinic resources. The receptionist assists patients
upon arrival to the clinic for an appointment. The registered nurse performs many
tasks during the patient’s chemotherapy treatment including seating the patient,
ordering the drug, checking vitals, etc. The charge nurse is considered the “head
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nurse” and oversees the clinic operations and availability of the two primary clinic re-
sources (registered nurses and chairs). The chemotherapy patients are also objects in
the oncology clinic. Although the chemotherapy patients have important properties
(patient identification number, treatment regimen, schedule, etc.), their behavior is
assumed to not have an impact the other models in the system. Therefore, patients
are represented as entities in the oncology clinic instead of atomic models.
A clinic station is a location within the clinic where a specified activity or service
is based. The oncology clinic is composed of three clinic stations: waiting room,
pharmacy, and chemotherapy chairs. The waiting room is the location where pa-
tients wait after check-in with the receptionist before the nurse assists them to a
chemotherapy chair. The pharmacy is the location where drug orders are received
from the registered nurse and prepared for the patient. The behavior of the waiting
room and the pharmacy is captured using atomic models. However, the chemother-
apy chairs, this is the location where patients sit to receive a drug infusion, are similar
to the patients in that they do not have behavior relevant to the other models in the
system. Thus, chemotherapy chairs are represented as entities in the system and not
atomic models. The fourth clinic station is the oncology clinic itself. The oncology
clinic is the location where chemotherapy patients are given treatment and it is com-
posed of other clinic stations (waiting room, pharmacy, chemotherapy chairs) and
human resources (receptionist, charge nurse, registered nurse). The oncology clinic
is modeled as a coupled model.
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Table 3.3: Performance Measures
Patient Perspective
Type I Delay Time (days) between the first scheduled appointment start
date and the state date recommended by the oncologist
Type II Delay Time (minutes) between the patient arriving to waiting
room and the patient being called by the nurse to start the
appointment
Type III Delay Time (minutes) the patient waits in the chemotherapy
chair before the nurse starts the patient’s chemotherapy
treatment
System Time Time (minutes) the patient spends at the oncology clinic
from arrival to the waiting room to discharge from the clinic
Management Perspective
Patient Throughput Number of patients served in the oncology clinic in a day
Chair Utilization Percentage of time the chair is occupied during clinic op-
erating hours
Nurse Utilization Percentage of time the nurse has one or more patients dur-
ing clinic operating hours
Nurse Overtime Time (minutes) that the nurse must work beyond normal
clinic operating hours
This dissertation aims to improve oncology clinic management by evaluating clinic
scheduling rules and operational policies from both patient and management per-
spectives. Table 3.3 lists and describes three patient performance measures used in
DEVS-CHEMO. Part of patient service satisfaction in oncology clinics is to improve
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the patient’s overall experience. The first performance measure of interest from the
patient’s perspective is type I delay. Type I Delay is the time between the first sched-
uled appointment start date and the start date recommended by the oncologist. This
performance measure is measured in days and is important because the timing of the
chemotherapy treatment regimens is crucial to the patient’s health status and re-
covery. Scheduling algorithms aim to begin the treatment regimen close to the start
date prescribed by the patient’s oncologist and the type I delay captures how well
the scheduling algorithm was able to accomplish this task.
Type II delay and type III delay are performance measures that capture the
delay that patients experience at the oncology clinic on the day of an appointment.
Type II Delay is the time between the patient arriving to the waiting room and
the patient being called by the nurse to start the appointment. Type III Delay is
the time the patient waits in the chemotherapy chair before the nurse starts the
patient’s chemotherapy treatment. Minimizing the three types of delay can improve
the overall patient service experience in the oncology clinic. The system time, that
is, the time a patient spends at the clinic, is important to minimize as well. Type II
and type III delay are both components of system time.
In addition to providing a high quality of service to patients, oncology clinics
must also operate from a business perspective. Table 3.3 also lists and describes
four management perspective performance measures used in DEVS-CHEMO. Patient
throughput, chair utilization, and nurse utilization are performance measures used
to assess the efficiency of the oncology clinic in a single day. Nurse overtime, the
amount of time each nurse must work beyond normal clinic operating hours, is a
performance measure that was particularly important to the industry professionals
who collaborated on this dissertation. Clinics with low nurse overtime can keep
overhead costs down and increase employee satisfaction.
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3.2.3 Model Abstraction
The DEVS-CHEMO simulation model is composed of nine atomic models and
three coupled models. Next are descriptions of the role of each model and whether
the model is classified as atomic or coupled.
CGENR (Atomic).
The call generator (CGENR) is an atomic model that creates a new chemother-
apy patient and sends a message to the scheduler requesting an appointment
schedule for the new patient. CGENR mimics the behavior of the chemotherapy
patient calling into the oncology clinic to request a chemotherapy appointment
schedule based on the treatment regimen prescribed by the oncologist.
SCHED (Atomic).
The scheduler (SCHED) is an atomic model that schedules all chemotherapy
appointments in the treatment regimen using a scheduling algorithm. SCHED
imitates the behavior of the scheduler human resource.
PGENR (Atomic).
The patient generator (PGENR) is an atomic model that generates patient
arrivals to the oncology clinic at their scheduled appointment date and time.
PGENR is used to model the arrival process of the patient for each appointment.
TRANSD (Atomic).
The tranducer (TRANSD) is an atomic model that captures data from other
atomic models and computes patient and system performance measures. TRANSD
is essential for analysis of clinic operations.
EF (Coupled).
The experimental frame (EF) is a coupled model that defines the environment
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for testing and evaluating the DEVS-CHEMO simulation model. EF couples
the CGENR, SCHED, PGENR, and TRANSD atomic models together.
RECEPT (Atomic).
The receptionist (RECEPT) is an atomic model that receives each patient who
arrives at the oncology clinic for an appointment, directs the patient to the
waiting room, and notifies the charge nurse of the patient’s arrival to the clinic.
RECEPT models the behavior of the receptionist human resource.
WAITROOM (Atomic).
The waitroom (WAITROOM) is an atomic model that represents the location
where patients wait after check-in until their assigned registered nurse is avail-
able to begin their chemotherapy treatment. WAITROOM models the behavior
of the waiting room clinic station.
PHARM (Atomic).
The pharmacist (PHARM) atomic model receives orders and prepares the chemother-
apy drugs for the patient’s chemotherapy treatment. PHARM imitates the
behavior of the pharmacy clinic station.
CHARGENURSE (Atomic).
The charge nurse (CHARGENURSE) atomic model oversees the clinic opera-
tions, manages patients and resources, assigns patients who are ready for treat-
ment to an available chemotherapy chair and registered nurse, and notifies the
appropriate registered nurse that their next patient is ready for treatment. The
CHARGENURSE atomic model also has the ability to reassign a patient to a
different clinic chair or nurse as needed. CHARGENURSE serves the role of
the charge nurse human resource.
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REGNURSE (Atomic).
The registered nurse (REGNURSE) atomic model retrieves a patient from the
waiting room, seats the patient in their assigned chemotherapy chair, orders
drugs from the pharmacy, checks the patient’s vital signs, picks up drugs from
the pharmacy, starts the patient’s chemotherapy drug infusion, monitors the
patient, and stops the patient’s chemotherapy drug infusion. The REGNURSE
is the most involved atomic model because it models the behavior of the most
active human resource, the registered nurse.
CHEMO (Coupled).
The chemotherapy clinic (CHEMO) is a coupled model that imitates the behav-
ior of the oncology clinic on the day of the patient’s appointment. CHEMO con-
sists of the essential oncology clinic human resources and clinic stations used on
the appointment day. Therefore CHEMO couples the RECEPT, WAITROOM,
PHARM, CHARGENURSE, and REGNURSE atomic models.
EF CHEMO (Coupled).
The EF CHEMO is a coupled model that defines the DEVS-CHEMO simulation
model. EF CHEMO couples the CHEMO coupled model and the EF coupled
model.
3.2.4 Performance Measures
The DEVS-CHEMO simulation model capture performance measures (listed in
Table 3.3) from the patient and management perspectives. Next is a discussion on
which atomic models these performance measures are associated with and how they
are collected. A few of these performance measures are treated as entities, which
represent a user-defined class with attributes and methods. An entity is different
from an atomic model because the behavior (state transitions and response to system
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events) of entity classes is not modeled.
Type I Delay.
Type I delay is modeled as a Wait1Time entity. This entity is created in the
SCHED atomic model after the scheduler finds an appointment schedule for the
patient. At this point, the SCHED has access to the information for computing
Type I Delay and passes the Wait1Time entity to the TRANSD for analysis. The
Wait1Time entity communicates the patient identification number and Type I
Delay to the TRANSD.
Type II Delay.
Type II delay is modeled as a Wait2Time entity. This entity is created in the
WAITROOM atomic model when the patient departs the waiting room. The
Wait2Time entity contains the patient identification number and clinic arrival
time and is passed to the TRANSD atomic model for analysis. The TRANSD
atomic model notes the time the message is received and uses the clinic arrival
time to compute the Type II Delay.
Type III Delay.
Type III delay is modeled as a Wait3Time entity. This entity is created by
the REGNURSE atomic model at the time the patient is discharged from the
clinic and sent to the TRANSD atomic model. The Wait3Time entity contains
the patient identification number, chair identification number, and chair arrival
time. The TRANSD atomic model notes the time the message is received and
uses the chair arrival time to compute the Type III Delay.
System Time.
System Time is computed in the TRANSD atomic model. The REGNURSE
atomic model creates a PatientChair entity at the time the patient is discharged
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from the oncology clinic and communicates it to the TRANSD atomic model.
The PatientChair entity contains the patient identification, chair identification,
and an indicator for whether the chair is unoccupied by a patient or not. Using
the PatientChair message, the TRANSD uses the patient identification number
to look up what time the patient arrived at the clinic and then compute the
system time for that patient.
Throughput.
Throughput is computed in the TRANSD atomic model. The REGNURSE
atomic model creates a PatientChair entity at the time the patient is discharged
from the oncology clinic and communicates it to the TRANSD atomic model.
The PatientChair entity contains the patient identification, chair identification,
and an indicator for whether the chair is unoccupied by a patient or not. When
the TRANSD receives this message, it increments the daily throughput counter
to indicate that another patient has been processed through the oncology clinic.
Chair Utilization.
Chair Utilization is computed in the TRANSD atomic model. The REGNURSE
atomic model creates a PatientChair entity at the time the patient is discharged
from the oncology clinic and communicates it to the TRANSD atomic model.
The PatientChair entity contains the patient identification, chair identification,
and an indicator for whether the chair is unoccupied by a patient or not. Using
the PatientChair message, the TRANSD uses the patient identification number
to look up what time the chair became occupied and then update the chair’s
utilization for the day.
Nurse Utilization.
Nurse Utilization is computed in the TRANSD atomic model. The REGNURSE
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atomic model creates a NurseTime entity at the time the patient is discharged
from the oncology clinic and communicates it to the TRANSD atomic model.
The NurseTime entity contains the nurse identification number and nurse start
time for the day. The TRANSD notes the time the message is received and uses
the nurse start time to compute nurse utilization for the current day.
Nurse Overtime.
Nurse Overtime is computed in the TRANSD atomic model. The REGNURSE
atomic model creates a NurseTime entity at the time the patient is discharged
from the oncology clinic and communicates it to the TRANSD atomic model.
The NurseTime entity contains the nurse identification number and nurse start
time for the day. The TRANSD notes the time the message is received and uses
the nurse start time to compute nurse overtime if the clinic operating hours are
over.
3.2.5 Atomic Models
Next is a description of the atomic model input ports, output ports, and states.
Additionally, the SCHED, CHARGENURSE, and REGNURSE atomic model state
transitions are described. The DEVS mathematical functions for these three same
atomic models are given in Appendix A.1.
CGENR Atomic Model
The CGENR (call generator) atomic model represents the oncologist identifying a
new cancer patient, prescribing a unique treatment regimen, and the patient request-
ing a series of appointments for the prescribed treatment regimen. In the DEVS-
CHEMO model, CGENR creates a new chemotherapy patient and sends a message to
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the scheduler requesting an appointment schedule for the new patient. CGENR has
no input ports but has one output port “out ApptRequest”. The “out ApptRequest
output port sends information to the SCHED atomic model. CGENR has two states:
“Idle” and “Generating”.
SCHED Atomic Model
The SCHED (scheduler) atomic model schedules all patient appointments in the
treatment regimen using a scheduling algorithm selected by the user. The SCHED
atomic model in shown in Figure 3.4. It has one input port “in ApptRequest” and
two output ports, “out ApptTimes and “out Wait1Time. The “out ApptTimes out-
put port sends information to the PGENR atomic model and the “out Wait1Time”
output port sends information to the TRANSD atomic model.
SCHED 
 
States: Scheduling 
 Idle  
 in_ApptRequest out_ApptTimes 
out_Wait1Time 
Figure 3.4: SCHED Block Diagram
The state transition of the SCHED atomic model is depicted in Figure 3.5. The
model has two states: “Idle” and “Scheduling”. The model is initialized in the “Idle”
state. A transition to the “Scheduling” state occurs when the model is in the “Idle”
state and a message ApptRequest is received at the “in ApptRequest” input port. A
method, Algorithm(); takes the information provided by the patient and performs
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the scheduling using the algorithm chosen by the user. Upon completion of this
task (processingT ime time has elapsed) and if there are no more appointment re-
quests (schedQueue.isEmpty() == true), the model transitions to the “Idle” state.
Mathematical details of the SCHED atomic model are given in Appendix A.1.
Idle 
processingTime elapsed 
& schedQueue.isEmpty() 
== true 
Scheduling 
if p == 
“in_ApptRequest” 
Figure 3.5: SCHED State Transition Diagram
PGENR Atomic Model
The PGENR (patient generator) atomic model generates patient arrivals to the
oncology clinic at their scheduled appointment date and time. PGENR has one input
port, “in ApptTimes”, and one output port, “out PatientAppt”. The “in ApptTimes”
input port receives information from the SCHED atomic model and the “out Patient-
Appt output port allows for transmitting information to the RECEPT atomic model.
PGENR has two states: “Idle” and “Generating”.
TRANSD Atomic Model
The TRANSD (transducer) atomic model captures data points from other atomic
models and computes the performance measures from Section 3.2.4. TRANSD has
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six input ports and zero output ports. The six input ports are “in Wait1Time”,
“in Wait2Time”, “in Wait3Time”, “in WaitRoomCapacity”, “in NurseTime”, and
“in PatientDepart”. The “in Wait1Time”, “in Wait2Time”, and “in Wait3Time”
input ports receive information from the SCHED, WAITROOM, and REGNURSE
atomic models respectively. The “in WaitRoomCapacity” input port receives infor-
mation from the WAITROOM while the “in NurseTime” and “in PatientDepart”
receive information from a REGNURSE atomic model. TRANSD has two states:
“Idle” and “Processing”.
RECEPT Atomic Model
The RECEPT (receptionist) atomic model receives each patient who arrives at
the oncology clinic for an appointment, directs the patient to the waiting room,
and notifies the charge nurse of the patient’s arrival to the clinic. RECEPT has
one input port “in PatientAppt” and one output port “out PatientAppt”. The
“in ApptTimes” input port receives information from the PGENR atomic model
and the “out PatientAppt output port sends information to the CHARGENURSE
and WAITROOM atomic models. RECEPT has three states: “Available”, “Serv-
ingPatient”, and “Closed”.
WAITROOM Atomic Model
The WAITROOM (waitroom) atomic model holds patients after they have left the
receptionist until the registered nurse calls the patient to begin their chemotherapy
treatment. WAITROOM has two input ports, “in PatientAppt” and “in PatientSeat-
ed”, and two output ports, “out Wait2Time” and “out WaitRoomCapacity”. The
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“in ApptTimes” input port receives information from the RECEPT atomic model
and the “in PatientSeated” output port receives information from the REGNURSE.
The “out Wait2Time and “out WaitRoomCapacity” output ports send information
to the TRANSD. RECEPT has three states: “Open”, “Processing”, and “Closed”.
PHARM Atomic Model
The PHARM (pharmacy) receives drug orders from the registered nurse, pre-
pares the chemotherapy drugs, and notifies the registered nurse when the drugs
are ready. PHARM has one input port, “in DrugOrder” and n output ports of
type “out DrugOrdern” where n is the number of registered nurses in the oncol-
ogy clinic. The “in DrugOrder” input port receives information from the REG-
NURSE atomic model and each “out DrugOrderi” output ports send information to
the corresponding REGNURSEi atomic model. PHARM has two states: “Idle” and
“PreparingOrder”.
CHARGENURSE Atomic Model
The CHARGENURSE (charge nurse) atomic model manages patients and clinic
resources. The primary responsibility of the CHARGENURSE is to assign patients
who are ready for treatment to an available chemotherapy chair and registered nurse.
CHARGENURSE has two input ports, “in PatientAppt” and “in NurseTask”, and n
output ports of type “out PatientApptn” where n is the number of registered nurses
in the oncology clinic. The “in PatientAppt” input port receives information from
the RECEPT atomic model and the“in NurseTask” input port receives information
from the REGNURSE atomic model. Each “out PatientAppti” output port sends a
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message to the corresponding REGNURSEi atomic model to notify the nurse that
a patient is available to begin their appointment. The CHARGENURSE atomic
model’s block diagram is shown in Figure 3.6.
CHARGENURSE 
 
States: Available 
 ProcessingPatient 
 ChairAvailable 
in_PatientAppt 
in_NurseTask 
out_PatientAppt1 
out_PatientAppt2 
out_PatientApptn 
. 
. 
. 
Figure 3.6: CHARGENURSE Block Diagram
The state transitions of the CHARGENURSE atomic model are depicted in Fig-
ure 3.7. The model has three states: “Available”, “ProcessingPatient”, and “ChairA-
vailable”. The model is initialized in the “Available” state. A transition to the “Pro-
cessingPatient” state occurs when the model is in the “Available” state and a mes-
sage PatientAppt is received at the “in PatientAppt input port. A transition to the
“ChairAvailable state occurs when the model is in the “Available” state and a mes-
sage NurseTask is received at the “in ChairAvailable input port. Both the “ChairA-
vailable” and “ProcessingPatient” states have a processing time processingT ime.
Once the processing time has elapsed in the “ChairAvailable” state, the model
transitions to the “Available” state if there are no more NurseTask entities wait-
ing (NTQueue.isEmpty() == true) or transition to the “ProcessingPatient” state
if there are PatientAppt entities waiting (CNQueue.isEmpty() == false). Once
the processing time has elapsed in the “ProcessingPatient” state, the model tran-
sitions to the “Available” state if there are no more PatientAppt entities waiting
(CNQueue.isEmpty() == true) or transition to the “ChairAvailable” state if there
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are PatientAppt entities waiting (NTQueue.isEmpty() == false). Mathematical
details of the CHARGENURSE atomic model can be found in Appendix A.1.
if p == 
“in_PatientAppt” 
Processing 
Patient ChairAvailable processingTime 
elapsed & 
CNQueue.isEmpty() == 
true 
Available 
if p ==  
“in_NurseTask” 
processingTime 
elapsed & 
NTQueue.isEmpty() 
== true 
processingTime elapsed & CNQueue.isEmpty() == false 
processingTime elapsed & NTQueue.isEmpty() == false 
Figure 3.7: CHARGENURSE State Transition Diagram
REGNURSE Atomic Model
The REGNURSE (registered nurse) atomic model is the most involved atomic
model in DEVS-CHEMO. The registered nurse retrieves a patient from the wait-
ing room, seats the patient in their assigned chemotherapy chair, orders drugs
from the pharmacy, checks the patient’s vital signs, picks up drugs from the phar-
macy, starts the patient’s chemotherapy drug infusion, monitors the patient, and
stops the patient’s chemotherapy drug infusion. REGNURSE has two input ports,
“in PatientAppt” and “in DrugOrder”, and six output ports, “out DrugOrder”, “out-
NurseTime”, “out Wait3Time”, “out PatientSeated”, “out PatientDepart”, “out -
NurseTask”. The “in PatientAppt” input port receives information from the RE-
CEPT atomic model and the “in DrugOrder” input port receives information from
the PHARM atomic model. The “out DrugOrder” output port sends information
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to PHARM, the “out NurseTask” output port sends information to the CHAR-
GENURSE, the “out PatientSeated” and “out PatientDepart” output ports sends
information to the WAITROOM and the TRANSD respectively. Finally, the “out -
NurseTime” and “out Wait3Time” output ports send messages to the TRANSD.
The REGNURSE atomic model in shown in Figure 3.8. The state transitions of
the REGNURSE atomic model are depicted in Figure 3.9. The model has twelve
states: “Available”, “CheckingWaitList”, “GettingPatient”, “SeatingPatient”, “Or-
deringDrug”, “CheckingVitals”, “WaitingOnDrug”, “StartingInfusion”, “Monitor-
ingPatients”, “StoppingInfusion”, “UpdateTRANSD”, and “Home”.
REGNURSE 
 
States:  
 Available 
 CheckingWaitList 
 GettingPatient 
 SeatingPatient 
 OrderingDrug 
 CheckingVitals 
 WaitingOnDrug 
 StartingInfusion 
 MonitoringPatients 
 StoppingInfusion 
 UpdateTRANSD 
 Home 
in_PatientAppt 
out_NurseTime 
in_DrugOrder 
out_Wait3Time 
out_PatientSeated 
out_DrugOrder 
out_NurseTask 
out_PatientDepart 
Figure 3.8: REGNURSE Block Diagram
The model is initialized in the “Home” state. A transition to the “Available” state
occurs when the oncology clinic opens. A message received on the “in PatientAppt”
input causes the REGNURSE to transition to the “CheckingWaitList” state. In the
“CheckingWaitList” state, if there is a patient waiting to start treatment (WaitList.-
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isEmpty() == true) and there is adequate time and capacity to start the patient’s
treatment (inadT imeCap() == false), then the REGNURSE transitions to “Get-
tingPatient”. From here, the REGNURSE transitions to a series of phases based
on elapsed times include “SeatingPatient”, “OrderingDrug”, and “CheckingVitals”.
If REGNURSE is in the “CheckingVitals” state and the drug order from the phar-
macy is ready (DrugReadyList.isEmpty() == false), then REGNURSE transi-
tions to “StartingInfusion”. Otherwise (if DrugReadyList.isEmpty() == true),
REGNURSE transitions to “WaitingOnDrug” until a message is received on the
“in DrugOrder” input port before transitioning to “StartingInfusion”. After the
infStartT ime has elapsed, REGNURSE returns to “CheckingWaitList”.
SeatingPatient 
Home 
orderTime 
elapsed 
nextTime 
elapsed 
seatingTime 
elapsed 
OrderingDrug 
CheckingVitals 
WaitingOnDrug 
StartingInfusion 
StoppingInfusion 
vitalsTime 
elapsed & 
DrugReadyLi
st.isEmpty() 
== true 
????in_DrugOrder? 
infStartTime 
elapsed 
Checking 
WaitList 
infStopTime elapsed 
p == 
?in_PatientAppt? 
numPatients >0 & 
(WaitList.isEmpty() 
== true || 
(WaitList.isEmpty() 
== false & 
inadTimeCap() == 
true)) 
Monitoring 
Patients 
UpdateTRANSD 
updateTime 
elapsed & 
clinic open 
WaitList.isEmpty() == 
true & numPatients == 
0 & stopInf == true 
p == 
?in_PatientAppt? 
GettingPatient 
gettingTime 
elapsed 
WaitList.isEmp
ty() == false & 
inadTimeCap()
== false 
Available 
clinic opens 
clinic closes 
WaitList.isEm
pty() == true & 
numPatients 
== 0 & stopinf 
== false 
vitalsTime 
elapsed & 
DrugReadyLi
st.isEmpty() 
== false 
updateTime 
elapsed & 
clinic closed 
Figure 3.9: REGNURSE State Transition Diagram
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From the “CheckingWaitList” state, if there are existing patients (numPatients >
0) and the REGNURSE is unable to start a patient’s treatment regimen (WaitList.−
isEmpty() == true OR (WaitList.isEmpty() == false & inadT imeCap() ==
true)), then REGNURSE transitions to “MonitoringPatients”. If the model is “Mon-
itoringPatients”, an input on “in PatientAppt” triggers a transition back to “Check-
ingWaitList”; otherwise, the nurse eventually needs to discharge a patient (nexttime
elapses) and transition to “StoppingInfusion” and then “CheckingWaitList”. If the
model is in “CheckingWaitList” and there are no patients (numPatients == 0),
no patients are waiting (WaitList.isEmpty() == true), and no patients were re-
cently discharged (stopInf == false), then the model transitions to “Available”. If
the model is in “CheckingWaitList” and there are no patients (numPatients == 0)
and no patients are waiting (WaitList.isEmpty() == true) but one or more patients
were recently discharged (stopInf == true), then the model transitions to “Update-
TRANSD”. After updating the transducer, REGNURSE transitions to “Available”
if the clinic is still open or transition to “Home” if the clinic is closed. Finally, if the
model is already in the “Available” state when the clinic closes, then REGNURSE
transitions to “Home”. Mathematical details of the REGNURSE atomic model can
be found in Appendix A.1.
3.2.6 Coupled Models
The DEVS-CHEMO simulation model is defined by the EF-CHEMO coupled
model which is composed of the the EF coupled model and the CHEMO clinic
coupled model. Next is a description of each coupled model’s input and output
ports.
56
EF 
TRANSD 
PGENR 
SCHED 
CGENR 
out_PatientAppt 
out_ApptRequest 
out_ApptTimes 
in_Wait1Time 
out_Wait1Time 
in_ApptTimes out_PatientAppt 
in_ApptRequest 
in_Wait2Time 
in_Wait3Time 
in_NurseTime 
in_WaitRoomCapacity 
in_PatientDepart 
in_Wait2Time 
in_Wait3Time 
in_NurseTime 
in_WaitRoomCapacity 
in_PatientDepart 
Figure 3.10: EF Block Diagram
EF Coupled Model
The EF (experimental frame) coupled model defines the environment for testing
and evaluating the DEVS-CHEMO simulation model. EF couples the CGENR,
SCHED, PGENR, and TRANSD atomic models as shown in Figure 3.10. EF has five
input ports (“in PatientChair”, “in Wait2Time”, “in Wait3Time”, “in NurseTime”,
and “in WaitRoomCapacity”) and one output port (“out PatientAppt”). EF has
five external input couplings. One of the external input couplings is the coupling
between EF’s “in Wait2Time” input port and TRANSD’s “in Wait2Time” input
port. There are three internal couplings (e.g., CGENR’s “out PatientAppt” output
port is coupled to SCHED’s “in PatientAppt” input port). Finally, EF has one
external output coupling where PGENR’s “out PatientAppt” output port is coupled
to EF’s “out PatientAppt” output port.
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PHARM 
RECEPT 
REGNURSE1 
in_PatientAppt out_PatientAppt 
out_PatientAppt1 
out_NurseTime 
out_PatientDepart 
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out_NurseTask 
CHARGE 
NURSE 
out_Wait2Time 
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out_PatientApptn 
. 
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. 
. 
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out_DrugOrdern 
out_PatientSeated 
in_PatientAppt 
in_PatientAppt 
in_PatientSeated 
out_Wait2Time 
out_WaitRoomCapacity 
in_PatientAppt 
in_NurseTask 
out_DrugOrder1 
in_DrugOrder 
in_PatientAppt1 
in_DrugOrder1 out_NurseTime 
out_Wait3Time 
out_PatientDepart 
. 
. 
. 
REGNURSEn 
Figure 3.11: CHEMO Block Diagram
CHEMO Coupled Model
The CHEMO (chemotherapy clinic) coupled model imitates the behavior of the
oncology clinic on the day of the patient’s appointment. CHEMO couples the
RECEPT, WAITROOM, PHARM, CHARGENURSE, and n REGNURSE atomic
models as shown in Figure 3.11. CHEMO has one input port (“in PatientAppt”)
and five output ports (“out NurseTime”, “out PatientDepart”, “out Wait2Time”,
“out Wait3Time”, and “out WaitRoomCapacity”). CHEMO has one external in-
put coupling where CHEMO’s “in PatientAppt” input port is coupled to RECEPT’s
58
“in PatientAppt” input port. If n is the number of REGNURSE atomic models, then
there are (2 + 5n) internal couplings within CHEMO. The coupling between CHAR-
GENURSE’s “out PatientAppti” output port and REGNURSEi’s “in PatientAppt”
input port is one of the internal couplings. Finally, CHEMO has (2 + 3n) external
output couplings such as the one between REGNURSEi’s “out Wait3Time” output
port and CHEMO’s “out Wait3Time” output port.
EF-CHEMO 
EF 
CHEMO 
out_Wait3Time 
out_PatientDepart 
out_NurseTime 
out_PatientAppt 
out_Wait2Time 
out_WaitRoomCapacity 
in_Wait2Time 
in_Wait3Time 
in_NurseTime 
in_PatientDepart 
in_WaitRoomCapacity 
in_PatientAppt 
Figure 3.12: EF-CHEMO Block Diagram
EF-CHEMO Coupled Model
The EF-CHEMO coupled model defines the DEVS-CHEMO simulation model.
EF-CHEMO couples EF and CHEMO as shown in Figure 3.12. EF-CHEMO does not
have input or output ports and therefore does not have any external input couplings
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or external output couplings. However, the coupling between EF’s “out PatientAppt”
output port and CHEMO’s “in PatientAppt” input port is one of the six internal
couplings in EF-CHEMO.
3.2.7 System Entity Structure
The system entity structure (SES) in Figure 3.13 is used to design simulation-
based sytems and shows the hierarchy associated with DEVS-CHEMO models. Using
the SES, a modeler can visualize the relationships between atomic and coupled mod-
els. In Figure 3.13, “x dec” implies that the model x can be decomposed into smaller
models. For example, “ef chemo dec” shows that EF CHEMO can be decomposed
into EF and CHEMO. Also in Figure 3.13, “y spec” means that model y is special-
ized and thus contains children that are variants of itself. For example, “genr spec”
shows that GENR has two specialized models: PGENR and CGENR.
EF CHEMO appears at the top of the SES which indicates that it is the highest
level coupled model and can be decomposed into two other coupled models EF and
CHEMO. The EF coupled model can decompose into four atomic models while the
CHEMO coupled model decomposes into five atomic models. Furthermore, note
that CHEMO is actually composed of HR (human resource) atomic models and
STATION (clinic station) atomic models. The HR models are specialized as the
receptionist (RECEPT) and nurse (NURSE) atomic models. The NURSE atomic
models are further specialized as the charge nurse (CHARGENURSE) and registered
nurse (REGNURSE) atomic models. The STATION atomic models are specialized
as the pharmacy (PHARM) and wait room (WAITROOM) atomic models.
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Figure 3.13: System Entity Structure (SES) of DEVS-CHEMO
3.2.8 Software Implementation
DEVS-CHEMO was implemented in DEVSJAVA [50], a Java-based modeling and
simulation software using the DEVS formalism. The DEVS-CHEMO model was im-
plemented using the Eclipse Standard environment. Each atomic and coupled model
was tested individually using Simulation View Version (SimView) 1.2. SimView al-
lows the modeler to visually inspect the model behavior by using test inputs and by
starting, stopping, or slowing the simulation run to view the simulation clock and
parameter values.
3.3 Application
The DEVS-CHEMO simulation model was verified using historical data from a
five-month period at a real oncology clinic. In this section, a description of the
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real oncology clinic setting at Scott & White Hospital is first given in Section 3.3.1.
Results of the DEVS-CHEMO model verification are reported in Section 3.3.2. Three
sets of experiments using DEVS-CHEMO are described and reported in Section 3.3.3.
The first set of experiments implemented several scheduling algorithms to gain insight
into oncology clinic management and operations. The second set of experiments
examined the impact that the number of nurses had on system performance. The
third set of experiments analyzed the sensitivity of system performance results to
the probability distributions for type II + III delay. Results are discussed for all
experiments in Section 3.3.5.
3.3.1 Real Oncology Clinic Setting
DEVS-CHEMO was used to build a simulation model of the outpatient oncology
clinic at Scott & White Hospital in Temple, Texas, USA. This clinic operates five
days a week from 08:00 to 17:00, Monday through Friday and typically has one
charge nurse and four to eight registered nurses on duty at any given time. This
clinic has 20 chemotherapy chairs in the oncology clinic, three of which are reserved
for emergencies and special appointments. Therefore, only 17 chairs are actively
used for “regular” scheduling purposes. There is always at least one receptionist and
one scheduler available in the oncology clinic. The number of oncologists who refer
patients to the clinic is not relevant to this study because their behavior was not
modeled in DEVS-CHEMO. The clinic treats an average of 23.5 patients a day.
When patients call the scheduler to get an appointment schedule, patients provide
their treatment regimen and start date. The scheduler then uses the As-Soon-As-
Possible (ASAP) algorithm to schedule chemotherapy patient appointments. The
scheduler begins with the recommended start date and ensures that the first appoint-
ment and all subsequent appointment dates can be accommodated by the availability
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of the chemotherapy chairs. The availability of the registered nurses are ignored in
the ASAP algorithm. If any appointment in the treatment regimen cannot be sat-
isfied, the scheduler moves all appointments by one day and checks again. This
process is repeated until all appointments are successfully scheduled. If possible, the
patient’s time preference is considered. However, DEVS-CHEMO ignores this aspect
of the problem since historical data on how and when this occurs was unavailable.
One important scheduling issue discussed at the time of this study is related to
the availability of the registered nurses. Under the ASAP algorithm, the oncology
clinic can have as many as 17 patients scheduled to begin treatment at 08:00 hours.
However, if six nurses are on duty, the one-to-one relationship between registered
nurses and patients during the first fifteen minutes of the appointment implies that
only six patients can be started on time, which delays the schedule for the rest of
the day. On the day of a patient’s chemotherapy appointment, the patient arrives
at the scheduled time (previously determined by the availability of a chemotherapy
chair), but the oncology clinic ignores the specific chair assignment and allows the
patient to be seated in any available chair.
3.3.2 Model Testing and Verification
The design of experiments utilized historical patient data from a five-month pe-
riod at the Scott & White Oncology Clinic. The raw data came from a nineteen week
period between April and September 2012. The clinic has 17 chemotherapy chairs
and historical data indicated that the number of registered nurses in the clinic varied
daily from 4 to 8 registered nurses (average: 5.64). The experiments assumed one
charge nurse, one receptionist, one scheduler, and three pharmacists in the pharmacy.
The clinic was assumed to operate for nine hours. Processing times in the
CGENR, SCHED, PGENR, TRANSD, WAITROOM, and CHARGENURSE atomic
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models were assumed to be zero. This is because the CGENR, PGENR, and TRANSD
models in the EF were doing data upkeep whereby information was stored, sent, or
received instantly. The scheduler (SCHED) does take time to make a scheduling
decision, but since all appointments were assumed to start the following day, the
time required to make a decision did not impact the system performance. In the
WAITROOM, a processing time was not needed (set to zero) because no one is there
to greet the patient. Finally, the CHARGENURSE was used to reassign patients
to new chairs and nurses upon arrival; this happens automatically in the real clinic
setting based on current availability so a processing time was not utilized in the ex-
periments. The receptionist was assumed to check-in one patient every minute. In
the REGNURSE atomic model, the data processing times were also assumed to be
zero because the models were also doing data upkeep when processing times were
used.
Historical data provided the time elapsed between the patient’s arrival to the
clinic and the infusion start time (type II + type III delay) for each appointment. The
DEVS-CHEMO model required this time to be broken into several steps. Using input
from interviews with the charge nurse as well as experimentation, it was determined
that the total time would be broken down as follows in the DEVS-CHEMO model:
10% for getting a patient from the waiting room, 20% seating a patient, 10% ordering
a drug, 15% for checking the patient’s vitals, 30% for preparing the drugs in the
pharmacy, and 10% for starting an infusion. The total does not sum to 100% because
another step, waiting for the drug to be ready from the pharmacy, is uncertain.
The model assumes a fixed time for each drug preparation in the pharmacy,
but a large queue of drug orders may require additional time since there are only
three pharmacists available. Stopping an infusion (discharge) was assumed to take
two minutes based on discussions with the charge nurse. It was assumed that all
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patients had an acuity level of one since information about the actual patient’s acuity
levels was unavailable. To ensure that acuity levels did not substantially impact the
system performance for model verification, the maximum acuity level for a nurse was
assumed to be five. This value was determined by dividing the number of chairs (17)
by the minimum number of nurses (4) and rounding up.
The model was verified by simulating the actual patient appointments from the
historical data. In this verification, 505 patients were scheduled from the historical
data at their actual appointment times and the system was analyzed for the 2070
resulting appointments. One hundred simulation runs of the historical events (ar-
rivals, infusions, discharges, etc.) were implemented and are referred to as HIST.
Each appointment in the historical data contained information on the patient’s ap-
pointment date, appointment time, arrival time, IV start time, IV stop time, drug
name(s), and each individual drug start and stop time(s). Data on type II and type
III delay was only available as the sum of the two measures in the historical data, and
is compared as type II + III delay. The actual values for the appointment duration,
arrival time, and arrival to IV time for each appointment were used in HIST. The
number of chairs and number of nurses available each day was also available. Data
type I delay, resource assignments, and resource utilization were not available for
analysis.
65
Table 3.4: Performance Results for Model Verification Using Historical Data
Data Source Performance Measure (units) AVG STDEV 90% CI
Historical Total Throughput (appts.) 2070.0 - -
Data Daily Throughput (appts.) 23.5 - -
(1 instance) Nurse Overtime (min.) (59) 19.00 14.91 -
Type II + III Delay (min.) 50.41 6.21 -
System Time (min.) 206.87 21.94 -
HIST: Total Throughput (appts.) 2070.0 0.0 (2070.0,2070.0)
Simulation Daily Throughput (appts.) 23.5 0.0 (23.5,23.5)
of Historical Nurse Overtime (min.) (60.89) 23.64 0.81 (23.51,23.77)
Events (100 Type II + III Delay (min.) 50.77 0.14 (50.75,50.80)
instances) System Time (min.) 206.98 0.05 (206.97,206.98)
HIST was conducted to demonstrate that the DEVS-CHEMO simulation could
reproduce the events in the historical data with relative accuracy. The throughput,
type II + type III delay, system time, and nurse overtime were compared to the sim-
ulation results in Table 3.4. For each result, the average (AVG), standard deviation
(STDEV), and 90% confidence interval (90% CI) are given. Entries with dash marks
(-) indicate that there was no need to compute the data value. The 90% CI’s for
the HIST data were calculated because the resource assignments in the historical
data were not known and thus the charge nurse randomly assigned patients to any
available registered nurse in HIST. Because these assignments were different for each
simulation run, the average nurse overtime, type II+III delay, and system time values
were different each time. HIST results reproduced results that were identical to the
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total and daily throughput with values of 2070 appointments and 23.5 appointments,
respectively. These results provide a cross-check that HIST used the exact number
of patients in the simulation runs as were present in the historical data.
For the three performance measures, type II + type III delay, system time, and
nurse overtime (all measured in minutes), results should be compared with caution.
In the historical data, the AVG column shows the average of the 2070 patient appoint-
ments while the STDEV column gives the standard deviation. However, in HIST, the
AVG column is the average of the one hundred simulations runs while the STDEV
column shows the standard deviation of the average of the hundred simulation runs
and the 90% CI column containing the confidence interval for those averages. HIST
reproduced averages within 1% for the delay and system time. For Nurse Overtime,
there were 59 instances where patients were discharged after the clinic’s closing time
and the average of those instances was 19 minutes with a STDEV of 15. HIST had
an average of 61 instances where nurses stayed overtime and the average of those
instances was 24 minutes. These nurse overtime values are only 4 minutes apart and
we consider that to be an acceptable difference considering information about the
nurse assignments were unknown. Thus, DEVS-CHEMO does provide a reasonably
accurate representation of the Scott & White oncology clinic operations.
3.3.3 Design of Experiments and Algorithms
The design of experiments sought to answer three questions. First, how should
patients be scheduled? Second, how does the number of nurses impact system perfor-
mance for a 20% increase in demand? Third, how do different distribution assump-
tions change the system performance results? To find these answers, three different
experiments were designed and conducted. This section first describes the simulation
parameters and design set-up, then gives the results of the three experiments.
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The simulation runs for the experiments with DEVS-CHEMO used the chair and
nurse assignments for scheduling purposes, but due to the stochastic nature of patient
arrivals and treatment duration at the clinic, it was unrealistic to rigidly apply these
rules. Instead, the assigned nurse and assigned chair were used only to schedule the
appointment times for the patient. However, those assignments were not necessarily
kept during the actual appointment. If the scheduling algorithm determined a nurse
or chair assignment, DEVS-CHEMO first tried to use that assignment if the resource
was available. Otherwise, DEVS-CHEMO utilizes a reassignment policy that re-
assigns the patient to the next available resource.
The reassignment policy was implemented because initial experiments showed
that maintaining resource assignments resulted in low utilization of some resources,
over-utilization for other resources, and unacceptable levels of clinic overtime. This
occurs because of the stochastic nature of patient treatment duration. When a
patient has a longer treatment duration than expected, they are likely still occupying
their chair when the next patient arrives to the clinic. At times a second chair may
be available for the instances where other patients had a shorter treatment duration
than expected. However, strict adherence to chair and nurse assignments requires
that the second chair remain empty. Instead the next patient must continue to
wait for the first patient to finish treatment and for the assigned chair to become
available. Under this rigid assignment policy, most subsequent appointments will
continue to be delayed and the clinic will stay open overtime to accommodate all
scheduled appointments, even though other resources may have been available for
use.
There are six parameters that are stochastic in the simulation run: number of
nurses working each day, arrival time, appointment duration, type I + type II delay,
treatment start date recommendation, and acuity levels. The first four of these
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stochastic parameters were analyzed from historical data. First, the number of nurses
working each day follows a uniform distribution with values ranging between four to
eight nurses. Historical data showed that 4,5,6,7, or 8 nurses were present on 13.1%,
27.3%, 39.4%, 18.2%, and 2% of the days, respectively,.
Second, the distribution for early or late arrivals for each patient was analyzed.
Patients were late roughly 24% of the time and the best data fit was weibull while
the remaining 76% of patients were early and best followed a gamma distribution fit.
Third, the appointment duration for each specific drug was stochastic. If historical
data on a specific drug had at least one hundred data points, then the distribution was
determined; otherwise the appointment duration time was sampled from the existing
pool of data values. Fourth, the type I + type II delay, or the time from arrival to
the clinic until the IV is started, was also analyzed for each patient appointment in
the historical data. In the simulation, this data value was stochastic and best follows
a gamma distribution.
The remaining two stochastic parameters are used for scheduling purposes, but
were not available in the historical data. Fifth, the treatment start date recom-
mended by the oncologist was generated using a uniform distribution between one
to seven days where each value had equal weight. Data on the start date recommen-
dation was unavailable and the equally-weighted uniform distribution was chosen
because it was assumed that the oncologist wants every patient to begin treatment
within one week.
Sixth, the acuity level for each appointment was also generated via simulation.
There are several ways to handle acuity levels in the literature [18, 24]. The acuity
levels can be based on appointment duration, drugs, or patient characteristics. Since
this is a new concept for the oncology clinic collaborating on this dissertation, ex-
pertise was unavailable on how to best implement acuity levels for this clinic. Thus,
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we assumed that the patient has an acuity level value of one occurring 70% of the
time, a value of two occurring 20% of the time, and a value of three occurring 10%
of the time, where three is the maximum acuity level for each patient. These per-
centages are true under the assumption that 70% of patients have a mild reaction
to the chemotherapy drugs, 20% have a moderate reaction, and 10% have a severe
reaction. The maximum acuity a single registered nurse can have at one time was
assumed to be five. This value was determined by taking the average acuity level of
the patients (1*0.7+2*0.2+3*0.1 = 1.4) and multiplying by the average number of
patients per nurse (17 patients divided by 5.6 nurses = 3.1), then rounding up.
The amount of time used to schedule and allocate time for each appointment
comes from a Drug Infusion Time Sheet that the clinic uses for scheduling purposes.
This sheet tells the scheduler how much time to allocate for each appointment, de-
pending on the drug used. The simulation uses the time from the Drug Infusion
Time Sheet to schedule patients, but the actual appointment duration was stochas-
tic based on analysis results from the historical data. Each day is divided into fifteen
minute time slots.
Each simulation day is an independent day in the system. In order to create
a warm-up period, a number of patient appointment requests are simulated to fill
the schedule on day zero, before the first simulation day begins for the clinic. The
historical data provided the average number of patients seen in the clinic each day
denoted by X. Since each patient has an average number of appointments, n, then
X
n
patients finish chemotherapy treatment each day. The clinic informed us that
they were scheduling patients D days into the future. Thus, DX
n
patients are already
on the schedule. For the simulation X = 23.5, n = 4.10, D = 30, thus 172 patients,
after rounding, were scheduled before the first simulation day to fill the schedule. The
frequency of scheduling requests was also computed. To do this, the length of each
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simulation day, T , in seconds is divided by the number of patients finishing treatment
each day, X
n
. Then patients were assumed to request appointment schedules every Tn
N
seconds. This simulation used T = 690 seconds each simulation day, thus patients
requested treatment every 120 seconds. During the five-month simulation period,
811 new patients are scheduled.
The performance measures listed in Table 3.3 were used to analyze simulation
results from the patient and management perspectives. The results for each schedul-
ing algorithm or nurse comparison comes from 100 simulation replications where the
clinic is simulated for a five-month period using a 300-day planning horizon. The
average, STDEV, and 90% CI’s for all performance measures were computed. The
simulations were conducted on a Dell Precision T7500 with an Intel(R) Xeon(R)
processor running at 2.4 GHz with 12.0 GB RAM.
Scheduling Algorithms
The first question asked was how patients should be scheduled? Four schedul-
ing algorithms were developed and implemented: ASAP, Collective, Individual, and
Nurse. Each algorithm varies by the type of resource used to make the scheduling
decision and the constraints or limitations associated with those resources. These al-
gorithms were designed to determine which resources were most important in schedul-
ing chemotherapy patient appointments. Next is a description of how each algorithm
makes decisions. Following the algorithm name, (C) indicates that a chair resource
is assigned to each patient appointment, (N) indicates that a nurse resource is as-
signed to each patient appointment, and (CN) indicates that both a chair and nurse
resource are assigned to each patient appointment.
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Individual Algorithm (CN)
Patients are scheduled using the chair and nurse availability and both a chair
and nurse are assigned for each patient appointment. The algorithm starts the
recommended date of the first appointment and considers each chair resource one-
at-a-time until a chair with an adequate number of time slots is found. Once a chair
is selected, the algorithm uses a similar procedure to find a nurse who can start the
appointment and handle the additional acuity level. The latter constraint requires
that the sum of the acuity levels of all patients assigned to the nurse is less than or
equal to the maximum acuity level. This algorithm is called “Individual” because
the maximum acuity level constraint is only checked for one individual nurse at a
time. If the constraint is satisfied, then the appointment schedule is kept; otherwise,
the nurse search process is resumed or another time slot is selected based on chair
availability.
The Individual algorithm is the most detailed algorithm and will prove to be the
preferred scheduling method. For this reason, the Individual algorithm is fully stated
using psuedocode. The remaining three algorithms are then described in reference
to the Individual algorithm’s code in Appendix A.2. All algorithms schedule one
patient at a time and assume a long planning horizon such that a solution can be
found within the planning horizon. Each algorithm knows the recommended start
date (startDate) of the first appointment and that there are n appointments in the
patient’s treatment regimen. The spacing between each appointment in the planning
horizon (regimenDates[]), the number of time slots required by each appointment
(numSlots[]), and the acuity level for each appointment (acuity[]) are all known,
where regimenDates[], numSlots[], and acuity[] are all data sets of size n. Addi-
tionally, each algorithm knows the number of chairs each day C, the number of time
slots each day S, and the number of nurses Nd working on day d. The Individual
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algorithm will schedule the treatment dates (treatDays[]), the starting time slots
(slots[]), chairs (chairs[]), and nurses (nurses[]). The treatDays[], slots[], chairs[],
and nurses[] are all data sets of size n. The five methods used in the Individual
algorithm are described next.
• setTreatDays(start, regimenDates[]): returns the treatment dates that begin
on start date start based on treatment regimen regimenDates[].
• checkTreatDays(regimenDates[]): increases every day in regimenDates[] by
one day until all are week days and returns those dates.
• StartSlot(d, numSlots, j, s): Begins looking in slot s of chair j on day d for
numSlots consecutive available slots and returns the slot number if found.
Else, if no space available, returns -1.
• Acuity(n, s, d, acuity, numSlots): returns true if nurse n can handle the addi-
tional load of acuity starting in slot s on day d for numSlots slots, else returns
false;
• Start(n, s, d): returns true if nurse n is available to start a new patient during
slot s on day d, else returns false;
The left arrow ← is used to denote assignment, & denotes the “and” operator, !
denotes the “not” operator, and == denotes the “equality” operator. The Individual
algorithm returns the char (chairs[]) and nurse (nurses[]) assignments. The specific
steps of the Individual algorithm, IndividualAlg(), are listed next.
IndividualAlg()
01. scheduled← false; firstDate← startDate;
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02. treatDays[]← setTreatDays(firstDate, regimenDates[]);
03. treatDays[]← CheckTreatDays(treatDays[]);
04. while(!scheduled)
05. for(i← 0; i < n; i+ +)
06. d← treatDays[i];
07. chairFound← false;
08. for(j ← 0; j < C; j + +)
09. s← 1;
10. while(s ≤ S)
11. s← StartSlot(d, numSlots[i], j, s);
12. if(s > 0)
13. nurseFound← false;
14. nurse← 1;
15. while(!nurseFound & nurse < Nd)
16. fail← 0;
17. startCheck ← Start(nurse, s, d);
18. if(!startCheck)
19. fail← fail + 1;
20. acuityCheck ← Acuity(nurse, s, d, acuity[i], numSlots[i]);
21. if(!acuityCheck)
22. fail← fail + 1;
23. if(fail == 0)
24. nurseFound← true;
25. else
26. nurse← nurse+ 1;
27. if(nurseFound)
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28. slots[i]← s; chairs[i]← j;nurses[i]← nurse;
29. chairFound← true; s← S; j ← C;
30. else
31. s← s+ 1;
32. else
33. s← S
34. if(!chairFound)
35. i← n;
36. if(chairFound)
37. scheduled← true;
38. else
39. firstDate← treatDays[0];
40. treatDays[]← setTreatDays(firstDate, regimenDates[]);
41. treatDays[]← CheckTreatDays(treatDays[]);
42. return treatDays[], slots[], chairs[], nurses[];
ASAP Algorithm (C)
In the ASAP algorithm, patients are scheduled using only the chair availability
and a chair is assigned for each patient appointment. This algorithm was the cur-
rent algorithm used in the oncology clinic at the time of this study. The ASAP
algorithm ignores nurse resources. The algorithm starts the recommended date of
the first appointment and considers each chair resource one-at-a-time until a chair
with an adequate number of time slots is found. If the chairs are unavailable for
the date, then all appointments are moved forward one day and the search process
begins again. Appendix A.2.1 provides more details on the ASAP algorithm.
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Collective Algorithm (C)
Patients are scheduled using the chair and nurse availability and a chair is assigned
for each patient appointment. The algorithm uses the same search procedure as the
ASAP to find an available chair. Once a chair is selected, the algorithm checks
two constraints. In the first constraint, the number of scheduled new starts is less
than or equal to the number of nurses on duty. In the second constraint, the sum
of the acuity levels of all patients for each time slot is less than or equal to the
maximum acuity level multiplied by the number of nurses on duty. This algorithm is
called “Collective” because the maximum acuity level constraint includes all patients
and nurses. If both constraints are satisfied, then the appointment schedule is kept;
otherwise, the chair search process is resumed. Appendix A.2.2 provides more details
on the Collective algorithm.
Nurse Algorithm (N)
Patients are scheduled using only the nurse availability and a nurse is assigned
for each patient appointment. The Nurse algorithm ignores chair resources. The
algorithm finds the recommended date of the appointment, considers each nurse re-
source one-at-a-time until a nurse is found that satisfies two constraints. In the first
constraint, the number of scheduled new starts is less than or equal to the num-
ber of nurses on duty. In the second constraint, the sum of the acuity levels of all
patients assigned to that nurse is less than or equal to the maximum acuity level.
If both constraints are satisfied, then the appointment schedule is kept; otherwise,
the nurse search process is resumed. If all nurses are unavailable for that date, then
all appointments are moved forward one day and the search process begins again.
Appendix A.2.3 provides more details on the Nurse algorithm.
76
Number of Nurses
The second question asked how the number of nurses impacted the system perfor-
mance for a 20% increase in demand for oncology clinic services. Nurses are the most
limited resource in the oncology clinic. The current average number of nurses in the
clinic is 5.64 nurses. This set of experiments assumes that the same number of nurses
are present each day. Now 967 patients are scheduled instead of 811 patients. The
ASAP algorithm was implemented for six instances with one hundred replications
each, where each simulation instance increases the number of nurses from 5 to 10.
Sensitivity Analysis
The third question was to determine how sensitive the performance results were
to changes in the probability distributions of the input factors. This was accom-
plished by changing the probability distribution assumptions for appointment dura-
tion. Specifically, changes were made to the probability distribution for type II +
III delay. Recall that type II + III delay is the time between the patient’s arrival
to the clinic and the time the infusion is started. In the data analysis for type II
+ III delay, the average time was 36.13 minutes and the standard deviation was
22.34 minutes. After performing a goodness-of-fit test, it was determined that the
three-parameter gamma distribution, Gamma(a, d, p), and the Weibull distribution,
Weibull(a,d), were a good fit. Here, a is the shape factor, d is the scale factor, and
p is the threshold factor. In this set of experiments, the number of nurses was set to
seven. The seven nurses were assumed to be present every day, as was done in the
number of nurse experiments.
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Table 3.5: Probability Distributions Used for Type II + III Delay
Parameters Statistics
Name a d p AVG STDEV
Gamma0 2.89 13.20 -2.07 36.13 22.34
Gamma1 7.00 5.16 - 36.13 13.65
Gamma2 5.00 5.10 - 25.50 11.40
Weibull1 1.69 40.53 - 36.13 22.34
Weibull2 1.69 28.56 - 25.50 11.10
Table 3.5 lists the five probability distributions used in the sensitivity analysis.
The first three probability distributions utilize the gamma distribution. Gamma0 has
an average of 36.13 minutes and a standard deviation of 22.34 minutes. Gamma1
has the same average value but the standard deviation was reduced to 13.65 min-
utes. This was done to see what would happen if the clinic improved operations to
achieve more consistent waiting times for the patients. For Gamma2 the average was
reduced to 25.50 minutes with a standard deviation of 11.40 minutes. Weibull1 has
the same average and standard deviation as Gamma0. The purpose of the change
was to examine the impact of using the Weibull distribution instead of the gamma
distribution. Weibull2 has the same average as Gamma2 and a standard deviation
of 11.10 minutes.
3.3.4 Simulation Results
Now the computational simulation results are presented. Discussion of the results
are appear in the next section.
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Table 3.6: Performance Results for Scheduling Algorithms (1 of 2)
Algorithm Performance Measure (units) AVG STDEV 90% CI
ASAP Total Throughput (appts.) 2629.8 65.6 (2619.1,2640.6)
Daily Throughput (appts.) 23.7 0.6 (23.6,23.8)
Chair Utilization (%) 49.58 1.33 (49.36,49.80)
Nurse Utilization (%) 84.05 1.89 (83.74,84.36)
Nurse Overtime+ (min.) 107.17 7.44 (105.94,108.39)
Nurse Overtime+ Count 253.51 14.08 (251.19,255.83)
Nurse Overtime (min.) 43.02 4.55 (42.27,43.76)
Type I Delay (days) 1.30 0.04 (1.30,1.31)
Type II Delay (min.) 21.41 2.71 (20.96,21.85)
Type III Delay (min.) 32.07 0.38 (32.01,32.13)
System Time (min.) 209.42 4.71 (208.65,210.20)
Collective Total Throughput (appts.) 2610.9 73.9 (2598.8,2623.1)
Daily Throughput (appts.) 23.5 0.7 (23.4,23.6)
Chair Utilization (%) 49.21 1.33 (48.99,49.43)
Nurse Utilization (%) 83.92 1.76 (83.63,84.21)
Nurse Overtime+ (min.) 104.52 6.01 (103.53,105.51)
Nurse Overtime+ Count 253.87 15.70 (251.29,256.45)
Nurse Overtime (min.) 630.55 10.30 (628.86,632.24)
Type I Delay (days) 1.33 0.05 (1.33,1.34)
Type II Delay (min.) 15.26 1.47 (15.02,15.51)
Type III Delay (min.) 31.96 0.43 (31.89,32.03)
System Time (min.) 203.33 3.44 (202.77,203.90)
Nurse Overtime+ excludes zero entries
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Table 3.7: Performance Results for Scheduling Algorithms (2 of 2)
Algorithm Performance Measure (units) AVG STDEV 90% CI
Individual Total Throughput (appts.) 2618.6 64.4 (2608.0,2629.2)
Daily Throughput (appts.) 23.6 0.6 (23.5,23.7)
Chair Utilization (%) 49.61 1.36 (49.38,49.83)
Nurse Utilization (%) 84.45 2.01 (84.12,84.78)
Nurse Overtime+ (min.) 103.26 5.25 (102.39,104.12)
Nurse Overtime+ Count 256.94 15.59 (254.38,259.50)
Nurse Overtime (min.) 42.02 3.71 (41.41,42.63)
Type I Delay (days) 1.35 0.05 (1.35,1.36)
Type II Delay (min.) 14.20 1.12 (14.02,14.38)
Type III Delay (min.) 32.01 0.42 (31.94,32.07)
System Time (min.) 203.24 4.01 (202.58,203.90)
Nurse Total Throughput (appts.) 2612.91 64.14 (2602.36,2623.46)
Daily Throughput (appts.) 23.54 0.58 (23.44,23.63)
Chair Utilization (%) 49.28 1.28 (49.07,49.49)
Nurse Utilization (%) 74.05 1.73 (73.76,74.33)
Nurse Overtime+ (min.) 94.54 9.20 (93.02,96.05)
Nurse Overtime+ Count 115.76 11.92 (113.80,117.72)
Nurse Overtime (min.) 17.37 2.57 (16.95,17.79)
Type I Delay (days) 1.49 0.11 (1.48,1.51)
Type II Delay (min.) 46.69 2.58 (46.27,47.12)
Type III Delay (min.) 32.24 0.41 (32.17,32.31)
System Time (min.) 234.63 4.85 (233.83,235.43)
Nurse Overtime+ excludes zero entries
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Scheduling Algorithms
The average run times of the ASAP, Collective, Individual, and Nurse scheduling
algorithms were 4.99 seconds, 5.41 seconds, 6.12 seconds, and 5.02 seconds respec-
tively. The results for the scheduling algorithm experiments are in Tables 3.6 and 3.7.
Each algorithm has results reported for the performance measures specified in Sec-
tion 3.2.4. The throughput is given as total throughput, or appointments (appts.),
for the five-month period. The nurse overtime is reported in two different ways. The
nurse overtime+ count is the number of nurses that work overtime in the five-month
period and nurse overtime+ is the average of the overtime during these instances
(zero entries are excluded). Nurse overtime is the average overtime among all nurses
during the five-month period (zero entries included). The total throughput, type I
delay, and some of the time-based performance measures (system time, type II de-
lay, type III delay, nurse overtime+, and nurse overtime) are depicted graphically in
Figures 3.14, 3.15, and 3.16.
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Figure 3.14: Results for Throughput for Scheduling Algorithms
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Figure 3.15: Results for Type I Delay for Scheduling Algorithms
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Figure 3.16: Results for Time-Based Performance Measure for Scheduling Algorithms
Number of Nurses
Table 3.8 shows the results of the experiments with the number of nurses. Only
the averages are listed in Table 3.8, but the full results (with STDEV and CI’s)
are provided in Appendix A.3. The average for the system time is depicted graph-
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ically in Figure 3.17 for each number of nurses used. Similarly, the type II delay,
nurse overtime+, and nurse overtime are depicted graphically in Figure 3.18 for each
number of nurses used.
Table 3.8: Performance Results for DEVS-CHEMO Nurse Experiments for ASAP
Algorithm
Number of Nurses
Performance Measures (units) 5 6 7 8 9 10
Total Throughput (appts.) 3092.9 3085.3 3090.2 3082.6 3098.7 3099.8
Daily Throughput (appts.) 27.9 27.8 27.8 27.8 27.9 27.9
Chair Utilization (%) 58.3 58.36 58.42 58.4 58.84 59.01
Nurse Utilization (%) 98.84 90.01 82.98 76.84 71.48 66.68
Nurse Overtime+ (min.) 113.37 100.3 98.82 98.78 100 98.73
Nurse Overtime+ Count 309.56 304.57 305.36 305.8 310.36 311.55
Nurse Overtime (min.) 63.26 45.9 38.87 34.04 31.09 27.72
Type I Delay (days) 1.31 1.31 1.31 1.31 1.31 1.32
Type II Delay (min.) 29.65 18.64 15.41 13.81 13.05 12.49
Type III Delay (min.) 31.73 32.01 32.24 32.6 32.97 33.23
System Time (min.) 217.65 207.37 204.06 202.84 202.5 202.41
Nurse Overtime+ excludes zero entries
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Figure 3.17: Results for System Time for Nurse Experiments
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Figure 3.18: Results for Time-Based Performance Measures for Nurse Experiments
Sensitivity Analysis
The results for the sensitivity analysis experiments are given in Table 3.9. G0,
G1, G2, W1, and W2 represent the Gamma0, Gamma1, Gamma2, Weibull1, and
Weibull2 probability distributions, respectively.
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Table 3.9: Performance Results for DEVS-CHEMO Sensitivity Analysis Experiments
Distribution
Performance Measures (units) G0 G1 G2 W1 W2
Total Throughput (appts.) 3090.2 3090.8 3083.4 3087.6 3086.2
Daily Throughput (appts.) 27.8 27.9 27.8 27.8 27.8
Chair Utilization (%) 58.42 57.26 54.38 56.82 53.47
Nurse Utilization (%) 82.98 81.75 77.05 80.74 75.67
Nurse Overtime+ (min.) 98.82 100.45 99.21 100.19 99.29
Nurse Overtime+ Count 305.36 286.38 254.8 290.82 258.15
Nurse Overtime (min.) 38.87 37.04 32.54 37.5 33.02
Type I Delay (days) 1.31 1.32 1.31 1.31 1.31
Type II Delay (min.) 15.41 14.24 10.91 13.89 10.69
Type III Delay (min.) 32.24 29.3 20.05 27.26 16.63
System Time (min.) 204.06 199.09 188.27 199.59 188.34
Nurse Overtime+ excludes zero entries
3.3.5 Discussion
The results provided in Section 3.3.4 provide insight into the questions about how
patients should be scheduled and how the number of nurses impacts system perfor-
mance. First, consider Tables 3.6 and 3.7 for the scheduling algorithms. The ASAP
algorithm had the highest total throughput of 2629 appointments (Figure 3.14) and
daily throughput values. However, the STDEV for both performance measures was
large enough that the average values of the Collective and Individual algorithms
fall within the 90% confidence interval for the ASAP algorithm. Therefore, the
ASAP algorithm was not necessarily an improvement over the Collective or Individ-
ual algorithm. The Collective, Individual, and Nurse algorithms had between 2613
appointments to 2619 appointments.
The chair utilization values for all four algorithms was between 49% and 50%. The
nurse utilization values were 84% to 85% for the ASAP, Collective, and Individual
algorithms, but the Nurse algorithm had a lower average nurse utilization of about
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74%. This indicates that the nurse is the limiting resource because scheduling based
strictly on nurse availability kept the nurse resources less busy during the normal
working hours.
The Nurse algorithm had the lowest average nurse overtime+ of around 95 min-
utes, 12% lower than the ASAP algorithm. The Collective and Individual algorithms
were 2% and 4%, respectively, lower than the ASAP algorithm for the average nurse
overtime+. The Nurse algorithm had fewer instances of nurse overtime (lowest nurse
overtime+ count) with 116 instances. Overall, the nurse overtime was lowest with
the Nurse algorithm with an average value of 17 minutes compared to the average
values of 42 to 43 minutes with the other three algorithms.
From the patient’s perspective, the ASAP algorithm had the lowest type I delay
value of 1.30 days (Figure 3.15). The Collective and Individual algorithms had
slightly higher values of 1.33 and 1.35 days, respectively. The Nurse algorithm had
the largest type I delay average value of 1.49 days. The Individual algorithm had
the best type II delay and system time average values (Figure 3.16). The Collective
algorithm was within 1% of the Individual algorithm for type III delay and system
time. However, the Nurse algorithm had a very high type II delay of around 47
minutes as compared to the 14 to 21 minutes with the other three algorithms. As a
result, the system time for the Nurse algorithm was 25 to 32 minutes higher than the
other algorithms as well. The Nurse algorithm does not adapt well to the stochastic
nature of the appointment duration and the patients end up waiting a long time in
the waiting room for their appointment to begin.
In summary of the scheduling algorithm experiment, the Collective and Individual
algorithms have similar system performance results when compared to the ASAP
and Nurse algorithms. The Individual algorithm is best for minimizing the patient
perspective’s performance measures of type II delay and system time. The ASAP
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algorithm is best for minimizing type I delay and maximizing throughput. Although
the Nurse algorithm best minimized the number of overtime instances and total
average overtime, the patient’s perspective performance measures were unacceptably
worse for system time and type II delay. Therefore, the Nurse algorithm is not
recommended for implementation in the real oncology clinic. The recommended
scheduling algorithm would be the Individual algorithm because it is best for the
most performance measures. Implementing the Individual algorithm over the ASAP
will not significantly impact the throughput and will increase type I delay by 0.05
days. However, the Individual algorithm reduces system time for the patient by 6
minutes (3% improvement), reduces type II delay by 7 minutes (34% improvement),
and reduces nurse overtime+ by 4 minutes (4%) improvement.
Second, consider the results of the the number of nurses experiments in Table 3.8.
The throughput does not show a consistent increasing or decreasing pattern as the
number of nurses increases from five to ten. The STDEVs for the total throughput
and daily throughput performance measures were large enough that the AVG values
all fall within the 90% CI’s and thus it can be concluded that the number of nurses
does not impact the throughput with ASAP algorithm. This observation is expected
because the nurses are ignored with the ASAP algorithm so modifying the number of
nurses should not impact the scheduling decisions. Similarly, the type I delay, type
III delay, and chair utilization appear to be independent of the number of nurses in
the oncology clinic.
However, the type II delay, system time, nurse overtime+, and nurse overtime all
decreased (Figures 3.17 and 3.18) as the number of nurses in the clinic increased from
five to ten nurses with the ASAP algorithm. The type II delay decreased because
more nurses are available which allows the patient’s infusion to start sooner. Since
type II delay is a component of system time, the system time decreases as well.
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More nurses are able to help start and monitor patient appointments so the nurse
overtime decreases, too . Also, the nurse utilization decreased as the number of
nurses increased because more nurses are handling similar work loads.
Considering Figures 3.17 and 3.18 again, observe that the concept of diminishing
returns is present. Thus, the performance measures of type II delay, system time,
nurse overtime+, and nurse overtime all decrease by a smaller percentage each time.
Although having more nurses improves each of these performance measures under
the ASAP algorithm, the improvement is smaller with each additional nurse. After
observing two steep drops from five to six nurses, then six to seven nurses for the four
performance measures, seven is the recommended number of nurses to have on duty
with the ASAP algorithm under a 20% increase in demand. The current average
number of nurses is around 5 nurses, then for a 20% increase in demand, having 7
nurses will results in lower system time by 14 minutes (6%) for patients and lower
nurse overtime by 24 minutes (39%).
Third, consider the results for the distribution experiments in Table 3.9. The re-
sults indicate a sensitivity in the type II and type III delay when changing the proba-
bility distribution and changing the parameters of the distribution. The throughput
and type I delay did not change because the scheduling decisions were made using
the planned times from the Drug Infusion Time Sheet. Using Gamma0 as a baseline,
the results indicate that the type II delay was reduced by 8% when the standard de-
viation was reduced by roughly 50% for Gamma1 and by 10% when the distribution
was changed to Weibull1. When both the standard deviation and average values
were reduced for Gamma2 and Weibull2, the type II delay decreased by 29% and
31%, respectively. As a result, the system time was reduced by 2% (Gamma1 and
Weibull1) and 8% (Gamma2 and Weibull2).
The type III delay was reduced by 9% and 15% for the Gamma1 and Weibull1
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probability distributions. The type III delay was reduced by 38% and 48% for the
Gamma2 and Weibull2 probability distributions. Similarly, the chair utilization and
nurse utilization were reduced by 2% and 3% for the Gamma1 and Weibull1 proba-
bility distributions, and by 7% and 9% for the Gamma2 and Weibull2 probability dis-
tributions. Finally, the nurse overtime+ was reduced by 4% and 5% for the Gamma1
and Weibull1 probability distributions, and by 15% and 16% for the Gamma2 and
Weibull2 probability distributions. In summary, reducing the average and standard
deviation for the type II + III delay improved system performance by reducing type
II delay (30%), type III delay (38%), resource utilization (8%), system time (8%),
and nurse overtime (15%).
3.4 Summary
The DEVS-CHEMO simulation is a new tool that allows for the modeling and
simulation of the scheduling process of oncology clinic resources (chairs and nurses)
and chemotherapy patients; the arrival process of the patients to the clinic on the
day of their appointment; and the patient chemotherapy treatment process. This
discrete event simulation of oncology clinic operations provides managers with a tool
for analyzing decision-making and operational policies within the oncology clinic.
The implementation of DEVS-CHEMO featured four performance measures from
the patient’s perspective (type I delay, type II delay, type III delay, and system
time) and four performance measures from the management’s perspective (through-
put, chair utilization, nurse utilization, and nurse overtime). DEVS-CHEMO was
developed using the DEVS formalism; it is a coupled model that consists of two
smaller coupled models, EF and CHEMO. EF is the experimental frame, a coupled
model containing four atomic models: PGENR, CGENR, TRANSD, and SCHED.
CHEMO is the chemotherapy clinic, a coupled model containing five atomic models:
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RECEPT, WAITROOM, PHARM, CHARGENURSE, and REGNURSE.
DEVS-CHEMO is a tool that oncology clinic managers can use to test decision
and operational policies before implementation in the clinic. In one set of exper-
iments, four scheduling algorithms were compared and it was determined that al-
though the current scheduling algorithm, ASAP, at Scott & White’s oncology clinic
may provide the best throughput and type I delay, the Individual algorithm was best
overall. Implementing the Individual algorithm over the current ASAP algorithm re-
duces system time for the patient by 3%, reduces type II delay by 34%, and reduces
nurse overtime by nearly 4%. In the second set of experiments, the number of nurses
was increased from five to ten nurses using the ASAP algorithm. The results showed
that the type II delay, system time, nurse utilization, nurse overtime+, and nurse
overtime, all decrease as the number of nurses increases. Due to the concept of di-
minishing returns, it was determined that the ideal number of nurses for the Scott &
White oncology clinic is seven nurses when the demand for oncology clinic services
is increased by 20%. Using an average of seven nurses will lower system time by 6%
and reduce overtime by 39%.
The system performance results for type II delay, type III delay, resource uti-
lization, system time, and nurse overtime seem to be sensitive to changes in the
type of the probability distribution and the parameters of the probability distribu-
tion. Therefore, data from a longer time period (e.g., 6-months to 1-year) would be
necessary to make conclusive results regarding the results of the sensitivity analysis
experiments.
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4. MEAN-RISK STOCHASTIC INTEGER PROGRAMMING MODEL FOR
CHEMOTHERAPY SCHEDULING
Scheduling oncology clinic appointments is challenging. The spacing between
each chemotherapy appointment is crucial to the patient’s health status and there-
fore each appointment needs to be scheduled as close to the start date recommended
by the oncologist as possible. Clinic resources should be allocated to the patient for
each appointment, but the nature of the nurse assignment is complicated because
of new patient starts and acuity levels. The appointment scheduling problem for
oncology clinics is stochastic in nature and deterministic models do not sufficiently
capture the scheduling process. Patient requests for appointments, treatment dura-
tion, and resource availability are all examples of stochastic parameters in oncology
clinic scheduling. In this chapter, several SIP models, termed SIP-CHEMO, are de-
veloped to address the complexities of the chemotherapy scheduling problem. The
SIP-CHEMO models reflect the constraints and objectives of the decision problem
and incorporate uncertainty into the decision problem. Some of the SIP-CHEMO
models also include mean-risk measures in order to better reflect the inherent “risk”
in the decision problem. This research develops the first optimization model for
scheduling chemotherapy appointments that incorporates uncertainty in problem
parameters and considers risk.
The rest of this chapter is organized as follows: Section 4.1 defines the chemother-
apy scheduling decision problem and gives an overview of mean-risk SIP problems.
The notation for the SIP-CHEMO models is given section 4.2. The risk-neutral
chemotherapy scheduling problem is stated in section 4.3 while section 4.4 defines
the risk-averse scheduling problem using two mean-risk measures. Real application
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parameters are described in Section 4.5 along with computational experiments. Sec-
tion 4.6 summarizes the chapter.
4.1 Introduction
4.1.1 Scheduling Chemotherapy Appointments
Information acquired through visits and communication with an outpatient on-
cology clinic provided valuable insight into the constraints and objectives that are
important for the SIP-CHEMO models. Once a patient is diagnosed with cancer,
an oncologist prescribes a unique treatment regimen, or series of chemotherapy ap-
pointments, to each cancer patient based on the patient’s current state of health.
A treatment regimen (Table 3.1) consists of a prescribed start date for the patient,
frequency of appointments (treatment day), suggested duration (in minutes), acu-
ity level, and chemotherapy drug name for each appointment. Treatment regimens
depend on the patient’s type of cancer, stage of cancer growth, and current health.
Therefore treatment regimens are unique to each individual patient.
Recall the chemotherapy scheduling process in Figure 3.1. The treatment regi-
men prescribed by the oncologist is sent to a scheduler to determine the appoint-
ment schedule and to allocate clinic resources for each appointment in the treat-
ment regimen. The scheduler must immediately schedule all appointments in the
treatment regimen to guarantee the availability of the later appointments. To max-
imize treatment effectiveness, these appointments should be scheduled as close to
the earliest state date recommended by the oncologist as possible. Delay from the
prescribed treatment date is referred to as type I delay. The scheduler must make
a chemotherapy scheduling decision, which allocates a specific date, time, and set of
clinic resources (e.g., chair and nurse) to each appointment in the patient’s treat-
ment regimen. The chemotherapy scheduling decision problem determines when to
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schedule all of the appointments in the chemotherapy patient’s treatment regimen
and to determine which resources to allocate to the patient at each appointment.
Chemotherapy chairs and nurses are both assigned to a patient for the entire
duration of their chemotherapy treatment. It generally takes around 15 to 30 minutes
to start the chemotherapy drug infusion for each patient. This process is called a
new start. During a new start, the nurse is primarily dedicated to starting the drug
infusion of that patient. As a result, each nurse is limited to one new start during
each time period. After completing a new start with a patient, the nurse is free to
continue monitoring all of their assigned patients.
Chemotherapy treatments are well-known for causing nausea and the cancer
weakens the immune system, both of which can severely deteriorate a patient’s state
of health. The side-affects can occur suddenly during chemotherapy administration.
Depending on the type and intensity of the treatment, the assigned nurse must pay
close attention to the patient in order to monitor the patient’s condition and reac-
tions to these side-affects. However, it is possible for each nurse to simultaneously
monitor the chemotherapy treatments of several patients at the same time. It is
crucial that the nurses are not over-utilized since they must be available to assist
patients experiencing adverse reactions to the chemotherapy drugs. To account for
this, the concept of acuity levels is used. An acuity level is a relative measure of
the nurse’s attention required by a patient during an appointment. Acuity levels are
assigned a value of one, two, or three, where an acuity level of three represents the
maximum attention required by the patient from the nurse. Each nurse can monitor
several patients at once provided that the sum of the acuity levels for all patients is
less than or equal to a pre-determined maximum acuity level for that nurse. Refer
to the example of acuity levels and new patient starts in Figure 3.3 of the previous
chapter for details.
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There are several stochastic parameters associated with the chemotherapy schedul-
ing problem. The side-affects of chemotherapy drugs can influence both the treat-
ment duration and acuity level during an appointment. If a patient is very sick,
the patient may require more attention from the nurse and in some cases, treatment
may be paused to allow the patient time to recover. This translates to a higher
acuity level and a longer appointment duration. Additionally, some patients take
longer to begin treatment because of small veins for the infusion needle or a clogged
port-a-catheter, among other things. Due to these variations, the acuity level and
treatment duration of an appointment are stochastic parameters.
The number of nurses on duty on a given day is also a stochastic parameter. This
is because nurses are the limiting resource when scheduling patients at the oncology
clinic collaborating on this research. When a nurse is unexpectedly unavailable on
a particular day (e.g., when a nurse calls in sick to work), then an understaffed
clinic will have difficulty adjusting. Therefore, nurse availability is assumed to be
stochastic in the decision problem to account for the possibility that a nurse may
not be able to complete their assigned responsibilities.
4.1.2 Mean-Risk Stochastic Integer Programming
SIP is used to formulate the chemotherapy scheduling problem because of stochas-
tic parameters. In SIP-CHEMO each patient is scheduled based on their treatment
regimen and the start date as prescribed by the oncologist. Mean-Risk SIP models
represent risk using both the expected value and a mean-risk function in the objec-
tive function to more accurately reflect the inherent uncertainty in a problem. A
mean-risk function has both a target value and a deviation measure from the target
value.
The mean-risk SIP approach was chosen for this problem for two reasons. First,
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mean-risk SIP allows for modeling different levels of risk using mean-risk measures
such as expected excess (EE) and absolute semideviation (ASD). Risk in this problem
is associated with delays in the treatment’s start date. When appointments do not
begin on the start date recommended by the oncologist, then the treatments become
less effective and delays pose risk to the patient’s health status. Second, scheduling
decisions in this problem are binary and have to be made ‘here-and-now’ for each
patient before observing future uncertainty. The second-stage decisions represent
the “recourse” decisions made after uncertainty is realized.
A mean-risk two-stage SIP [34] can be stated as follows:
SIP: Min E[f(x, ω˜)] + λD[f(x, ω˜)],
s.t. Ax ≥ b
x ∈ Rn¯1 × Zn′1 ,
(4.1)
where x is the first-stage decision vector and f(x, ω˜)) = c>x + Q(x, ω˜). The vector
c ∈ Rn1 (where n1 = n¯1 +n′1) is the first-stage cost vector, b ∈ Rm1 is the right-hand
side, A ∈ Rm1×n1 is the first-stage constraint matrix, and ω˜ is a multi-variate discrete
random variable with an outcome (scenario) ω ∈ Ω with probability of occurrence
pω. The random variable ω˜ is defined on the probability space, (Ω,A,P) where Ω
is the set of all possible outcomes, A is the set of events, and P is the probability
measure. E : F → R denotes the expected value, where F is the space of all real
random cost variables f : Ω → R satisfying E[|f(ω˜)|] < ∞. Modeling problems
using only the expectation in the objective makes the formulation risk-neutral. To
introduce risk, a risk measure D : F 7→ R is used resulting in the so-called mean-
risk stochastic program, where λ > 0 is a suitable weight factor that quantifies the
tradeoff between expected cost and risk. D measures the dispersion (variability) of
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the random variable f(x, ω˜). Common deviation measures in the literature include
conditional value-at-risk (CVaR), EE, and ASD.
For any outcome (scenario) ω, the recourse function Q(x, ω) is given by the
following standard second-stage subproblem:
Q(x, ω) =Min q(ω)>y
s.t. W (ω)y ≥ r(ω)− T (ω)x
y ∈ Rn¯2 × Zn′2 .
The vector q(ω) ∈ Rn2 is the second-stage cost vector, W (ω) ∈ Rm2×n2 (where n2 =
n¯2+n
′
2) is the recourse matrix, r(ω) ∈ Rm2 is the right-hand side, and T (ω) ∈ Rm2×n1
is the technology matrix. A scenario defines the realization of the stochastic problem
data {q(ω), r(ω),W (ω), T (ω)}.
The SIP-CHEMO models developed in this section utilize the EE and ASD mean-
risk measures. These two deviation measures are suitable for this problem because
they minimize the risk of deviation from the recommended start date and minimize
deviation from an acceptable level of scheduling conflicts. Next, the EE and ASD
risk measures are defined.
Given a target η ∈ R and λ > 0, EE [26] is defined as
φEEη(x) = E[max{f(x, ω˜)− η, 0}].
It is the expected value of the excess over the target η ∈ R. Substituting D := φEEη
in (4.1) results in SIP with EE as follows:
Min x∈X E[f(x, ω˜)] + λφEEη(x). (4.2)
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Assuming a finite number of scenarios ω ∈ Ω, each with probability of occurrence
p(ω), λ ≥ 0, and a target level η ∈ R, problem (4.2) is equivalent to the following
formulation [26]:
SIP-EE: Min c>x+
∑
ω∈Ω
p(ω)q(ω)>y(ω) + λ
∑
ω∈Ω
p(ω)ν(ω) (4.3)
s.t. T (ω)x+W (ω)y(ω) ≥ r(ω), ∀ω ∈ Ω
− c>x− q(ω)>y(ω) + ν(ω) ≥ −η, ∀ω ∈ Ω
x ∈ X, y(ω) ∈ Zn¯2+ × Rn
′
2
+ , ν(ω) ∈ R+,∀ω ∈ Ω.
The ASD model is obtained by replacing the target value in EE with the expected
(mean) value E[f(x, ω˜)] and is given as φASD(x) = E[max{f(x, ω˜) − E[f(x, ω˜)], 0}].
ASD reflects the expected value of the excess over the mean value. Setting D := φASD
in (4.1), results in the following SIP with semideviation:
Min x∈X E[f(x, ω˜)] + λφASD(x). (4.4)
Similarly to the EE problem, note that
φASD(x) ≡ E[max{f(x, ω˜),E[f(x, ω˜)]}] − E[f(x, ω˜)],
give the DEP formulation for ASD. Given λ ∈ [0, 1], problem (4.4) is equivalent to
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the following formulation [26] :
SIP-ASD: Min (1− λ)c>x+ (1− λ)
∑
ω∈Ω
p(ω)q(ω)>y(ω) + λ
∑
ω∈Ω
p(ω)ν(ω) (4.5)
s.t. T (ω)x+W (ω)y(ω) ≥ r(ω), ∀ω ∈ Ω
− c>x− q(ω)>y(ω) + ν(ω) ≥ 0, ∀ω ∈ Ω
− c>x−
∑
ω∈Ω
p(ω)q(ω)>y(ω) + ν(ω) ≥ 0, ∀ω ∈ Ω
x ∈ X, y(ω) ∈ Zn¯2+ × Rn
′
2
+ , ν(ω) ∈ R, ∀ω ∈ Ω.
4.2 Problem Definition and Notation
This section defines the notation for the SIP-CHEMO models. Consider a new pa-
tient whose oncologist has recommended a unique treatment regimen and start date.
The treatment regimen specifies the number of appointments, number of days to rest
between each appointment, the duration, acuity level, and chemotherapy drugs for
each appointment. The availability of chemotherapy chair and nurse resources as
well as the current schedule of appointments are known. An appointment schedule
for this new patient is needed. The schedule should specify the start date, time
slot, chair assignment, and nurse assignment for each appointment of the treatment
regimen.
The chemotherapy scheduling problem assumes a finite planning horizon. Let
set D be the days in the planning horizon where D¯ is the last day of the planning
horizon. Chemotherapy nurses expected to be on duty on day d are in the set Jd and
the chemotherapy chairs on day d are the set Kd. The number of nurses working on
day d is J¯d. All chair and registered nurse resources within each set are assumed to
have the same properties and are therefore interchangeable.
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Each day in the planning horizon is divided into time slots of equal length and
the same number of time slots exist each day, which are specified by the set S. The
size of the set S is S¯. The set Sd is the set of time slots available on day d while
Sdk is the set of time slots available on day d for chair k. Note that
⋃
k∈Kd S
dk = Sd,
Sdk ⊆ Sd, Sdk ⊆ S, and Sd ⊆ S.
Table 4.1: Sets Used in the SIP-CHEMO Models
D: Set of days in the planning horizon, indexed by d
Jd: Set of nurses expected to work on day d, indexed by j
Kd: Set of available chairs on day d, indexed by k
S: Set of time slots for the clinic’s operating hours, indexed by s
Sd: Set of available time slots on day d, indexed by s
Sdk: Set of available time slots on day d for chair k, indexed by s
T : Set of days in the treatment regimen, indexed by t
Ud1 : {uˆ|uˆ = max(1, s− rt + 1)...max(1, s), uˆ ∈ Sd}
Ω : Set of scenarios, indexed by ω
Jd(ω): Set of nurses working on day d for scenario ω, indexed by j
Udk1 (ω): {uˆ|uˆ = max(1, s− rt(ω) + 1)...max(1, s), uˆ ∈ Sdk}
Udk2 (ω): {uˆ|uˆ = max(1, S¯ − rt(ω) + 2)...S¯, uˆ ∈ Sdk}
Each patient has a unique treatment regimen denoted by the set T . The set T is
unique to each patient and specifies which days the patient has an appointment. The
size of set T , |T | = n, specifies the number of appointments in the patient’s treatment
regimen. Consider T = {t1, t2, t3} = {1, 8, 15} where the patient has three treatments
specified by t1, t2, and t3 respectively. Note that t2− t1 = 8−1 = 7 indicates that the
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second appointment should be seven days after the first appointment. Set T should
be defined such that t1 = 1 and tn is the length of the treatment regimen. All sets
used in the SIP-CHEMO models are defined in Table 4.1.
The expected acuity level for appointment t of the treatment regimen is given
by at, but the actual acuity level may be different. Similarly, the number of time
slots expected to be needed for appointment t of the treatment regimen is rt, but
the actual number of time slots used may be different. The treatment start date
recommended by the oncologist is specified by dstart. This date must be part of the
planning horizon such that dstart ∈ D. The objective is to schedule the first date
of the treatment regimen as close to this recommended start date as possible. The
penalty for each day (either early or late) is δdelay.
Each patient appointment needs two resource assignments: a chemotherapy nurse
and a chemotherapy chair. The patient must be assigned to the same chair for the
duration of the appointment and no other patient should be assigned to that chair at
the same time. Therefore, there is a one-to-one relationship between a patient and a
chair for the duration of the appointment. The patient is also assigned to one nurse
for the duration of the appointment. However, nurses can have multiple patients
assigned to them during the same time slot. There are two constraints associated
with the patient to nurse assignments. First, the nurse can only start one patient’s
appointment during a time slot. After starting the patient’s appointment, nurses
can have multiple patients for the remainder of the appointment slots provided that
the sum of all their patient’s acuity levels at that time is less than or equal to a
predefined maximum acuity level, amax.
There are a number of existing patients whose appointments have already been
scheduled. For those existing patients on the schedule, let bjds be the acuity of the
patient who has been assigned to nurse j during slot s on day d. The acuity across
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all nurses on day d in slot s is
∑
j∈Jd
bjds = qds. If a nurse j is assigned to start a
patient on day d in slot s, let njds = 1, otherwise njds = 0.
There are three types of uncertainty considered in this problem formulation. A
scenario is the realization of an outcome for the number of nurses on duty, acuity
level, and appointment duration for each appointment in the patient’s treatment
regimen. The set Ω represents a finite set of scenarios indexed by ω. First, the
number of nurses on duty may decrease because a nurse may be unable to work that
day. Jd(ω) is the set of nurses working on day d in scenario ω. The number of nurses
available during the realization of any scenario ω is assumed to be less than or equal
to the number of nurses originally scheduled to work, therefore Jd(ω) ⊆ Jd,∀ω ∈ Ω.
Second, the acuity level can increase or decrease during the realization of a specific
scenario, although acuity levels are still bounded between one and three. Recall that
the expected acuity level for appointment t of the treatment regimen is at, but the
actual acuity level given the realization of scenario ω is at(ω). Third, the length of
the appointment can increase or decrease, e.g., more or fewer time slots are needed.
Recall that the number of time slots expected to be needed for appointment t of the
treatment regimen is rt, but the actual number of time slots used for the realization
of scenario ω is rt(ω).
One constraint imposes an upperbound on the combined patients’ acuity levels
during a time slot. For time slot s on day d, the maximum acuity level across all
patients that the J¯d nurses can handle is J¯d ∗ amax. However, ods(ω) = J¯d(ω) ∗ amax
is an upperbound on the maximum acuity level that the nurses can handle on day d
in slot s for scenario ω. All of the parameters used in the SIP-CHEMO models are
in Table 4.2.
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Table 4.2: Problem Parameters for the SIP-CHEMO Models
D¯ : = max{d|d ∈ D} last day of the planning horizon
S¯: = max{s|s ∈ S} last time slot of the clinic’s operating hours
J¯d: = |Jd| the number of nurses working on day d
T¯ : = max{t|t ∈ T} the last day, or length, of treatment regimen cycle
at: Acuity level on day t of the treatment regimen, at ∈ {1, 2, 3}
amax: Maximum acuity level per nurse in one time slot
bjds: Acuity on day d of existing patients for nurse j in slot s
dstart: Treatment start day recommended by the oncologist
rt: Number of time slots needed for appointment t of the treatment regimen
δdelay: Penalty for each day of treatment delay
δslots : Penalty for time slot s
δslot: Penalty for each additional time slot
δα: Penalty for α overtime variable
δβ: Penalty for β excess acuity variable
δγ: Penalty for γ new start variable
δδ: Penalty for δ overlap variable
njds: = 1 if nurse j is starting an existing patient on day d during time slot s,
0 otherwise
qds: Sum of the acuity levels of existing patients on day d in slot s
J¯d(ω): =|J¯d(ω)| number of nurses working on day d in scenario ω
at(ω): Acuity level on day t of their treatment regimen in scenario ω
rt(ω): Number of time slots needed for appointment t in scenario ω
ods(ω): = J¯
d(ω)∗amax, the maximum acuity level load that the nurses can handle
on day d in slot s in scenario ω
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4.3 Risk-Neutral SIP-CHEMO Scheduling Problem
This section first defines the formulation of the risk-neutral (RN) SIP-CHEMO
model. RN is defined first because it is the simplest of the SIP-CHEMO models.
The remaining two SIP-CHEMO models are extensions of RN. The decision vari-
ables, objective, and constraints are described for the first- and second-stages of
the RN SIP-CHEMO model. Then an algorithm is developed to improve solution
performance.
4.3.1 First-Stage
There are three primary decisions that need to be made here-and-now and these
are defined in Table 4.3. Let xd be a binary decision variable that indicates if the first
appointment in the treatment regimen begins on day d, also known as the start date.
Let yd
t
ks be a binary decision variable that indicates if appointment t of the patient’s
treatment regimen is scheduled for day d in chair k during time slot s. Finally, let
vˆdjs be a binary decision variable that indicates if nurse j is assigned to start the
patient during slot s on day d. The decision variable for the chair assignment is
separated from the decision variable with the nurse assignment because they have
different constraints for subsequent time slots.
Table 4.3: Risk-Neutral First-Stage Decision Variables
xd: xd = 1 if the first treatment is on day d, xd = 0 otherwise.
yd
t
ks: y
dt
ks = 1 if the t
th treatment starts in chair k during slot s on day d, yd
t
ks = 0
otherwise.
vˆdjs: vˆ
d
js = 1 if nurse j is scheduled to start the patient during slot s on day d,
vˆdjs = 0 otherwise.
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The first-stage objective (4.6a) is to minimize the deviation from the desired
start date of the first appointment and to minimize the penalties associated the
each time slot. It is expected that δdelay ≥ δslots ∀s because moving the appointment
backwards or forwards one day has larger consequences than moving the appointment
backward or forward one time slot. By defining δslots appropriately, one can encourage
appointments to be scheduled early in the day, late in the day, or even consider patient
preferences for certain times of the day.
Constraint (4.6b) links the xd decision variable and the y
dt
ks decision variable by
forcing agreement on the start date of the first treatment in the treatment regimen.
Constraint (4.6c) is necessary to make sure that the rest periods between appoint-
ments is consistent with the recommendation the oncologist made for the patient’s
treatment regimen. Constraint (4.6d) creates the requirement that each appointment
in the patient’s treatment regimen is scheduled. If this constraint is not satisfied,
then the problem is infeasible and the planning horizon should be extended. Con-
straint (4.6e) requires that the sum of the acuity levels of all nurses assigned to a
nurse during any given time slot is less than or equal to amax. Constraint (4.6f) links
the yd
t
ks decision variable to the vˆ
d
js decision variable such that all patients scheduled
to start must have a nurse assigned. Constraint (4.6g) limits the number of new
patient starts for a nurse during a time slot to one or fewer. Constraints (4.6h)-(4.6j)
are binary constraints.
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RN: Min
∑
d∈D
[δdelay ∗ |d− dstart|xd +
∑
t∈{t|t∈T,t≤d}
∑
k∈Kd
∑
s∈Sdk
δslots ∗ yd
t
ks] + E[f(x, y, vˆ, ω˜)]
(4.6a)
s.t. xd −
∑
k∈Kd
∑
s∈Sdk
yd
1
ks = 0,∀d ∈ D (4.6b)
− xd +
∑
k∈Kd
∑
s∈S(d+t−1),k
y
(d+t−1)t
ks ≥ 0,∀d ∈ 1...(D¯ − T¯ + 1), ∀t ∈ T, d ≥ t
(4.6c)∑
d∈{d|d∈D,d≥t}
∑
k∈Kd
∑
s∈Sdk
yd
t
ks = 1,∀t ∈ T (4.6d)
−
∑
u∈Ud1
at ∗ vˆdju ≥ bjds − amax,∀d ∈ D, ∀j ∈ Jd,∀s ∈ S (4.6e)
∑
j∈Jd
vˆdjs −
∑
t∈{t|t∈T,t≤d}
∑
k∈{k|k∈Kd,s∈Sdk}
yd
t
ks = 0,∀d ∈ D, ∀s ∈ Sd (4.6f)
− vˆdjs ≥ njds − 1,∀d ∈ D, ∀j ∈ Jd,∀s ∈ Sd (4.6g)
xd ∈ {0, 1},∀d ∈ D (4.6h)
yd
t
ks ∈ {0, 1},∀d ∈ D, ∀k ∈ Kd,∀s ∈ Sdk,∀t ∈ T, d ≥ t (4.6i)
vˆdjs ∈ {0, 1},∀d ∈ D, ∀s ∈ Sd,∀j ∈ Jd (4.6j)
4.3.2 Second-Stage
The second-stage decision variables are the recourse decision variables. There are
four types of scheduling conflicts that can occur from the realization of uncertainty:
overtime, excess acuity, new starts, and appointment overlaps. Each scheduling
conflict is modeled as a second-stage decision variable given in Table 4.4. First, an
increase in the appointment duration can cause overtime for the clinic. Let αd(ω)
be a continuous decision variable that indicates the number of overtime slots caused
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by the realization of scenario ω on day d. Second, an increase in acuity level or a
decrease in the number of nurses can cause the maximum acuity level for a time
slot to be exceeded. Let βds (ω) be a continuous decision variable that indicates the
amount of excess acuity in time slot s on day d in scenario ω.
Third, a decrease in the number of nurses on duty can cause scheduling problems
with the schedule for starting patient appointments if the nurse who does not come
in to work was assigned to start a patient’s appointment that day. Let γdjs(ω) be
a continuous decision variable that indicates if an nurse j is not able to start the
assigned patient during day d in slot s under scenario ω. Fourth, an increase in
appointment duration can cause the appointment to overlap another appointment
already scheduled. Let δdks(ω) be a continuous decision variable that indicates if an
appointment overlaps an existing appointment in chair k on day d in time slot s
for scenario ω. Each of these four continuous decision variables has an associated
penalty of δα, δβ, δγ, δδ respectively.
Table 4.4: Risk-Neutral Second-Stage Decision Variables
αd(ω): (overtime variable) number of overtime slots for the clinic on day d in
scenario ω
βds (ω): (excess acuity variable) excess acuity above the maximum for all nurses
during slot s on day d in scenario ω
γdjs(ω): (new start variable) indicates if nurse j is unable to start an assigned
patient on day d in slot s in scenario ω
δdks(ω): (overlap variable) indicates if an appointment overlaps an existing ap-
pointment in chair k on day d in slot s in scenario ω
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For each outcome (scenario) ω ∈ Ω of ω˜:
Min f(x, y, vˆ, ω˜) =
∑
d∈D
[δα ∗ αd(ω) + δβ
∑
s∈S
βds (ω) + δ
γ
∑
s∈Sd
∑
j∈Jd\Jd(ω)
γdjs(ω)
+ δδ
∑
k∈Kd
∑
s∈S\Sdk
δdks(ω)] (4.7a)
s.t. αd(ω) ≥
∑
t∈{t|t∈T,t≤d}
∑
k∈K
∑
s∈Udk2 (ω)
(S¯ − rt(ω)− s+ 3) ∗ ydtks,∀d ∈ D (4.7b)
βds (ω) ≥ qds − ods(ω) +
∑
t∈{t|t∈T,t≤d}
∑
k∈K
∑
u∈Udk1 (ω)
at(ω) ∗ ydtku, ∀d ∈ D, ∀s ∈ S
(4.7c)
γdjs(ω) ≥ vˆdjs + njds,∀d ∈ D, ∀s ∈ Sd,∀j ∈ Jd\Jd(ω) (4.7d)
δdks(ω) ≥
∑
t∈{t|t∈T,t≤d}
∑
u∈Udk1 (ω)
yd
t
ku,∀d ∈ D, ∀k ∈ Kd,∀s ∈ S\Sdk (4.7e)
αd(ω) ≥ 0,∀d ∈ D (4.7f)
βds (ω) ≥ 0,∀d ∈ D, ∀s ∈ S (4.7g)
γdjs(ω) ≥ 0, ∀d ∈ D, ∀s ∈ Sd,∀j ∈ Jd\Jd(ω) (4.7h)
δdks(ω) ≥ 0,∀d ∈ D, ∀k ∈ Kd,∀s ∈ S\Sdk (4.7i)
The second-stage formulation is stated in (4.7). The second-stage objective (4.7a)
minimizes scheduling conflicts for overtime, excess acuity, new starts, and appoint-
ment overlaps by minimizing the sum of all second-stage decision variables with their
respective penalties δα, δβ, δγ, and δδ. Constraint (4.7b) determines the number of
overtime slots for the clinic in scenario ω, which may occur if rt(ω) > rt. In the
second-stage, patients assigned to nurses that are unable to come to work need to
be re-allocated to other nurses on duty. Because some nurses may be unavailable for
some scenarios, the individual nurse acuity is no longer limited to amax. Instead, the
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sum of acuity levels of all patients scheduled for each time slot is less than or equal
to the collective maximum acuity ods(ω) = J¯
d(ω) ∗ amax of all nurses on duty. The
collective acuity requirement is used because the nurses that are available must work
together to handle the patients who had been assigned to the absent nurse.
Constraint (4.7c) determines if any time slots have excess acuity for scenarios in
which at(ω) > at and\or J¯d(ω) < J¯d. Constraint (4.7d) determines if any nurses
that are unable to work (e.g., scenarios in which J¯d(ω) < J¯d) have been assigned to
start a patient’s appointment. Constraint (4.7e) determines if the new appointment
overlaps any existing appointments, which can occur in scenarios where rt(ω) > rt.
Finally, constraints (4.7f) - (4.7i) define all second-stage variables to be non-negative.
4.3.3 Simplification of SIP-CHEMO formulation
When solving SIP-CHEMO, there are several ways to keep the problem tractable.
Three of these approaches are: generating only necessary constraints, using a small
number of scenarios, and branching using the xd decision variable. The first approach
is to only generate only necessary constraints in the second-stage formulation. Note
that overtime and overlapping appointments can only be caused when rt(ω) > rt.
Therefore, only generate constraints (4.7b) and (4.7e) for such scenarios. Similarly,
excess acuity can only exist when at(ω) > at, therefore, only generate constraints
(4.7c) for such scenarios.
The second approach to simplifying SIP-CHEMO involves using only a limited
number of scenarios so that the set Ω is relatively small. SIP-CHEMO is suitable
for this approach because all three stochastic parameters are limited to two or three
scenarios. The acuity levels can only take three values and it is assumed that only
one nurse will call in sick on any given day and thus |Jd(ω)| = 2. The third stochastic
parameter, treatment duration, is discrete and bounded between zero and S¯. In the
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realistic setting, if the size of each time slot s is reasonably large (e.g., 15 or 30
minutes), then the treatment regimen may only change by a few time slots and thus
be limited to a few (e.g., three to five) scenarios as well.
The third and final approach is to separate the decision problem using the treat-
ment regimen and set D. When a potential start date is selected from set D, then
the spacing between appointments, as determined by the treatment regimen in set T
(constraints (4.6c)), reduces the scope of days in set D to size |T |. This approach is
similar to a branch-and-cut approach in which one chooses a start date d by setting
xd = 1. One can then determine the following appointment dates using set T and
thereby reduce |D| = |T |. Observe then that there is a need to only create variables
yd
t
ks for d = di and t = ti when di and ti correspond to element i in sets D and T
respectively.
The objective increases as one selects d farther from dstart. Thus, there is an
algorithm, MinAlg(), that first checks xd = d
start, then searches values in the neigh-
borhood (e.g., dstart + 1, dstart − 1, etc.) to find the start date d that results in the
minimum objective value. Furthermore, this approach eliminates the need for con-
straint (4.6c). It should also be noted that each appointment t ∈ T is a separable
problem now, too, because the start time and resource assignments of each appoint-
ment is independent of the other appointment start times and resource assignments.
Next, pseudocode is used to describe the algorithm MinAlg() that identifies the
best solution x∗. The methods (functions) used in the solution search algorithm are
first described and then the algorithm, MinAlg(), is stated. The methods used are:
• inSetD(Dˆ): returns true if for each d ∈ Dˆ, then d ∈ D; returns false other-
wise.
• getDHat(d): returns set D of size |T | where d1 = d.
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• solve(Dˆ): returns (x∗, obj∗) after solving an SIP-CHEMO problem instance
(e.g., problem RN in (4.6)) using D = Dˆ where x∗ is the solution and obj∗ is
the objective value.
This search method assumes there is a global minimum value for the SIP-CHEMO
problem instance near dstart. The search method first finds the solution using xdstart =
1. Afterwards, the algorithm searches above and then below that initial dstart value
until finding maxFail worse objective values in each direction. When the maxFail
worse objective values are found above (below) the dstart value, then posStop (negStop)
becomes true. For simplicity, assume there is a solution for each start date and cor-
responding set of dates Dˆ when the method solve(Dˆ) is used. The left arrow ←
is used to denote assignment, & is the “and” operator, ! is the “not” operator, and
== is the “equal to” operator. The steps of the MinAlg() algorithm are stated next.
MinAlg()
01. obj∗ ←∞, negStop← false, posStop← false, done← false, fail← 0;
02. d← dstart;
03. Dˆ ← getDHat(d);
04. while (!done)
05. if(inSetD(Dˆ))
06. (x, obj) ← solve(Dˆ);
07. if (obj < obj∗)
08. obj∗ ← obj, x∗ ← x;
09. else
10. fail← fail + 1;
11. if (fail ≥ maxFail & posStop == false)
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12. posStop← true, fail← 0, d← dstart;
13. else if (fail ≥ maxFail & negStop == false)
14. negStop← true;
15. else
16. if (!posStop)
17. d← d+ 1;
18. else if (!negStop)
19. d← d− 1;
20. if (posStop & negStop)
21. done← true;
22. else
23. Dˆ ← getDHat(d);
24. return x∗, obj∗
The MingAlg() algorithm identifies the optimal solution x∗ and optimal objective
value obj∗ to problem (4.6).
4.4 Risk-Averse SIP-CHEMO Scheduling Problem
This section develops two additional SIP-CHEMO models that utilize the EE and
ASD mean-risk measures. These two deviation measures are suitable for this problem
because they minimize the risk that comes from deviating from the recommended
start date. Next, the RN SIP-CHEMO model is adapted to include the EE and ASD
risk measures.
4.4.1 Expected Excess
The RN chemotherapy scheduling problem ((4.6) and (4.7)) was adapted to the
deterministic equivalent formulation (4.3) for EE. The adapted model, EE, is:
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EE: Min
∑
d∈D
[δdelay ∗ |d− dstart|xd +
∑
t∈{t|t∈T,t≤d}
∑
k∈Kd
∑
s∈Sdk
δslots ∗ yd
t
ks]
+
∑
ω∈Ω
p(ω) ∗
∑
d∈D
[δα ∗ αd(ω) +
∑
s∈S
δβ ∗ βds (ω) +
∑
s∈Sd
∑
j∈Jd\Jd(ω)
δγ ∗ γdjs(ω)
+
∑
k∈Kd
∑
s∈S\Sdk
δδ ∗ δdks(ω)] + λ ∗
∑
ω∈Ω
p(ω)ν(ω) (4.8a)
s.t. Constraints (4.6b), (4.6d)− (4.6j) (4.8b)
Constraints (4.7b)− (4.7i) (4.8c)
−
∑
d∈D
[δdelay ∗ |d− dstart|xd +
∑
t∈{t|t∈T,t≤d}
∑
k∈Kd
∑
s∈Sdk
δslots ∗ yd
t
ks]
−
∑
d∈D
[δα ∗ αd(ω) + δβ
∑
s∈S
βds (ω) + δ
γ
∑
s∈Sd
∑
j∈Jd\Jd(ω)
γdjs(ω)
+ δδ
∑
k∈Kd
∑
s∈S\Sdk
δdks(ω)] + ν(ω) ≥ −η,∀ω ∈ Ω (4.8d)
ν(ω) ≥ 0,∀ω ∈ Ω (4.8e)
In problem (4.8), a new decision variable ν(ω) was introduced. The objective is
stated in (4.8a) which now has one additional summation for the expected value of
the new decision variable multiplied by lambda. Several constraints were unmodified
as indicated by (4.8b) and (4.8c). Two additional constraints were needed: the
complicating constraint (4.8d) and the non-negative constraint (4.8e) for the new
decision variable.
4.4.2 Absolute Semideviation
The RN chemotherapy scheduling problem ((4.6) and (4.7)) was adapted to the
deterministic equivalent formulation (4.5) for ASD. The adapted model, ASD, is:
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ASD: Min (1− λ)
∑
d∈D
[δdelay ∗ |d− dstart|xd +
∑
t∈{t|t∈T,t≤d}
∑
k∈Kd
∑
s∈Sdk
δslots ∗ yd
t
ks]
+ (1− λ) ∗
∑
ω∈Ω
p(ω)
∑
d∈D
[δα ∗ αd(ω) + δβ
∑
s∈S
βds (ω) (4.9a)
+ δγ
∑
s∈Sd
∑
j∈Jd\Jd(ω)
γdjs(ω) + δ
δ
∑
k∈Kd
∑
s∈S\Sdk
δdks(ω)] + λ ∗
∑
ω∈Ω
p(ω)ν(ω)
s.t. Constraints (4.6b), (4.6d)− (4.6j) (4.9b)
Constraints (4.7b)− (4.7i) (4.9c)
−
∑
d∈D
[δdelay ∗ |d− dstart|xd +
∑
t∈{t|t∈T,t≤d}
∑
k∈Kd
∑
s∈Sdk
δslots ∗ yd
t
ks]
−
∑
d∈D
[δα ∗ αd(ω) +
∑
s∈S
δβ ∗ βds (ω) +
∑
s∈Sd
∑
j∈Jd\Jd(ω)
δγ ∗ γdjs(ω)
+
∑
k∈Kd
∑
s∈S\Sdk
δδ ∗ δdks(ω)] + ν(ω) ≥ 0,∀ω ∈ Ω (4.9d)
−
∑
d∈D
[δdelay ∗ |d− dstart|xd +
∑
t∈{t|t∈T,t≤d}
∑
k∈Kd
∑
s∈Sdk
δslots ∗ yd
t
ks]
−
∑
ω∈Ω
p(ω)
∑
d∈D
[δα ∗ αd(ω) +
∑
s∈S
δβ ∗ βds (ω) +
∑
s∈Sd
∑
j∈Jd\Jd(ω)
δγ ∗ γdjs(ω)
+
∑
k∈Kd
∑
s∈S\Sdk
δδ ∗ δdks(ω)] + ν(ω) ≥ 0,∀ω ∈ Ω (4.9e)
ν(ω) free, ∀ω ∈ Ω (4.9f)
In problem (4.9), a new decision variable ν(ω) was also needed. The objective
(4.9a) for ASD now has the original objective (4.6a) multiplied by 1 − λ and one
additional summation for the expected value of the new decision variable multiplied
by lambda. Several constraints were unmodified as indicated by (4.9b) and (4.9c).
Three additional constraints were needed: two complicating constraints (4.9d)and
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(4.9e) and the unbounded, continuous constraint (4.9f) for the new decision variable.
4.5 Computational Experiments
The SIP-CHEMO models were analyzed using data from a real outpatient on-
cology clinic. This section first describes the real oncology clinic setting at Scott &
White Hospital and then provides details on the setup for the computational exper-
iments for SIP-CHEMO. The first set of experiments implemented five scheduling
models and compared their performance. The second set of experiments examined
the impact that the λ value had on scheduling performance for the EE and ASD
SIP-CHEMO models. Finally, the third set of experiments analyzed how the target
value of η impacted the EE SIP-CHEMO model. Results from the computational
experiments are discussed at the end of this section.
4.5.1 Design of Experiments
The outpatient oncology clinic at Scott & White Hospital in Temple, Texas,
USA operates five days a week for nine hours each day. The clinic typically has one
charge nurse and four to eight registered nurses on duty at any given time. There are
17 chemotherapy chairs that are regularly used in the oncology clinic for scheduling
purposes. The clinic treats an average of 23.5 patients each day. The DEVS-CHEMO
simulation (Chapter 3) was used to evaluate each SIP-CHEMO model’s performance.
Patients were sampled from a database of historical patient data from a five-
month period at the Scott & White oncology clinic. The database contained 505
sample patients. On average there were around four appointments in each patient’s
treatment regimen, but actual values ranged from one appointment to 21 appoint-
ments . The maximum acuity a single registered nurse could have was assumed to
be five (amax = 5). All experiments assumed a four-month planning horizon and
simulated the clinic operations for one-month to collect information on the system
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performance. For scheduling purposes, time slots were assumed to be 30 minutes
each because the clinic currently uses time slots of this length. With nine operating
hours, there were 18 time slots in each day.
Creating scenarios is an important part of the experimental design for the SIP-
CHEMO models. For each scheduling problem solved, there were 12 scenarios. The
12 scenarios came from combining three outcomes of appointment duration, two
outcomes of acuity levels, and two outcomes of number of nurses. An example of
these outcomes is shown in Table 4.5. The three outcomes of stochastic appointment
duration were created by generating a time for each appointment using historical
data. The times depend on the drug(s) used in that appointment and each outcome
is equally weighted. If historical data on a specific drug had at least one hundred
data points in the historical database, then the distribution was determined and the
appointment duration was generated using the distribution. Otherwise, the appoint-
ment duration was sampled from the existing pool of data values because there were
not enough data values to determine the distribution. The number of time slots was
then found by dividing the appointment duration by the time per slot and rounding
to the nearest integer value.
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Table 4.5: Example SIP-CHEMO Outcomes
Treatment No. Outcome Appointment Duration (slots) Probability
1;8;10
1 4;3;4 0.33
2 5;3;3 0.33
3 3;4;5 0.33
Treatment No. Outcome Acuity Probability
1;8;10
1 1;1;2 0.50
2 1;3;1 0.50
Days Outcome No. of Nurses Probability
1 5;7;6 0.90
2 4;6;5 0.10
For the two outcomes of acuity levels, the acuity level at each appointment was
generated with a value of one occurring 70% of the time, a value of two occurring
20% of the time, and a value of three occurring 10% of the time. It was assumed
that there was a 10% probability of an employee taking a vacation or sick day. This
assumption came from the Bureau of Labor statistics by citing the average sick and
vacation time for a ten-year employee. Finally, the original number of nurses was
assumed to be available 90% of the time. However, the second outcome of the number
of nurses assumed that one less nurse is available on each appointment day and this
outcome occurred with 10% probability. There were 12 outcomes because 3 x 2 x 3
= 12 and combining the outcomes from Table 4.5 results in the 12 scenarios in Table
4.6 for a start date on day eight (x8 = 1).
116
Table 4.6: Example SIP-CHEMO Scenarios with x8 = 1
ω Prob. Days Treatment No. Appt. Dur. Acuity No. of Nurses
1 0.15 8;15;17 1;8;10 4;3;4 1;1;2 5;7;6
2 0.15 8;15;17 1;8;10 5;3;3 1;3;1 5;7;6
3 0.15 8;15;17 1;8;10 3;4;5 1;1;2 5;7;6
4 0.15 8;15;17 1;8;10 4;3;4 1;3;1 5;7;6
5 0.15 8;15;17 1;8;10 5;3;3 1;1;2 5;7;6
6 0.15 8;15;17 1;8;10 3;4;5 1;3;1 5;7;6
7 0.02 8;15;17 1;8;10 4;3;4 1;1;2 4;6;5
8 0.02 8;15;17 1;8;10 5;3;3 1;3;1 4;6;5
9 0.02 8;15;17 1;8;10 3;4;5 1;1;2 4;6;5
10 0.02 8;15;17 1;8;10 4;3;4 1;3;1 4;6;5
11 0.02 8;15;17 1;8;10 5;3;3 1;1;2 4;6;5
12 0.02 8;15;17 1;8;10 3;4;5 1;3;1 4;6;5
The penalties for the delta values in the SIP-CHEMO objective functions (4.6a),
(4.8a), and (4.9a) were determined by converting the units of each variable into
acuity. Recall that one time slot has a maximum acuity amax and one day has S¯
time slots. Therefore, 1 slot = amax and 1 day = S¯ ∗ amax. Then δβ = 1 because the
β decision variable already represents acuity. Next δγ = amax and δδ = amax because
the γ and δ decision variables are both indicators for a time slot. The α decision
variable also represents time slots and thus one could use δα = amax. However,
early experiments revealed that this penalty was not large enough to impact the
solution. Therefore, the penalty measure for α was set to δα = 0.5 ∗ amax ∗ S¯. Since
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the x decision variable represents one day, then δdelay = S¯ ∗ amax. Note that the y
decision variable represents a time slot. In the SIP-CHEMO models, later time slots
were penalized more heavily and thus the model rewarded appointments that started
early in the day. Since this is a penalty term used to avoid unnecessary gaps between
appointments, one-tenth of the value was used and thus δslots = 0.1 ∗ s ∗ amax.
The first research question for SIP-CHEMO requires a comparison of five schedul-
ing methods. When patients call the scheduler to get an appointment schedule, pa-
tients provide their recommended treatment regimen and start date. In the real on-
cology clinic, the scheduler uses a scheduling algorithm called the as-soon-as-possible
(ASAP) algorithm. The ASAP algorithm uses only the availability of the chemother-
apy chairs to schedule the patient’s appointments and ignores the availability of the
registered nurses. Psuedocode for the ASAP algorithm is given in Appendix A.2. The
Individual algorithm performed best in Chapter 3 and is included here for comparison
as well. Details on the Individual algorithm are given in Appendix A.2. The first
experiment compared the ASAP and Individual algorithms to three SIP-CHEMO
models: RN, EE, and ASD. These models used λ = 0.5 in the first experiment and
the EE model used a target value of two days with η = 2 ∗ S¯ ∗ amax. This value
was chosen to indicate that moving more than two days from the recommended start
date can cause risk to the patient’s state of health.
The second research question examined how the value of λ in the EE and ASD
scheduling models impacts the system performance. In this experiment, the EE and
ASD SIP-CHEMO models were used to schedule patients while a value of 0.5 and
1.0 was used for λ for each model. The EE model used η = 1 ∗ S¯ ∗ amax. The labels
of ASD 05 and ASD 10 were used to label the ASD mean-risk SIP-CHEMO model
simulation runs with λ = 0.5 and λ = 1.0 respectively. Similarly, the names of EE 05
and EE 10 were used to label the EE mean-risk SIP-CHEMO model simulation runs.
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Finally, the third research question focused on how the value of η impacts the
system performance. Recall that η is the target value for the EE mean-risk SIP-
CHEMO model. In all simulation runs, λ = 0.5 and the value of η changes with
η = 0.0, η = 1∗ S¯ ∗amax, and η = 2∗ S¯ ∗amax in the simulation runs labeled EE-Eta0,
EE-Eta1, and EE-Eta2 respectively.
In all three experiments, the system performance was captured by simulating the
clinic performance for one-month using DEVS-CHEMO. There were 170 patients
initially scheduled to fill the schedule with five to six additional appointment re-
quests each day until 276 patients were scheduled. DEVS-CHEMO gives system
performance results on the type I delay, type II delay, type III delay, system time,
throughput, chair utilization, nurse utilization, and nurse overtime.
The throughput results are reported as the total throughput, or appointments
(appts.), for the month and the average daily throughput. The nurse overtime is
reported in two different ways. The nurse overtime+ count is the number of times
that a nurse had to work overtime during the month and nurse overtime+ is the
average of the overtime on those occasions (zero entries are excluded). Nurse overtime
is the average overtime among all nurses during the simulation period (zero entries
included). The next subsection provides the average for each performance measure
from DEVS-CHEMO in the 100 replications of each experiment. The experiments
were all conducted on a Dell Precision T7500 with an Intel(R) Xeon(R) processor
running at 2.4 GHz with 12.0 GB RAM.
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4.5.2 Results and Discussion
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Figure 4.1: Results for Throughput for Scheduling Models
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Figure 4.2: Results for System Time Performance Measures for Scheduling Models
The first set of experiments compared five scheduling algorithms (Table 4.7). All
SIP-CHEMO models (RN, EE, and ASD) outperformed the ASAP and Individual
algorithms for several performance measures such as total throughput (Figure 4.1),
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system time (Figure 4.2), type II delay, nurse overtime+, and nurse overtime (Figure
4.3). The EE model had the highest total throughput (473 appointments) and the
lowest type II delay (16 minutes), type III delay (32 minutes), and system time (208
minutes). The RN model had the lowest nurse overtime+ (95 minutes) and nurse
overtime (31 minutes).
Table 4.7: Performance Results for Scheduling Models
Experiments
Performance Measures (units) ASAP Individual RN EE ASD
Total Throughput (appts.) 467.5 458.4 471.8 473.4 472.1
Daily Throughput (appts.) 23.4 22.9 23.6 23.7 23.6
Chair Utilization (%) 50.24 49.18 50.28 50.48 50.49
Nurse Utilization (%) 83.68 85.76 81.37 82.67 82.46
Nurse Overtime+ (min.) 116.96 108.71 94.96 98.33 99.64
Nurse Overtime+ Count 45.32 47.29 36.75 39.28 39.83
Nurse Overtime (min.) 46.91 45.19 30.64 34.17 34.97
Type I Delay (days) 1.36 1.63 1.55 1.54 1.54
Type II Delay (min.) 28.46 18.69 16.57 16.44 716.89
Type III Delay (min.) 32.26 32.20 32.26 32.23 32.28
System Time (min.) 221.39 211.39 208.02 207.97 209.00
Simulation Run Time (sec.) 1.46 1.32 67.78 86.00 102.84
ASAP has the lowest type I delay (1.4 days) because the algorithm schedules
patients as quickly as possible and ignores the nurse resource. Aside from the ASAP
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algorithm, the SIP-CHEMO models have the lowest type I delay (Figure 4.4) with
1.5 days. The SIP-CHEMO models take much longer to run than the two algorithms
which took only 1 to 2 seconds each. The run times for the SIP-CHEMO models
increase as the number of constraints increases in the RN, EE, and ASD models
which took an average of 68, 86, and 103 seconds to run, respectively. EE is the
preferred SIP-CHEMO model because it had the best performance measures for the
most categories. The EE SIP-CHEMO model held type I delay within 0.2 days while
making improvements in other performance measures such as throughput (increased
1%), overtime (reduced 27%), system time (reduced 6%), and type II delay (reduced
42%) when compared to the ASAP algorithm. Thus, it can be concluded that the
SIP-CHEMO models supersede the decisions made using just the DEVS-CHEMO
simulation model scheduling algorithms. The standard deviation and 90% confidence
intervals for each performance measure for the five models is in Tables B.1, B.2, and
B.3 in Appendix B.
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Figure 4.4: Results for Type I Delay for Scheduling Models
The second set of experiments investigated the impact of lambda on the system
performance. Table 4.8 contains the averages for each performance measure from
100 replications of DEVS-CHEMO using the EE and ASD SIP-CHEMO models.
The λ value was set to 0.5 in EE 05 and ASD 05 and was set to 1.0 for EE 10 and
ASD 10. ASD 05 outperforms ASD 10 for total throughput by 37 appointments and
type I delay by 1.9 days. ASD 05 had roughly 2 more appointments per day and
improved type I delay by 40%. ASD 10 had lower nurse overtime+ (by 19 minutes),
nurse overtime+ count (by 8 instances), nurse overtime (by 12 minutes), type II delay
(by 5 minutes), type III delay (17 seconds), and system time (by 4 minutes) than
ASD 05. Although ASD 10 is better then ASD 05 for more performance measures,
these small improvements do not seem significant enough to justify two fewer patient
appointments each day. Comparatively, for the EE model (η = 1∗ S¯ ∗amax was used)
there was little difference in using λ = 0.5 or λ = 1.0 for the EE 05 and EE 10
experiments, respectively. The throughput only differed by 2 appointments (<1%)
and type I delay by 0.01 days (1%).
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Table 4.8: Performance Results for the λ Experiments
Performance Measures (units) ASD 05 ASD 10 EE 05 EE 10
Total Throughput (appts.) 474.8 476.7 472.1 434.8
Daily Throughput (appts.) 23.7 23.8 23.6 21.7
Chair Utilization (%) 50.90 50.69 50.49 46.68
Nurse Utilization (%) 83.05 82.24 82.46 73.97
Nurse Overtime+ (min.) 99.85 99.78 99.64 79.73
Nurse Overtime+ Count 40.41 39.29 39.83 32.36
Nurse Overtime (min.) 35.61 34.31 34.97 22.74
Type I Delay (days) 1.54 1.55 1.54 2.57
Type II Delay (min.) 17.25 16.80 16.89 11.97
Type III Delay (min.) 32.44 32.43 32.28 31.99
System Time (min.) 209.77 207.77 209.00 204.85
The third set of experiments investigated the impact of eta on system performance
for the EE SIP-CHEMO model (Table 4.9). The results indicate that there is very
little difference in the system performance results based on η. The type I delay
was around 1.5 days and daily throughput was about 24 appointments for all three
experiments. The system time was between 208 and 210 minutes while the nurse
overtime was 39 to 41 minutes. Although the target value eta impacted the scheduling
decision, it did not substantially influence the system performance.
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Table 4.9: Performance Results for the η Experiments
Performance Measures (units) EE-Eta0 EE-Eta1 EE-Eta2
Total Throughput (appts.) 472.6 474.8 473.4
Daily Throughput (appts.) 23.6 23.7 23.7
Chair Utilization (%) 50.64 50.90 50.48
Nurse Utilization (%) 82.43 83.05 82.67
Nurse Overtime+ (min.) 98.13 99.85 98.33
Nurse Overtime+ Count 40.41 40.41 39.28
Nurse Overtime (min.) 34.82 35.61 34.17
Type I Delay (days) 1.54 1.54 1.54
Type II Delay (min.) 16.79 17.25 16.44
Type III Delay (min.) 32.27 32.44 32.23
System Time (min.) 209.23 209.77 207.97
4.6 Summary
The SIP-CHEMO optimization models are for the problem of scheduling chemother-
apy patients, chairs, and nurses under uncertainty. SIP-CHEMO aims to determine
an optimal appointment schedule for a new chemotherapy patient who has been pre-
scribed a unique treatment regimen and recommended start date. The appointment
duration, acuity levels, and nurse resource availability were assumed to be stochas-
tic. A risk-neutral formulation for the chemotherapy decision problem was developed.
The first-stage decisions determined an appointment time and resource assignment
while minimizing the type I delay and appointment start times. The second-stage
objective minimized clinic overtime, excess acuity assignments, conflicts with new
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patient starts, and conflicts with overlapping appointment times.
The risk-neutral formulation was extended to include two mean-risk measures.
EE aims to minimize expected value of the excess over a target value. ASD is similar
but instead uses the mean value as the target and thus minimizes the expected value
of the excess over the mean value. An algorithm was developed that branched on
the start date to improve the solution speed of the model. Together, the RN, EE,
and ASD models constitute the three SIP-CHEMO models.
Three sets of experiments were then designed and conducted to answer three ques-
tions. First, can any of the three SIP-CHEMO models outperform current algorithms
for scheduling patients at a real outpatient oncology clinic? All three SIP-CHEMO
models, RN, EE, and ASD, were found to outperform the algorithms for most perfor-
mance measures. Using the SIP-CHEMO models, throughput increased by 1%, type
II delay decreased by 41%, system time decreased by 6%, nurse overtime+ decreased
by more than 15%, and nurse overtime decreased by more than 25% over the current
scheduling methods. The EE model had the highest total throughput, lowest type II
delay, type III delay, and system time. Second, how does the value of lambda impact
system performance when using the EE and ASD mean-risk SIP-CHEMO models?
There was little different for the EE mean-risk SIP CHEMO model, but the ASD
model performed best with lower risk values. Third, does the value of eta for the EE
mean-risk SIP-CHEMO model impact the system performance? No, there was little
variation depending on the value of η used in the experiments.
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5. INTEGRATED SIMULATION AND OPTIMIZATION FOR ONCOLOGY
CLINIC OPERATIONS
5.1 Introduction
In real complex systems, data uncertainties often evolve over time. DMs are
sometimes required to make important system decisions prior to observing uncer-
tain events. Uncertainty can occur in a number of important problem parameters
such as task duration or demand. Often the decisions epochs occur during discrete
times periods and influence future decisions. The time between each decision epoch
may be unknown. Stochastic optimization is useful in determining a combination
of stochastic conditions that would result in best system performance. Yet, even
with stochastic optimization, decision-making is not trivial. Often, it is still impos-
sible to model the system using an explicit mathematical formulation. In such case,
simulation of the system performance under a combination of conditions becomes
necessary in order to model uncertain events and evaluate possible decision options.
Information obtained from the simulation can also be used to improve the stochastic
optimization model in order to find a set of decisions that perform well under the
realization of uncertain events.
Stochastic optimization has evolved into a viable approach for decision-making
under uncertainty. However, much of the progress has been made under simplifying
assumptions such as, closed-form objective functions, precise knowledge of a static
underlying probability distribution, and decisions do not influence the future deci-
sions. In many practical applications, however, these simplifying assumptions are not
appropriate. Scheduling decisions made in one time period impact future decisions.
Therefore, simulation of the underlying system is necessary in order to make any
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data-driven decisions. Consequently, SIP alone is not always adequate for optimal
decision-making.
Discrete event simulation has been shown to be a useful tool for evaluating com-
plex systems under a given combination of conditions. However, simulation mod-
els are traditionally designed without knowledge of mathematical decision models.
Therefore, simulation alone is generally not sufficient when it comes to making op-
timal decisions under uncertainty. A new framework for combining stochastic opti-
mization with simulation is needed, whereby the stochastic optimization and system
simulation models interact and exchange information leading to solutions that adapt
to changes in system data. This chapter first defines a new framework for integrated
DEVS and mean-risk SIP, termed DEVS-SIP.
DEVS-SIP can be applied to a variety of applications with challenging decision
problems. Scheduling chemotherapy patient appointments is a challenging decision
problem that aims to determine a date, time, chair, and nurse for each appointment
in a patient’s treatment regimen that yields optimal system performance. Requests
for new chemotherapy patient appointments arrive over time and the scheduling
decision must be made right away. This type of scheduling is called online scheduling.
In online scheduling, decisions are made one-at-a-time where the current state of
the system and past decisions are known but knowledge of future events, including
future decision requests, are not known. Online scheduling is challenging because
the uncertainty in the problem makes it difficult to find an optimal solution. Future
requests for appointments also compete for the limited clinic resources, thus the
current decision impacts the future scheduling decision options. In chemotherapy
appointment scheduling, the scheduling problem is even more challenging because of
other uncertain parameters such as appointment duration, acuity levels, and resource
availability. Furthermore, the uncertainty as well as the interaction between clinic
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resources and patients makes it difficult to evaluate the scheduling decisions.
This chapter also implements the DEVS-SIP framework for oncology clinic oper-
ations. This dissertation work is the first to address uncertainty in oncology clinic
operations and scheduling by using an integrated simulation and optimization ap-
proach. The DEVS-SIP framework is developed and used as a template for combining
the DEVS-CHEMO simulation from Chapter 3 and the SIP-CHEMO models from
Chapter 4. The new model, called DEVS-SIP-CHEMO, is an integrated simulation
and optimization approach that improves the chemotherapy appointment scheduling
decisions in order to obtain better system performance.
This dissertation chapter provides details for developing and implementing DEVS-
SIP-CHEMO. Computational experiments evaluate the effectiveness of DEVS-SIP-
CHEMO. The objective of the experiments for DEVS-SIP-CHEMO is to determine
a) if using the integrated DEVS-SIP-CHEMO model to schedule patient appoint-
ments has better system performance than using SIP-CHEMO and DEVS-CHEMO
models alone; b) if yes, then how much improvement on system performance is ob-
served for each stopping criterion; c) how the results vary between the EE and ASD
versions of the SIP-CHEMO models.
The rest of this chapter is organized as follows: the DEVS-SIP framework is
described in section 5.2. Details for implementing DEVS-SIP-CHEMO, including
how to select stopping criteria, are provided in section 5.3. Computational experi-
ments were conducted and the results are discussed in section 5.4. Finally section
5.5 contains a summary of the chapter.
5.2 DEVS-SIP Framework
To integrate simulation and optimization, the literature shows that either the
optimization model is used to optimize the simulation model’s parameters or the
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simulation model is used solely to generate predictions (scenarios) for the optimiza-
tion model. A simulation and optimization framework was designed to have a strong
coupling between the simulation (DEVS) and optimization (SIP) models. The cou-
pling is strong because it is defined using the DEVS formalism and the two models
rely on one another for input. The real system of interest, which is subject to data
uncertainties, is first abstracted and modeled using both DEVS and SIP. The SIP
model captures the decision-making aspects of the system at a high level in terms of
time, while the DEVS model captures the system dynamics at a finer scale in terms
of time and space.
5.2.1 DEVS-SIP Model
The current specification of DEVS models developed by [51] is extended to realize
the DEVS-SIP paradigm. The DEVS-SIP framework described in Figure 1.1, depicts
a real system with a DM who needs to make and implement decisions for the real
system over time. Each decision arises at unknown time periods, influences future
decisions, and is subject to uncertain problem parameters. The DEVS-SIP frame-
work depicted in Figure 5.1 has a simulation model in place of the DM. In order to
model the real system and the DM, the DEVS simulation is needed to generate each
decision epoch, implement the decision, mimic the clinic operations, and capture the
system performance. This simulation, DEVS-DM, runs from time 0 to H where H
defines the length of time required for analysis, known as the simulation period. A
system database initializes DEVS-DM at time 0. This initialization step defines im-
portant system parameters from the real system and defines stochastic distributions
for sampling uncertain outcomes. Known parameters such as the number of resources
are defined during initialization. The distributions of uncertain parameters, such as
task duration or demand, are defined during initialization as well.
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Figure 5.1: The DEVS-SIP Framework for Decision-Making Under Uncertainty
DEVS-DM also portrays the role of the DM and generates a decision request i at
time ti where 0 ≤ ti ≤ H. The decision request i is modeled by the SIP model. The
SIP model has some parameters initialized from the system database, while other
details are defined by the decision request i. The SIP model, termed SIP, makes a
decision at time ti over a planning horizon of length D − ti, where D is the length
of the original planning horizon of interest. It is assumed that D > H. DEVS-DM
also provides SIP with information on previous decisions 1,2,...,i-1 that were made
during earlier decision periods.
Once the SIP model is formulated and solved, the optimization decision i is
implemented in a second simulation model, DEVS-SIM. DEVS-SIM is intended to
represent DEVS-DM beginning at time ti. Therefore DEVS-SIM is initialized using
the current simulation parameters from DEVS-DM at time ti. Decisions 1,2,...,i-
1 are also included in the initialization of the DEVS-SIM simulation. DEVS-SIM
simulates the real system from time ti to time H, and uses an algorithm to predict
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decisions i + 1, i + 2, ..., n at times t∗i , t
∗
i+1, ..., t
∗
n where ti ≤ t∗i ≤ t∗i+1 ≤ ... ≤ t∗n ≤ H
and n is the number of decision periods in the simulation period H. DEVS-SIM
is necessary in order to simulate future decision requests, predict future decisions,
realize uncertain events, and analyze the impact of the decisions in time period H.
The DEVS-SIM simulation computes performance measures which are then com-
pared to a set of stopping criteria. The stopping criteria are based on pre-established
thresholds for the performance measures that are set by the DM or their supervisor.
The stopping criteria may also be time-based in order to find a decision in an accept-
able time period. If the performance measures do not satisfy the stopping criteria,
then the performance measures are used to update the SIP model’s constraints and
parameters. The SIP is re-solved and the decision search process continues until a
decision satisfies the stopping criteria. By including the time-based stopping criteria,
such as a limit on the number of iterations spent searching for an acceptable solu-
tion, then the time-based stopping criteria is guaranteed to stop the decision search
process. Once the stopping criteria is satisfied, the final optimization decision i from
SIP is sent to DEVS-DM for implementation. DEVS-DM simulation continues until
the end of the simulation period H.
DEVS-­‐DM  
SIP  out_Parameters 
  DEVS-SIP 
out_SIPDec 
in_SIPDec_k out_Update 
out_SystemData 
out_SIPDec_k 
DEVS-­‐SIM  in_SystemData 
in_Parameters 
in_Update 
in_SIPDec 
Figure 5.2: DEVS-SIP Block Diagram
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The notation from [28] is adopted to give a detailed mathematical definition of
DEVS-SIP. The DEVS-SIP framework couples two DEVS simulation models (also
coupled models) to the SIP optimization model as shown in Figure 5.2. DEVS-
SIP has five internal couplings. First, DEVS-DM’s “out Parameters” output port is
coupled to SIP’s “in Parameters” input port while DEVS-DM’s “out SystemData”
output port is coupled to DEVS-SIM’s “in SystemData” input port. Then, SIP’s
“out SIPDec k” output port is coupled to DEVS-SIM’s “in SIPDec k” input port.
Finally, DEVS-SIM’s “out Update” output port is coupled to SIP’s “in Update”
input port and DEVS-SIM’s “out SIPDec” output port is coupled to DEVS-DM’s
“in SIPDec” input port.
DEVS-SIP Coupled Model.
DEVS-SIP = (XM , YM , D, {Md|d ∈ D}, EIC,EOC, IC) where,
XM = ∅ is the set of input ports and values;
YM = ∅ is the set of output ports and values;
D = {DEVS-DM, SIP, DEVS-SIM};
MDEVS-DM,MSIP ,MDEVS-SIM are DEVS models;
EIC = ∅ is the external input couplings;
IC = {((DEVS-DM, “out Parameters”), (SIP, “in Parameters”)),
((DEVS-DM, “out SystemData”), (DEVS-SIM, “in SystemData”)),
((SIP, “out SIPDec k”), (DEVS-SIM, “in SIPDec k”)),
((DEVS-SIM, “out Update”), (SIP, “in Update”)),
((DEVS-SIM, “out SIPDec”), (DEVS-DM, “in SIPDec”)), } is the internal cou-
plings;
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EOC = ∅ is the external output couplings.
Each input port or output port passes a message. The class message is derived
from class bag and holds instances of class content, with slots for port, p, and value,
val. The latter carries an entity instance transmitted from sender to receiver. An
entity is characterized as the base class for all classes of objects to be put into
containers. The value val can be an instance of any derived class of entity, whether
defined by the system or user. The entity passed along the internal coupling between
DEVS-DM and SIP using their respective “in SystemData” input ports is called
the SystemData entity. All entities are named after their ports such that entity X is
passed from the out X output port to the in X input port. A brief description of the
purpose of the SystemData entity and other entities in DEVS-SIP are given in Table
5.1. The entities are containers that transmit data between DEVS models. Specific
attributes and methods for each entity are dependent on the problem and application.
The attributes are next described in relation to their purpose in DEVS-SIP and to
the mean-risk SIP parameters and decision variables.
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Table 5.1: Description of DEVS-SIP Entities
Entity Brief Description
Parameters Contains parameters from the DEVS-DM simulation that are
used in the formulation of the SIP model.
SystemData Contains important parameters from the DEVS-DM simulation
that initialize the DEVS-SIM simulation, including the start
time of the DEVS-SIM simulation and any previous decisions
before time ti.
SIPDecision k Contains the decision from the SIP model that is implemented
and evaluated by the DEVS-SIM simulation.
Update Contains revised parameters for the SIP model based on evalu-
ation in the DEVS-SIM simulation model.
SIPDecision Contains the decision that meets the stopping criteria in the
DEVS-SIM simulation that is implemented in the DEVS-DM
simulation.
The Parameters entity contains parameters for the decision from the DEVS-DM
simulation that is used in the formulation of the SIP model. The Paraemters entity
defines A, b, c,W (ω), T (ω), q(ω), and r(ω) for each ω ∈ Ω. The SystemData entity
contains parameters from the DEVS-DM simulation that initialize the DEVS-SIM
simulation. These parameters include the start time of the DEVS-SIM simulation
and all decisions 1,2,...,i-1 made prior to time ti. The purpose of the SystemData
entity is to provide information that allows DEVS-SIM to replicate DEVS-DM at
time ti. Entity SIPDecision k contains the information for the decision from the SIP
model made at time ti that is implemented and evaluated by the DEVS-SIM simula-
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tion. This information is the decision variables x and y. The Update entity contains
information that revises the parameters for the SIP model based on evaluation in
the DEVS-SIM simulation model. This information includes revised parameters for
A, b, c,W (ω), T (ω), q(ω), and r(ω) for each ω ∈ Ω. Finally, the SIPDecision entity
is the decision, x and y, that met the stopping criteria in the DEVS-SIM simulation
and is then implemented in the DEVS-DM simulation.
This section detailed a new paradigm for decision-making under uncertainty in
complex problem settings. DEVS-SIP formally defines an integrated simulation and
optimization framework for use in a variety of applications. DEVS-SIP is suitable
for decision problems that cannot be formulated using a closed-form mathematical
expression and involve dynamic changes to the problem data over time. This kind of
decision-making framework is necessary in many practical applications that require
decisions over time in a rolling horizon manner.
Implementation of the DEVS-SIP framework requires coordination between the
two model types: DEVS simulation and SIP optimization. DEVSJAVA is suitable
for implementation of the DEVS model and CPLEX Concert Technology is suitable
for the SIP model. By using DEVSJAVA and CPLEX Concert Technology, DEVS-
SIP can be implemented using the Java programming language in the integrated
environment of Eclipse to allow for easy communication between the DEVS and SIP
models. The following two questions related to the iterative DEVS-SIP process are
investigated in this chapter
1. What is a suitable stopping criteria for the DEVS-SIP model?
2. What type of modifications should be made to the SIP model at each iteration?
The answers to these two questions are unique as they rely on the type of per-
formance measures used for the application. However, the following sections provide
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insight on how the stopping criteria and SIP modifications can be chosen.
5.3 DEVS-SIP-CHEMO Model
5.3.1 Overview
The DEVS-SIP framework from section 5.2 was adapted to the chemotherapy
scheduling problem at an outpatient oncology clinic. Let DEVS-CHEMO-DM be
the simulation model of the oncology clinic that serves in the role of the DM. Let
SIP-CHEMO be the optimization model that solves the chemotherapy appointment
scheduling problem using mean-risk SIP. Finally, let DEVS-CHEMO-SIM also be a
simulation model of the oncology clinic that tests decisions from SIP-CHEMO before
implementation. DEVS-CHEMO-DM and DEVS-CHEMO-SIM are both implemen-
tations of the DEVS-CHEMO model from Chapter 3.
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Figure 5.3: DEVS-SIP-CHEMO for Oncology Clinic Operations
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The details of the DEVS-SIP-CHEMO model are in Figure 5.3. DEVS-CHEMO-
DM is the primary simulation program, evaluated from time period 0 to H, that
mimics the the oncology clinic operations. When DEVS-CHEMO-DM generates
appointment request i at time ti, the scheduler (SCHED atomic model) within DEVS-
CHEMO-DM utilizes SIP-CHEMO to make decision i. The SIP-CHEMO model
formulates the problem with deterministic and stochastic parameters to determine
a schedule for all of the patient’s chemotherapy appointments from appointment
request i that fall within decision period D.
Once the schedule is determined, DEVS-CHEMO-SIM implements the scheduling
decision i as well as past scheduling decisions 1,2,...,i-1 that have already been made.
Possible future decisions i + 1, i + 2, ..., n are also generated and implemented in
DEVS-CHEMO-SIM at times t∗i , t
∗
i+1, ..., t
∗
n where n is the last decision in simulation
period H. DEVS-CHEMO-SIM simulates oncology clinic operations from time ti
until H. The system performance from DEVS-CHEMO-SIM is evaluated and used
to modify SIP-CHEMO. This process continues until the stopping criteria are met.
Suggestions for determining the stopping criteria are discussed later in this section.
Once decision i from the SIP-CHEMO model leads to performance measures from
the DEVS-CHEMO-SIM simulation model that satisfy the stopping criteria, then
decision i is implemented in DEVS-CHEMO-DM. This process continues until the
end of time period H.
5.3.2 Chemotherapy Scheduling Problem and the DEVS-SIP Framework
The nature of the chemotherapy appointment scheduling problem makes the prob-
lem suitable for the DEVS-SIP framework which combines simulation and optimiza-
tion for improved decision-making. Table 5.2 shows how the DEVS-SIP framework
addresses each challenging attribute of the chemotherapy scheduling problem.
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Table 5.2: Attributes of the Chemotherapy Scheduling Problem and the DEVS-SIP
Framework
Attributes DEVS-SIP Approach
Decision epochs DEVS-CHEMO-DM generates appointment requests one-at-
a-time.
Uncertain parame-
ters
SIP-CHEMO is a SIP model of the chemotherapy appoint-
ment scheduling decision.
Unknown future
appointment re-
quests
DEVS-CHEMO-SIM generates future appointment requests
and uses an algorithm to make and subsequently implement
possible future scheduling decisions.
Realization of un-
certainty
DEVS-CHEMO-DM and DEVS-CHEMO-SIM each imple-
ment realizations of different scenarios (e.g., appointment du-
ration, acuity levels, etc.).
Impact of decision
on future decisions
Decisions made by SIP-CHEMO are implemented in DEVS-
CHEMO-SIM along with possible future appointment re-
quests and their possible scheduling decisions.
Complex resource
interactions
DEVS-CHEMO-DM and DEVS-CHEMO-SIM are simula-
tions that models the complex behavior of each resource (re-
ceptionist, pharmacists, nurses, chairs).
Risk Risk is modeled using mean-risk SIP-CHEMO.
Patient requests for appointment schedules are scheduling decisions that arise over
time. The first simulation model, DEVS-CHEMO-DM, simulates the appointment
requests. The uncertain problem parameters such as acuity levels, appointment
duration, and resource availability motivate the need to use the SIP-CHEMO models
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to determine the patient’s appointment schedule. Additionally, the mean-risk SIP-
CHEMO models allow the DM to make risk-averse decisions in order to keep the
waiting time, system time, and overtime low. Because the decisions have to be
made online with only current knowledge of the system, an integrated simulation
and optimization approach is needed.
After SIP-CHEMO makes an appointment schedule for the patient, DEVS-CHEMO-
SIM implements the decision, along with previous decisions, and simulates future ap-
pointment requests and uses an algorithm to predict those decisions. The realization
of uncertain parameters as well as the complexity of patient and resource interac-
tions are also handled by the DEVS-CHEMO-SIM simulation model. The results of
the DEVS-CHEMO-SIM simulation model are used to update SIP-CHEMO and this
process continues until an acceptable level of system performance is met. DEVS-SIP-
CHEMO allows the scheduler to make a set of decisions and revise those decisions
once they have been evaluated through simulation. Once the decisions have met
the one of the stopping criteria set by the scheduler, the decisions are implemented
in the DEVS-CHEMO-DM simulation model. Similar to the DEVS-CHEMO-SIM
simulation, this model also incorporates the realization of uncertainty and simulates
clinic resources and patients.
5.3.3 Block Diagram and Entities
The DEVS-SIP-CHEMO entities that are sent and received through the input
and output ports (Figure 5.4) are listed in Table 5.3. The Parameters entity defines
A, b, c,W (ω), T (ω), q(ω), and r(ω) for each ω ∈ Ω for the SIP-CHEMO model. The
Parameters entity is created in the DEVS-CHEMO-DM simulation model when an
appointment request is generated. Tables 4.1 and 4.2 list specific attributes for the
Parameters entity.
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Figure 5.4: DEVS-SIP-CHEMO Block Diagram
The SystemData entity contains important parameters from the DEVS-CHEMO-
DM simulation that initialize the DEVS-CHEMO-SIM simulation at time ti. The
attributes of the SystemData entity include the start time ti and the previous deci-
sions 1,2,...,i-1 before time ti for the chair, nurse, and patient appointment schedules.
Information about about oncology clinic setting such as the number of resources,
service time distributions, etc. are also included. The purpose of the SystemData
entity is to provide information that allows DEVS-CHEMO-SIM to be a duplicate
of DEVS-CHEMO-DM at time ti.
Entity SIPDecision k contains the information for the decision from the SIP-
CHEMO model made at time ti that is implemented and evaluated by the DEVS-
CHEMO-SIM simulation. This information is the decision variables x, y(ω), and
ν(ω). The Update entity includes updated parameters for A, b, c,W (ω), T (ω), q(ω),
and r(ω) for each ω ∈ Ω that is used to revise the parameters for the SIP-CHEMO
model based on evaluation in the DEVS-CHEMO-SIM simulation model. Finally, the
SIPDecision entity is the decision, x, y(ω), and ν(ω), that met the stopping criterion
in the DEVS-CHEMO-SIM simulation; it is the decision that is to be implemented
in the DEVS-CHEMO-DM simulation.
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Table 5.3: Description of DEVS-SIP-CHEMO Entities
Entity Brief Description
Parameters A, b, c and W (ω), T (ω), q(ω), and r(ω) for each ω ∈ Ω.
SystemData Start time ti of the DEVS-CHEMO-SIM simulation and previ-
ous decisions 1,2,...,i-1 before time ti for the chair, nurse, and
patient appointment schedules. Information about about oncol-
ogy clinic setting such as the number of resources, service time
distributions, etc. are also included.
SIPDecision k Decisions x, y(ω), and ν(ω) from the SIP-CHEMO model which
specify the start date and time for each appointment as well as
the chair and nurse resource assignments.
Update Contains revised parameters for the SIP-CHEMO model
based on evaluation from the DEVS-CHEMO-SIM simulation
model. The update entity has revisions for the A, b, c and
W (ω), T (ω), q(ω), and r(ω) for each ω ∈ Ω parameters.
SIPDecision Contains the decision, x, y(ω), and ν(ω), that met the stop-
ping criterion in the DEVS-CHEMO-SIM simulation and is to
be implemented in the DEVS-CHEMO-DM simulation.
5.3.4 Stopping Criteria
The stopping criteria for each application is determined by the DM or their super-
visor. In oncology clinic operations, the scheduler is the DM. Stopping criteria should
be based on the performance measures. In the case of chemotherapy appointment
scheduling, performance measures are collected from both the patient and manage-
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ment’s perspective. The patient’s perspective performance measures are type I delay,
type II delay, type III delay, and system time. Type I delay is the difference between
the prescribed start date and the actual start date of the first appointment. Type II
delay is the time elapsed between the patient’s arrival to the clinic and the time the
patient is called by the registered nurse. The delay patient’s experience after being
called for treatment but before the chemotherapy drug infusion begins is called the
type III delay. System time is the total time that the patient is in the oncology
clinic, from arrival to discharge. From the management’s perspective, the through-
put, resource utilization, and nurse overtime are important performance measures.
Throughput is the total number of patient appointments the clinic has during a de-
fined time period. Resource utilization measures the percent of time that a resource
is used during a day. Nurse overtime is the amount of time that nurses stay beyond
the clinic closing time to finish assisting patients receiving treatment.
The DM should analyze each performance measure and identify which measures
are suitable stopping criteria. A starting point is to select stopping criteria with
high variation in order to set thresholds so that the iteration between the simulation
and optimization models drive the performance measure toward a targeted threshold
value. Additionally, the measures chosen should be related to the new patient that
was most recently scheduled at time ti by SIP-CHEMO because this schedule is
the only one that can be modified on the next iteration between SIP-CHEMO and
DEVS-CHEMO-SIM. This patient’s schedule relates to appointment (or decision)
request i, so this patient will now be referred to as patient i.
In the DEVS-CHEMO-SIM simulation, the type I delay is already known be-
cause the decision of when to start the appointment for patient i has already been
determined. Thus, type I delay can be measured without simulation for patient i.
The results from the simulations in Chapters 3 and 4 showed small changes across
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decision models for the type III delay values, thus there is little to be gained by
targeting this performance measure. Therefore, the focus on stopping criteria from
the patient perspective is on the system time and the type II delay. Since the system
time is dependent on the patient’s treatment regimen, this performance measure is
modified to be the time beyond the expected system time, which will be referred to
as the system time+.
From the management’s perspective, the throughput, resource utilization, and
nurse overtime performance measures can be evaluated with DEVS-CHEMO-SIM.
Patient i’s schedule does impact throughput, but it can be difficult to determine
whether this is a positive or negative impact and how to adjust the scheduling deci-
sion to obtain improvement. Resource utilization is similar to type II delay in that
there was little variation in previous computational experiments. Nurse overtime was
identified as an important measure for the clinic collaborating on this study. Because
of this and the high variation in overtime results in the previous experiments, nurse
overtime is a strong candidate for the stopping criteria from the management’s per-
spective. However, the stopping criteria should relate to patient i. Note that nurses
stay overtime if a patient stays overtime. Therefore, patient overtime, or the amount
of time that patient i stays beyond clinic operating hours, is used to estimate nurse
overtime.
As previously mentioned, some of the stopping criteria may also be time-based
in order to find a decision in a timely manner. The scheduler can consider setting
a maximum time (e.g., 30 seconds) on the total time it takes to iterate between
SIP-CHEMO and DEVS-CHEMO-SIM models or set a maximum number of itera-
tions. It was determined through preliminary computational experiments that the
latter, setting a maximum number of iterations works well for the chemotherapy
appointment scheduling problem.
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Table 5.4: Stopping Criteria for DEVS-SIP-CHEMO
Stopping Criteria Performance Measure Suggested Threshold Values
(A) Patient Overtime 0 minutes
(B) Type II Delay 15 minutes
(C) System Time+ 15 minutes
(D) Max Number Iterations 10 iterations
A threshold value is required for each performance measure that serves as a
stopping criterion. The threshold values represent a target value for each performance
measure. Table 5.4 shows each performance measure selected as a stopping criterion
in DEVS-SIP-CHEMO as well as suggested threshold values. In order to drive nurse
overtime down to 0 minutes, the patient overtime threshold is 0 minutes. Therefore,
when stopping criterion (A) (patient overtime) is invoked, if the DEVS-CHEMO-SIM
simulation runs indicate patient i stayed overtime (> 0 minutes) for an appointment,
then the SIP-CHEMO model will reschedule patient i’s appointments on the next
iteration. A suggested threshold value of 15 minutes is used for the type II delay and
system time+ performance measures. If patient i’s type II delay exceeds 15 minutes
when stopping criterion (B) is invoked or if patient i stays longer than 15 minute past
their expected appointment time when stopping criterion (C) is invoked, then the
patient’s appointments are rescheduled on the next iteration between the simulation
and optimization model.
The fourth stopping criterion is important because it specifies a maximum num-
ber of iterations between the SIP-CHEMO and DEVS-CHEMO-SIM models for each
patient scheduled. When stopping criterion (D) is invoked, then at most 10 itera-
tions occur between the simulation and optimization models to determine patient
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i’s schedule. This achieves two things: 1) limits the time spent searching for an
improved solution to 10 attempts total, 2) guarantees that a solution will be found
and the search process will not enter an infinite loop.
5.3.5 Modifications
Now that performance measures have been selected, it is important for the sched-
uler to also determine how the results can update the SIP-CHEMO model. This can
be achieved a number of ways. For example, the objective can be modified, parame-
ters can be changed, or constraints can be added. The important concept is that the
modifications should be built off the the performance measure that caused the ad-
justment. For example, if the performance measures indicate a high level of patient
overtime, then the penalty for overtime could be increased in the SIP-CHEMO objec-
tive. Several modifications based on stopping criteria A, B, and C were investigated.
The most effective modifications found for DEVS-SIP-CHEMO are summarized in
Table 5.5. Two types of modifications are shown for the patient overtime (A) stop-
ping criterion and one modification each is shown for the type II delay (B) stopping
criterion and the system time+ (C) stopping criterion. Next is a description of these
modifications.
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Table 5.5: SIP-CHEMO Modifications in the DEVS-SIP-CHEMO Model
Modification Stopping Criterion Modification
(1) (A) Patient Overtime Add constraint: block start date in fu-
ture schedules
(2) (A) Patient Overtime Change parameter: increase appoint-
ment duration by one time slot
(3) (B) Type II Delay Add constraint: block appointment’s
starting time slot
(4) (C) System Time+ Add constraint: block appointment’s
starting time slot
Modification (1): Blocking a Start Date
One objective of the SIP-CHEMO model is to start patients as early in the
day as possible in order to avoid unnecessary gaps in the schedule. This objective
was achieved by setting penalties for each time slot via the δslots penalty parameter.
Once a possible scheduling decision for patient i is suggested by SIP-CHEMO and
implemented in DEVS-CHEMO-SIM, the simulation capture’s the patient overtime
for every appointment t that occurs during the simulation horizon H. If any of the
patient overtime values for these appointments exceeds the threshold for stopping
criterion (A), then modification (1) can be invoked on the next iteration in SIP-
CHEMO. If appointment tˆa¯i caused patient i’s overtime on iteration a¯i, then the
scheduler presumes that the appointment was already scheduled to start at one of
the earliest time slots on that day as possible. Therefore, selecting an alternative
time slot, chair assignment, or nurse assignment, on the same day for appointment
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tˆa¯i is unlikely to show improvement in patient i’s overtime. Because the spacing in
the patient’s treatment regimen is strict, then appointment tˆa¯i ’s date is dependent
on the start date for patient i which is referred to as start date dˆa¯i . This motivates
the use of modification (1), which adds a constraint to block the start date dˆa¯i from
patient i’s future schedules. Using the notation for SIP-CHEMO that was introduced
in Chapter 4, then the following constraint can be added to the SIP-CHEMO model:
xdˆa¯i
= 0 ∀a¯i ∈ A¯i
where A¯i is the set of iterations in which stopping criterion (A) was violated for
patient i. If modification (1) is being used, then the constraint remains in effect
for each iteration a¯i of SIP-CHEMO for patient i so that the start date dˆa¯i is not
selected again.
Modification (2): Increasing Appointment Duration
Once a possible scheduling decision for patient i is suggested by SIP-CHEMO and
implemented in DEVS-CHEMO-SIM, the simulation capture’s the patient overtime
for every appointment t that occurs during the simulation horizon H. If any of the
patient overtime values for these appointments exceeds the threshold for stopping
criterion (A), then modification (2) can be invoked on the next iteration in SIP-
CHEMO. If appointment tˆa¯i caused patient i’s overtime on iteration a¯i, then one
solution is to increase the expected duration of appointment tˆa¯i . By doing so, one
of two things can occur. On the next iteration, the appointment may occur on the
same day, but start earlier or receive a different chair or nurse assignment. Otherwise,
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because the appointment is expected to last longer, it may be best to change the
appointment date. This modification allows the model to determine whether it is
best to modify the start date and thus impact the type I delay or to simply chose
another assignment on this same day. Using the notation for SIP-CHEMO that
was introduced in Chapter 3, then modification (2) forces the following parameter
changes:
Original Value Modified Value
rtˆa¯i rtˆa¯i + |A¯i|
rtˆa¯i (ω) rtˆa¯i (ω) + |A¯i|
where A¯i is the set of iterations in which stopping criterion (A) was violated for
patient i. If modification (2) is being used, then the number of time slots increases
by one for each time that the stopping criterion was violated until the scheduled
appointment time is early enough to avoid overtime for patient i.
Modification (3): Block Appointment Time Slot for Type II Delay
DEVS-CHEMO-SIM also captures the type II delay for every appointment t
for patient i that occurs during simulation horizon H. If any of the type II delay
values for these appointments exceeds the threshold for stopping criterion (B), then
modification (3) is invoked on the next iteration in SIP-CHEMO. If appointment tˆb¯i
caused patient i’s type II delay on iteration b¯i to exceed the threshold on day dˆb¯i , then
one solution is to block the time slot, sˆb¯i , that was scheduled for appointment tˆb¯i on
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day dˆb¯i . This modification was chosen on the basis that a number of other patients
are scheduled at the same time and the combination of all appointments, acuity
levels, etc. caused a delay for patient i’s appointment tˆb¯i on day dˆb¯i . Modification
(3) moves this appointment to another time slot on either the same or a different
day. The additional constraint also blocks all possible chair assignments at this time,
too. Using the notation for SIP-CHEMO that was introduced in Chapter 4, then
the following constraint can be added to the SIP-CHEMO model:
∑
k∈Kdˆb¯i
y
dˆ
tˆb¯i
b¯i
ksˆb¯i
= 0 ∀b¯i ∈ B¯i
where B¯i is the set of iterations in which stopping criterion (B) was violated for
patient i. If modification (3) is used, then the constraint remains in effect for each
iteration b¯i in SIP-CHEMO for patient i so that the start slot sˆb¯i on day dˆb¯i for
appointment tˆb¯i is not used again.
Modification (4): Block Appointment Time Slot for System Time
Modification (4) is the same as modification (3) except that it is invoked for
when stopping criterion (C) based on system time+ exceeds the threshold value. If
appointment tˆc¯i caused patient i’s system time
+ on iteration c¯i to exceed the thresh-
old on day dˆc¯i , then one solution is to block the time slot, sˆc¯i , that was scheduled
for appointment tˆc¯i on day dˆc¯i . This modification was chosen on the basis that a
number of other patients are scheduled at the same time and the combination of all
appointments, acuity levels, etc. caused a delay for patient i’s appointment tˆc¯i on
day dˆc¯i . Modification (4) is as follows:
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∑
k∈Kdˆc¯i
y
dˆ
tˆc¯i
c¯i
ksˆc¯i
= 0 ∀c¯i ∈ C¯i
where C¯i is the set of iterations in which stopping criterion (C) was violated for
patient i. If modification (4) is used, then the constraint remains in effect for each
iteration c¯i in SIP-CHEMO for patient i so that the start slot sˆc¯i on day dˆc¯i for
appointment tˆc¯i is not used again.
5.4 Computational Experiments
The DEVS-SIP-CHEMO model was analyzed using data from a real outpatient
oncology clinic. The design of experiments for DEVS-SIP-CHEMO is described in
the first subsection. The second subsection gives experiment results and discusses
their implications.
5.4.1 Design of Experiments
The objective of the design of experiments for DEVS-SIP-CHEMO is to de-
termine: a) if using the integrated DEVS-SIP-CHEMO model to schedule patient
appointments has better system performance than using SIP-CHEMO and DEVS-
CHEMO models alone; b) if yes, then how much improvement on system performance
is observed for each stopping criterion; c) how the results vary between the EE and
ASD versions of the SIP-CHEMO models.
To test the DEVS-SIP-CHEMO model, the DEVS-CHEMO simulation and the
SIP-CHEMO models from the previous two chapters were used. The experiments
utilized data from the outpatient oncology clinic at Scott & White Hospital in Tem-
ple, Texas. The clinic was open five days a week for nine hours each day. There were
between four to eight registered nurses and seventeen chemotherapy chairs available
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each day. The patients were sampled from a database of historical patient data from
a five-month period at the Scott & White oncology clinic. The database contained
five-hundred and five model patients. There were an average of four appointments
per treatment regimen. The maximum acuity a single registered nurse can have at
one time was assumed to be five.
All experiments assumed a four-month planning horizon H and a one-month
simulation period D. Time slots were assumed to be thirty minutes each, thus there
are eighteen time slots in each day. Creating scenarios was an important part of the
experimental design for the SIP-CHEMO models. The twelve scenarios developed in
Table 4.6 were used in the DEVS-SIP-CHEMO experiments and the penalty values
are kept the same for the SIP-CHEMO models. All DEVS-CHEMO variables from
the experiments in Chapter 3 were used again, unless otherwise specified. The DEVS-
CHEMO-SIM simulation model used the ASAP algorithm from Chapter 3 to predict
the schedules of future patients i+ 1, i+ 2, ...n. The SIP-CHEMO model uses either
the EE or ASD models for risk-averse decision-making. In both models, λ value is
0.5 and EE uses η = 1 ∗ S¯ ∗ amax.
To test the DEVS-SIP-CHEMO design of experiments objectives, a combination
of stopping criteria, modifications, and threshold values was developed in a total of
fourteen experiments, which are listed in Table 5.6. The ASD and EE experiments
use only SIP-CHEMO to schedule patients and the “-” value for the three columns
indicates that none of the stopping criteria or modifications were used. Next, the
modifications (1)-(4) were implemented for the EE and ASD algorithms as EE 1-
EE 4 and ASD 1- ASD 4 respectively. The fifth (EE 5 and ASD 5) and sixth (EE 6
and ASD 6) experiments combined modifications (1) and (3) and then (2) and (4)
respectively to determine if multiple improvements in performance measures can
be achieved at the same time. All experiments using stopping criteria have the
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stopping criterion (D) time-based performance measure which limits the total number
of iterations to ten. As mentioned earlier, this is useful for reducing speed and
guaranteeing that a solution can be found.
Table 5.6: DEVS-SIP-CHEMO Experiments
Name Stopping Criterion Modification Threshold Values
EE - - -
EE 1 (A),(D) (1) 0 minutes, 10 iterations
EE 2 (A),(D) (2) 0 minutes, 10 iterations
EE 3 (B),(D) (3) 15 minutes, 10 iterations
EE 4 (C),(D) (4) 15 minutes, 10 iterations
EE 5 (A),(B),(D) (1),(3) 0 minutes, 15 minutes, 10 iterations
EE 6 (A),(C),(D) (2),(4) 0 minutes, 15 minutes, 10 iterations
ASD - - -
ASD 1 (A),(D) (1) 0 minute, 10 iterations
ASD 2 (A),(D) (2) 0 minutes, 10 iterations
ASD 3 (B),(D) (3) 15 minutes, 10 iterations
ASD 4 (C),(D) (4) 15 minutes, 10 iterations
ASD 5 (A),(B),(D) (1),(3) 0 minutes, 15 minutes, 10 iterations
ASD 6 (A),(C),(D) (2),(4) 0 minutes, 15 minutes, 10 iterations
Preliminary experiments were conducted to determine the threshold values for
each stopping criterion. These values were eluded to earlier in Table 5.4. The Scott
& White oncology clinic wishes to eliminate nurse overtime. Thus the lowest possible
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threshold value of 0 minutes was selected for the patient overtime stopping criteria.
Preliminary results showed that a target value of 0 minutes helped drive the nurse
overtime towards 0 minutes and still allowed the solution search process to end
quickly. Therefore, 0 minutes was used as the threshold value for patient overtime.
For the system overtime+ and type II delay performance measures, it was assumed
that patients would be willing to wait between 0 to 15 minutes for their appointment
to begin. Therefore, 15 minutes was implemented for a threshold value for both
performance measures. Again, this value lent itself toward quick and meaningful
solution results. Preliminary testing also experimented with reducing the threshold
value to 5 or 10 minutes for type II delay and system overtime+, but results showed
that little or no improvement could be made and only slowed down the search process.
The maximum number of iterations was also used as a stopping criterion and this
value was set to ten iterations. In the experiments, patient schedule iterations in
DEVS-SIP-CHEMO had an average of 2-3 iterations. In most experiments, between
eight to fifteen patient schedules (2-6%) required the upperbound of ten iterations
to find a solution.
In all DEVS-SIP-CHEMO experiments listed in Table 5.6, the system perfor-
mance was captured by simulating the clinic performance for one-month. There
were 172 patients initially used to fill the schedule with 5 to 6 additional patients
generated each day. During the one-month simulation period, DEVS-SIP-CHEMO
schedules 276 patients. DEVS-SIP-CHEMO provides system performance results on
the type I delay, type II delay, type III delay, system time, throughput, chair uti-
lization, nurse utilization, and nurse overtime. The total throughput is a measure of
how many appointments occurred during the simulation period. Average run times
in seconds for each experiment variation are also stated in the results section.
The throughput results are reported as the total throughput, or appointments
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(appts.), for the month and the average daily throughput. The nurse overtime is re-
ported in two different ways. The nurse overtime+ count is the number of nurses that
had to work overtime in the five-month period and nurse overtime+ is the average
of the overtime required during these instances (zero entries are excluded). Nurse
overtime is the average overtime among all nurses during the one-month simulation
period (zero entries included). The next subsection provides the average for the each
of these performance measures over the ten replications for each experiment. Ten
replications were sufficient for obtaining observable improvement over the previous
scheduling algorithms and models. The simulations were conducted on a Dell Pre-
cision T7500 with an Intel(R) Xeon(R) processor running at 2.4 GHz with 12.0 GB
RAM.
5.4.2 Results and Discussion
This subsection first compares the DEVS-CHEMO, SIP-CHEMO, and DEVS-
SIP-CHEMO models. Results for DEVS-SIP-CHEMO are then discussed for the EE
and ASD models separately under different combinations of stopping criteria and
modifications. General observations are also made about stopping criteria used in
DEVS-SIP-CHEMO.
Comparison of the Three Models: DEVS-CHEMO, SIP-CHEMO, and
DEVS-SIP-CHEMO
The DEVS-CHEMO (simulation), SIP-CHEMO (optimization), and DEVS-SIP-
CHEMO (simulation and optimization) models were tested under the same condi-
tions and the results are depicted in Table 5.7. The ASAP algorithm was used to rep-
resent the DEVS-CHEMO model. The EE model with λ = 0.5 and η = 1∗S¯∗amax was
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used for SIP-CHEMO and DEVS-SIP-CHEMO. Additionally, the constraints from
EE 5 were used for the DEVS-SIP-CHEMO model. In the results, DEVS-CHEMO
had the lowest type I delay of 1.35 days. The SIP-CHEMO model had the highest
throughput of 474 appointments. The DEVS-SIP-CHEMO model, which targeted
patient overtime and type II delay, had the lowest nurse overtime of 1 minute (re-
duced more than 90%), lowest nurse overtime+ of 19 minutes (reduced 67%), lowest
type II delay of 11 minutes (reduced 36% to 61%), and lowest system time of 199
minutes (reduced by 4% and 9%).
DEVS-SIP-CHEMO holds throughput within 1% when compared to both DEVS-
CHEMO and SIP-CHEMO. Type I delay for DEVS-SIP-CHEMO is within 1% of
SIP-CHEMO and only 0.31 days longer (23% increase) when compared to DEVS-
CHEMO. Additionally, the average run times increase from 1 second with DEVS-
CHEMO, to 94 seconds with SIP-CHEMO, to 541 seconds with DEVS-SIP-CHEMO.
The scheduler can improve patient satisfaction with lower type II delay, type III
delay, and system time and reduce nurse overtime by 90% using DEVS-SIP-CHEMO
without sacrificing much on throughput and type I delay. Thus, DEVS-SIP-CHEMO
supersedes the performance of using simulation or optimization alone.
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Table 5.7: Performance Results for Scheduling Models
Models
Performance Measures (units) DEVS- SIP- DEVS-SIP-
CHEMO CHEMO CHEMO
Total Throughput (appts.) 466.0 474.3 467.7
Daily Throughput (appts.) 23.3 23.7 23.4
Chair Utilization (%) 49.40 50.06 48.86
Nurse Utilization (%) 75.04 74.76 71.36
Nurse Overtime+ (min.) 58.00 57.26 19.15
Nurse Overtime+ Count 46.61 28.90 8.90
Nurse Overtime (min.) 22.19 13.94 1.36
Type I Delay (days) 1.35 1.64 1.66
Type II Delay (min.) 28.11 17.07 10.87
Type III Delay (min.) 32.26 32.65 31.85
System Time (min.) 218.40 206.51 198.51
Simulation Run Time (sec.) 1.59 93.85 540.68
Results for EE
The results for DEVS-SIP-CHEMO using the EE model are listed in Table 5.8.
EE (SIP-CHEMO) has one of the highest throughput values (474 appointments) and
lowest type I delay (1.64 days), but the model performs poorly for other performance
measures with the highest nurse overtime, nurse overtime+, type II delay, and sys-
tem time. DEVS-SIP-CHEMO holds the throughput and type I delay values to an
acceptable level and makes improvements on the other performance measures. Con-
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sider the total throughput in Figure 5.5 and the type I delay (details in Table 5.8).
Most of the experiments EE 1 - EE 6 which use DEVS-SIP-CHEMO have lower to-
tal throughput than EE by 3 to 8 appointments; EE 4 is the one exception. This is
because patient appointments may have to be spread out over more days (thus lower
daily throughput) in order to achieve acceptable levels of overtime, system time, etc.
The lowest throughput (466 appointments) was observed for EE 2 in which roughly
eight fewer appointments during the one-month simulation period. The highest type
I delay was observed for EE 1 (1.76 days) but the value is still less than 2 days for
type I delay and is only a 7% change from EE. The results for the type III delay and
resource utilization did not yield any interesting patterns for the DEVS-SIP-CHEMO
analysis and are not discussed, though the values for these performance measures are
in Table 5.8.
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Figure 5.5: Results for Throughput for EE
Next, refer to Figure 5.6 which shows results for the nurse overtime+, nurse
overtime, and type II delay. When looking at the two measures for nurse overtime,
the results show that EE 1, EE 2, EE 5, and EE 6 were successful in driving the
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patient overtime, and subsequently the nurse overtime+ and nurse overtime, towards
zero. All four of these experiments have lower nurse overtime+ values than the other
three experiments (EE, EE 3, and EE 4) by 18% (10 minutes) to 66% (38 minutes)
and lower nurse overtime by 18% (2 minutes) to 90% (12 minutes). In fact, when
reducing patient overtime (A) is combined with reducing type II delay (B) and system
time (C) in experiments EE 5 and EE 6 respectively, the lowest values were observed
with 19 to 25 minutes for nurse overtime+ and 1 to 2 minutes for nurse overtime.
Additionally, refer to Figure 5.7 which shows the average man-hours of overtime
for the clinic. When patient overtime (A) is not targeted by DEVS-SIP-CHEMO
(EE, EE 3, EE 4), then over 22 man-hours of overtime are required by the oncology
clinic nurses during the one-month period. However, when patient overtime (A) is
targeted in EE 1 and EE 2 then this value is reduced to six or seven hours. Nurse
overtime+ man-hours were further reduced to two to four hours a month when other
performance measures (B) or (C) are also targeted by DEVS-SIP-CHEMO in EE 5
and EE 6.
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Figure 5.6: Results for Time-Based Performance Measures for EE
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Figure 5.7: Results for Nurse Overtime+ Man-Hours for EE
Also depicted in Figure 5.6 is the type II delay for all EE DEVS-SIP-CHEMO
experiments. The type II delay was highest at 17 minutes for EE and EE 2, in which
the type II delay was not targeted. However, for experiments EE 3 and EE 5 where
type II delay was targeted, then the type II delay was reduced to 10 minutes, roughly
a 40% reduction. Figure 5.8 graphically depicts the system time average for the seven
EE DEVS-SIP-CHEMO experiments. Like the type II delay, the system time was
highest for EE with 207 minutes. In the EE 3, EE 4, EE 5, and EE 6 experiments,
the system time is lower at 198 to 199 minutes. Interestingly, the lowest system
time occurs in EE 5 when the type II delay was targeted because type II delay is
a component of system time. For the case of EE 5, the total improvement was
an 8 minute reduction in system time over the EE experiment without DEVS-SIP-
CHEMO. The average (AVG), standard deviation (STDEV), and 90% confidence
interval (CI) for the EE 5 experiments are listed in Appendix C.1 in Table C.1.
Data for the other EE DEVS-SIP-CHEMO experiments was intentionally omitted
for conciseness.
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Figure 5.8: Results for System Time for EE
Results for ASD
The results for the ASD DEVS-SIP-CHEMO results are listed in Table 5.9. ASD
(SIP-CHEMO) has one of the highest throughput values (474 appointments) and the
lowest type I delay (1.54 days), but the model has the highest nurse overtime+, nurse
overtime, type II delay, and system time. DEVS-SIP-CHEMO holds the throughput
and type I delay values to an acceptable level and makes improvements upon the
other performance measures. Consider the total throughput in Figure 5.9 and the
type I delay (details in Table 5.9). Most of the experiments ASD 1 - ASD 6 which
use DEVS-SIP-CHEMO have lower throughput than ASD. The exception to this is
ASD 3 which has higher total throughput of 476 appointments. The lowest through-
put (452 appointments) occurred for ASD 5 which also has the lowest average type
II delay of 10 minutes. ASD, ASD 1, and ASD 2 have the highest type II delay
of 14 to 15 minutes. The results for the type III delay and resource utilization did
not yield any interesting patterns for the DEVS-SIP-CHEMO analysis and are not
discussed, though the values for these performance measures are in Table 5.9.
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Figure 5.9: Results for Throughput for ASD
Next, refer to Figure 5.10 which shows results for the nurse overtime+, nurse
overtime, and type II delay. When looking at the two measures for nurse overtime,
the results show that ASD 1, ASD 2, ASD 5, ASD 6 all drive the patient overtime,
and subsequently the nurse overtime+ and nurse overtime, towards zero. All four of
these experiments have lower nurse overtime+ values. In fact, when reducing patient
overtime (A) is combined with reducing type II delay (B) and system time (C)
in experiments EE 5 and EE 6 respectively, then the results are best for overtime.
Additionally, refer to Figure 5.11 which shows the average man-hours of overtime for
the clinic. When patient overtime (A) is not targeted by DEVS-SIP-CHEMO, then
over 23 man-hours of overtime are required by the oncology clinic nurses during the
one-month period. However, when patient overtime (A) is targeted alone then this
value is reduced to 5 or 6 hours and reduced to 3 or 4 hours a month when other
performance measures (B) or (C) are also targeted by DEVS-SIP-CHEMO in ASD 5
and ASD 6.
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Figure 5.10: Results for Time-Based Performance Measures for ASD
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Figure 5.11: Results for Nurse Overtime+ Man-Hour for ASD
Also depicted in Figure 5.10 is the type II delay for all seven ASD DEVS-SIP-
CHEMO experiments. The type II delay was highest at 14 to 15 minutes for ASD,
ASD 1, and ASD 2, in which the type II delay was not targeted. However, for
experiments ASD 3 and ASD 5 where type II delay was targeted, then the type
II delay was reduced to 10 or 11 minutes, roughly a 30% reduction. Figure 5.12
graphically depicts the system time average for the seven ASD DEVS-SIP-CHEMO
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experiments. Like the type II delay, the system time was highest for ASD with
around 204 minutes. In the ASD 4, ASD 5, and ASD 6 experiments, the system
time is less than 200 minutes. The lowest system time value occurs in ASD 5 when
the type II delay was targeted. For the case of ASD 5, the total improvement was a
six minute reduction in system time from the ASD experiment without DEVS-SIP-
CHEMO. The AVG, STDEV, and 90% CI for the ASD 6 experiments are listed in
Appendix C.1 in Table C.2. The same data for the other ASD DEVS-SIP-CHEMO
experiments was intentionally omitted for conciseness.
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Figure 5.12: Results for System Time for ASD
General Observations
It is apparent in the results that it is difficult to simultaneously optimize all
performance measures at once. Typically, a model with a high throughput value
also has low type I delay but the system time, overtime, etc. are all higher. If
the primary objective of the clinic is to achieve a high throughput and low type
I delay, then DEVS-SIP-CHEMO is not valuable. However, if the clinic prefers
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to keep throughput and type I delay at acceptable levels, but to make noticeable
improvements in other performance measure, then DEVS-SIP-CHEMO is suitable
for such a task.
DEVS-SIP-CHEMO does work improve targeted performance measures. Because
type II delay is a component of system time, then results show that targeting either
one of these values also yields improvement in the other. In general, targeting mul-
tiple performance measures yielded better results than targeting each performance
measure individually. In the EE DEVS-SIP-CHEMO experiments, EE 5, which uses
stopping criteria for patient overtime (A) and type II delay (B) and modifications
(1) and (3), yielded the best results all around. This decision is based on the fact
that EE 5 has high total throughput and low type I delay and system time (within
1% to 3%), but also yields improvements in nurse overtime (90%), nurse overtime+
(67%), and type II delay (36%) over using SIP-CHEMO alone.
In the ASD DEVS-SIP-CHEMO experiments, ASD 6, which uses stopping cri-
teria for patient overtime (A) and system time (C) and modifications (2) and (4),
yielded the best results all around. This decision is based on the fact that ASD 6
has acceptably high total throughput but also yields low values for nurse overtime
(4 minutes), type II delay (12 minutes), and system time (200 minutes). EE 5 is
preferred to ASD 6 because it has slightly higher total throughput (by 1 patient),
smaller type I delay (by 0.1 days), type II delay (by 1 minute), nurse overtime+ (by
8 minutes), nurse overtime (by <1 minute), and system time (by 1 minute).
5.4.3 Feasibiliy of Implementation in a Real Oncology Clinic
An important point that has yet to be discussed, is how practical would it be
to utilize DEVS-SIP-CHEMO in a real oncology clinic? To answer this question,
consider Figure 5.13. A scheduler would request a schedule using SIP-CHEMO
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and the iterations would proceed using DEVS-CHEMO-SIM. Observe that DEVS-
CHEMO-DM is omitted from the diagram because its purpose was to generate the
requests and analyze the results over the simulation period. However, in a real
setting, actual patients generate requests through the scheduler and the system is
analyzed in real time using real data. Once DEVS-CHEMO-SIM identifies a solution
that has satisfied the stopping criteria, then the solution is reported to the scheduler
who can then implement the decision in the real oncology clinic. In the results section,
DEVS-SIP-CHEMO took roughly nine minutes to run. However, it takes only a few
seconds to actually schedule one patient. In fact, for the preferred experiment that
implemented three stopping criteria, EE 5, the average time to schedule a patient
was 3.95 seconds. Therefore, DEVS-SIP-CHEMO is possible to implement in a real
setting and achieve results in a timely manner.
System Data 
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SIP-­‐CHEMO   DEVS-­‐CHEMO-­‐SIM  
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Optimization 
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Figure 5.13: The Concept of the DEVS-SIP-CHEMO Framework for Oncology Clinic
Operations
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5.5 Summary
DEVS-SIP-CHEMO is a viable solution approach for the problem of scheduling
chemotherapy appointments at an outpatient oncology clinic. The integrated simula-
tion and optimization methodology is a novel approach that addresses the challenging
problem aspects of online scheduling, uncertainty in problem parameters, risk-averse
decision-making, and system performance evaluation. DEVS-SIP-CHEMO is the
first model to consider risk-aversion and uncertain problem parameters for oncology
clinic operations.
One simulation model, DEVS-CHEMO-DM, simulates the oncology clinic op-
erations for a predefined simulation period. Each time an appointment request
occurs from a new patient, the scheduling decision is determined by a mean-risk
SIP-CHEMO optimization model. The SIP-CHEMO model then implements and
evaluates the decision in a second simulation model, DEVS-CHEMO-SIM. DEVS-
CHEMO-SIM simulates all current decisions and predicts future decisions using a
scheduling algorithm. If the system performance satisfies stopping criteria set by
the scheduler, or DM for the oncology clinic, then the most recent solution is imple-
mented in DEVS-CHEMO-DM. Otherwise, the SIP-CHEMO model is revised and
the search process for an implementable decisions continues until one or more stop-
ping criteria are satisfied. DEVS-CHEMO-DM continues throughput the end of the
simulation period and reports system performance results to the DM.
In order to determine if DEVS-SIP-CHEMO did out-perform the SIP-CHEMO
optimization models alone, four stopping criteria were utilized based on patient over-
time, type II delay, system time+, and a maximum number of iterations. The latter
was used to guarantee convergence to a solution in a reasonable time frame. Four
types of modifications were used to either add constraints or modify parameters in
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the SIP-CHEMO model. Computational experiments used six variations of stopping
criteria and modifications within DEVS-SIP-CHEMO and were each applied using
the EE and ASD mean-risk measures.
Computational results showed that DEVS-SIP-CHEMO did improve the chemother-
apy appointment scheduling decisions by obtaining better system performance. Al-
though it is difficult to simultaneously optimize all performance measures at once,
DEVS-SIP-CHEMO performs well if the clinic prefers to keep throughput and type
I delay at acceptable levels while making noticeable improvements in overtime, type
II delay, and system time. Targeting multiple performance measures was better than
targeting performance measures individually. EE 5, which uses stopping criteria for
patient overtime and type II delay, yielded the best results. EE 5 has acceptably
high total throughput and low type I delay (within 1 to 3%), but also yields im-
provements in nurse overtime (90%), nurse overtime+ (67%), system time (4%), and
type II delay (36%) over using SIP-CHEMO alone.
DEVS-SIP-CHEMO is possible to implement in a real setting and achieve results
in a timely manner. Although the full version of DEVS-SIP-CHEMO takes around
nine minutes to simulate a one-month period and schedule 276 patients, only part of
the model is required in a real implementation setting. The iterations between the
SIP-CHEMO and DEVS-CHEMO-SIM models are the only components required
to schedule a new patient in a real setting. For the preferred model using EE, it
only took an average of 3.95 seconds to schedule one new patient, thus DEVS-SIP-
CHEMO would be practical to implement in a real oncology clinic.
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6. CONCLUSIONS AND FUTURE RESEARCH
6.1 Conclusions
This dissertation advances the state-of-the-art in stochastic programming with
simulation by contributing new concepts, models, and algorithms for a variety of
applications. DEVS and SIP have been extended to a new level beyond some of
the traditional impractical assumptions. The extensions include the development
of a formal coupling between DEVS and SIP, incorporating a decision component
within a simulation model, development of non-static probability distributions for
SIP (generated via DEVS), and non-closed-form objective functions for SIP (mod-
eled, evaluated, and revised via DEVS). An important feature of DEVS-SIP is that
it allows for automated online (or real-time) system data update for both DEVS and
SIP models, thus enabling decision-making over time adapting to dynamic changes
in the problem data. This kind of decision-making framework is necessary in many
practical applications such as oncology operations management where a decisions
have to be made at discrete time periods over a rolling horizon.
One contribution of this work is DEVS-CHEMO (Chapter 3), which is a dis-
crete event simulation model of oncology clinic operations designed using the DEVS
formalism. DEVS-CHEMO provides results for performance measures from the pa-
tient’s perspective and from the management’s perspective. DEVS-CHEMO was
implemented using DEVSJAVA and is a tool that oncology clinic managers use to
test decisions and operational policies before implementation in the clinic. Four
algorithms were derived and implemented and results indicate that scheduling con-
straints for both nurse and chair resources led to the best overall system performance.
It was found that assigning patients to both chairs and nurses improved system per-
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formance by reducing appointment duration 3%, reducing type II delay by 34%,
and reducing nurse overtime+ by 4% when compared to the current scheduling al-
gorithm. A sensitivity analysis on the number of nurse resources in the clinic also
demonstrated how to use DEVS-CHEMO to determine ideal staffing levels. The
DEVS-CHEMO chapter was important because it developed a simulation model of
oncology clinic operations and provides a tool for analyzing decision-making and op-
erational policies within the oncology clinic. Although other simulation models have
been developed, DEVS-CHEMO allowed for easy integration with the SIP-CHEMO
optimization model.
A second contribution of this work is SIP-CHEMO (Chapter 4), which is an
optimization model for scheduling chemotherapy appointments. The SIP-CHEMO
optimization models are the first optimization models for the chemotherapy decision
problem of scheduling chemotherapy patients, chairs, and nurses that consider uncer-
tain problem parameters and risk. A risk neutral (RN) model was first developed and
then risk-averse SIP-CHEMO models for expected excess (EE) and absolute semi-
deviation (ASD) were developed to allow DMs to consider risk preferences in their
scheduling decisions. SIP-CHEMO determines an optimal appointment schedule for
a new chemotherapy patient who has been prescribed a unique treatment regimen
and suggested appointment start date. The appointment duration, acuity level, and
nurse resource availability were assumed to be stochastic. Computational experi-
ments for SIP-CHEMO showed that all three SIP-CHEMO models, RN, EE, and
ASD, outperformed the algorithms that were developed with DEVS-CHEMO. The
chapter on SIP-CHEMO is important because a risk-averse optimization model was
developed that outperforms the original scheduling algorithms to achieve better over-
all system performance. Using the SIP-CHEMO models, the throughput increased
by 2%, waiting time decreased by 35%, system time decreased by 4%, and nurse
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overtime decreased by 24% when compared to the current scheduling algorithm.
Another contribution of this work is the DEVS-SIP framework (Chapter 5), a
new paradigm for decision-making under uncertainty. DEVS-SIP formally defines an
integrated simulation and optimization framework for use in a variety of applications.
DEVS-SIP is suitable for decision problems that cannot be formulated using a closed-
form mathematical expression and involve dynamic changes to the problem data
over time. This kind of decision-making framework is necessary in many practical
applications that require decisions under uncertainty over time in a rolling horizon
manner.
Combining DEVS-CHEMO and SIP-CHEMO using the DEVS-SIP framework
led to the development of the fourth and final contribution, DEVS-SIP-CHEMO,
an integrated simulation and optimization model for scheduling chemotherapy pa-
tient appointments. DEVS-SIP-CHEMO enables data-driven decision-making for
both strategic and operational planning in outpatient oncology clinics. The inte-
grated simulation and optimization methodology is a novel approach that addresses
the challenging problem aspects of online scheduling, uncertainty in problem parame-
ters, risk-averse decision-making, and the problem of being unable to model a closed-
form objective for the decision problem. Four stopping criteria were utilized based
on system performance measures as well as four modifications to the SIP-CHEMO
model. Computational results showed that DEVS-SIP-CHEMO does improve the
chemotherapy appointment scheduling decisions by obtaining better system perfor-
mance. Additionally, DEVS-SIP-CHEMO can handle complex decision problems in
a timely manner.
The chapter on DEVS-SIP-CHEMO is important because it showed that com-
bining simulation and optimization can yield better system performance than either
method alone. DEVS-SIP-CHEMO kept throughput and waiting time for the first
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appointment within 1% but improved nurse overtime by 90%, nurse overtime+ by
67%, and type II delay by 36% when compared to SIP-CHEMO. However, caution
should be taken when considering the results for all models because the results are
dependent on the treatment regimens and appointment duration observed from the
limited five-month data set available at the time of this study. As shown in Chapter
3, the system performance results seem to be sensitive to changes in the probability
distribution assumptions for the type II + type III delay.
DEVS-SIP has the potential to address challenging aspects of many important
decision problems in a variety of applications. For the case of oncology clinic appoint-
ment scheduling, optimal decisions under uncertainty provide an improved patient-
centered experience and reduce clinic overtime. Other potential applications include
resource scheduling for large-scale wildfires or the military land move problem.
6.2 Future Research
The work presented in this dissertation is a step forward in addressing oncology
clinic scheduling problems, but there are a few remaining aspects to the problem
which serve as motivation for future research. The scope of the work in this disserta-
tion for oncology clinic scheduling was limited to the drug infusion appointment. One
extension would be to consider patient appointments for blood work and visits with
the oncologist as well. Scheduling the blood exams, oncologist visit, and infusion
appointment sequentially would pose new challenges to the scheduler. Furthermore,
rescheduling is an important component of the chemotherapy scheduling problem.
As future work, rescheduling of appointments can be incorporated in the models
by assuming a certain percentage of appointments are rescheduled or modified due
to poor blood test results. The DEVS-CHEMO and SIP-CHEMO models would
then release the chair and nurse resources for the rescheduled appointments and the
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new appointments would then be considered a new treatment regimen, which can
be formulated as a decision problem in SIP-CHEMO. Incorporating the reschedul-
ing feature will more accurately reflect the challenges faced by the scheduler in the
oncology clinic.
The current implementation assumes stochastic appointment duration based on
drug infusion times in the historical data. In reality, how and when the appointment
duration changes is also patient-dependent. This is because the patient may have
adverse reactions to the drug or take a long time to begin treatment because the
nurse has difficulty setting up the patient’s IV, which can also be captured with
acuity levels. In light of this, another extension would be to model the patient as
an atomic model in DEVS-CHEMO such that the patient’s health status impacts
appointment duration and acuity levels.
In the optimization model, the current formulation determines appointment dates
and start times. The scheduler determines how much time to allocate for the ap-
pointment, which has been assumed to be the planned time provided by the oncology
clinic. An extension for the SIP-CHEMO model would be to reformulate the prob-
lem to also determine the amount of time to allocate to each appointment. The EE
and ASD mean-risk measures implemented in SIP-CHEMO are deviation measures.
Another extension would be to model the problem using other mean-risk measures
such as quantile deviation (QDEV). Also, the SIP-CHEMO models take significantly
longer to solve with CPLEX than with algorithms. Although steps have been taken
to simplify these models, current implementations still solve the deterministic equiv-
alent formulation. One future direction would be to implement a decomposition
method to further improve the solution speed for the SIP-CHEMO models.
Finally, there are improvements that can be made to DEVS-SIP-CHEMO regard-
ing the stopping criteria and modifications. Although a few other ideas were explored,
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a more detailed analysis on other stopping criteria and modifications would help gain
further insight on whether more substantial improvements can be made. Improving
the solution speed of SIP-CHEMO would also help complete this analysis quickly.
Additionally, a more detailed guide for how to select stopping criteria and choose
modifications for DEVS-SIP would help users in other application areas determine
how to adapt their application to the DEVS-SIP framework to obtain improvements
in system performance.
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APPENDIX A
DEVS-CHEMO MODEL
A.1 DEVS-CHEMO Atomic Model Mathematical Definitions
This appendix section uses the standard parallel DEVS [50] notation and adopts the notation
from [28] to give detailed mathematical expressions of some of the DEVS-CHEMO atomic models.
Additionally, ∧ represents the “and” operator, == is the assignment operator, || is the “or” operator.
SCHED Atomic Model.
DEV SSCHED = (XM , YM , S, δext, δint, δcon, λ, ta) (A.1)
where,
XM = {(p, v)|p ∈ IPorts, v ∈ Xp} is the set of input ports and values, IPorts = {“in Appt-
Request”}, and Xin ApptRequest = V1 is an arbitrary set of values;
YM = {(p, v)|p ∈ OPorts, v ∈ Yp} is the set of output ports and values, OPorts = {“out Appt-
Times”, “out Wait1Time”}, and Yout ApptTimes and Yout Wait1Time are arbitrary set of values;
S = {“Idle”, “Schedule”} ×R+,0 × V1 is the set of sequential states.
External Transition Function:
δext((phase, σ,ApptRequest), e, (p, v))
= (“Scheduling”, ts, ApptRequest), if phase == “Idle”∧ p == “in ApptRequest”,
newSchedule = Algorithm(ApptRequest);
= (phase, σ − e,ApptRequest), otherwise.
Internal Transition Function:
= (“Idle”,∞, ApptRequest), if phase == “Scheduling”∧ schedQueue.isEmpty() == true.
Confluence Function:
δcon((s, ta(s), x) = δext(δ(s), 0, x).
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Output Function:
λ(phase, σ,ApptRequest)
= (“out ApptTimes, ApptT imes), if phase ==“Scheduling”, where ApptT imes is the message
sent to PGENR;
= (“out Wait1Time,Wait1Time), if phase ==“Scheduling”, where Wait1Time is the mes-
sage sent to TRANSD.
Time Advance Function:
ta(phase, σ,ApptRequest) = σ.
CHARGENURSE Atomic Model.
DEV SCHARGENURSE = (XM , YM , S, δext, δint, δcon, λ, ta) (A.2)
where,
XM = {(p, v)|p ∈ IPorts, v ∈ Xp} is the set of input ports and values, IPorts = {“in Patient-
Appt”, “in NurseTask”}, and Xin PatientAppt = V1, and Xin NurseTask = V2 are arbitrary sets
of values;
YM = {(p, v)|p ∈ OPorts, v ∈ Yp} is the set of output ports and values, OPorts = {“out Pat-
ientAppt1”, “out PatientAppt2”, ..., “out PatientApptn”}, and Yout PatientAppt1,
Yout PatientAppt2, ..., Yout PatientApptn are arbitrary sets of values;
S = {“Available”, “ProcessingPatient”, “ChairAvailable”} × R+,0 × V1 × V2 is the set of
sequential states.
External Transition Function:
δext((phase, σ,msg), e, (p, v))
= (“ProcessingPatient”, processingT ime,msg), if phase == “Available”∧ p == “in Nurse-
Task;
= (“ChairAvailable”, processingT ime,msg), if phase == “Available”∧ p == “in Patient-
Appt”;
= (phase, σ − e,msg), otherwise.
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Internal Transition Function:
= (“ChairAvailable”, processingT ime,msg), if phase == “ProcessingPatient”∧NTQueue.−
isEmpty() == false;
= (“ProcessingPatient”, processingT ime,msg), if phase == “ChairAvailable”∧ CNQueue.−
isEmpty() == false;
= (“Available”,∞,msg), if phase == “ProcessingPatient”∧ CNQueue.isEmpty() == true;
= (“Available”,∞,msg), if phase == “ChairAvailable”∧ NTQueue.isEmpty() == true.
Confluence Function:
δcon((s, ta(s), x) = δext(δ(s), 0, x).
Output Function:
λ(phase, σ,msg)
= (“out PatientAppti, PatientAppt), if phase == “ProcessingPatient”∧ outputType == 1,
where PatientAppt is the message sent to REGNURSEi.
REGNURSE Atomic Model.
DEV SREGNURSE = (XM , YM , S, δext, δint, δcon, λ, ta) (A.3)
where,
XM = {(p, v)|p ∈ IPorts, v ∈ Xp} is the set of input ports and values, IPorts = {“in Patient-
Appt”, “in DrugOrder”}, and Xin PatientAppt = V1, and Xin DrugOrder = V2 are arbitrary sets
of values;
YM = {(p, v)|p ∈ OPorts, v ∈ Yp} is the set of output ports and values, OPorts = {“out Drug-
Order”, “out NurseTime”, “out Wait3Time”, “out PatientChair”, “out NurseTask”}, and
Yout DrugOrder, Yout NurseTime, Yout Wait3Time, Yout PatientChair, and Yout NurseTask are arbitrary
sets of values;
S = {“Available”, “CheckingWaitList”, “GettingPatient”, “SeatingPatient”, “OrderingDrug”,
“CheckingVitals”, “WaitingOnDrug”, “StartingInfusion”, “MonitoringPatients”, “Stopping-
Infusion”, “UpdateTRANSD”, and “Home”} ×R+,0 × V1 × V2 is the set of sequential states.
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External Transition Function:
δext((phase, σ,msg), e, (p, v))
= (“CheckingWaitList”, checkT ime,RN), if phase == “MonitoringPatients”∧ p == “in -
PatientApppt”;
= (“CheckingWaitList”, checkT ime,RN), if phase == “Available”∧ p == “in PatientAppt”;
= (“StartingInfusion”, infStartT ime,RN), if phase == “WaitingOnDrug”∧ p == “in Drug-
Order”;
= (phase, σ − e,RN), otherwise.
Internal Transition Function:
= (“Available”, openT ime,RN), if phase == “Home”, where openT ime is the remaining
time the clinic is open for the day;
= (“GettingPatient”, gettingT ime,RN), if phase == “CheckingWaitList”∧ WaitList.is−
Empty() == false∧ inadT imeCap() == false;
= (“SeatingPatient”, seatingT ime,RN), if phase == “GettingPatient”;
= (“OrderingDrug”, orderT ime,RN), if phase == “SeatingPatient”;
= (“CheckingVitals”, vitalT ime,RN), if phase == “OrderingDrug”;
= (“WaitingOnDrug”,∞, RN), if phase == “CheckingVitals”∧ vitalsT imeElapsed()∧Drug−
ReadyList.isEmpty() == true;
= (“StartingInfusion”, infStartT ime,RN), if phase == “CheckingVitals”∧ vitalsT ime−
Elapsed()∧ DrugReadyList.isEmpty() == false;
= (“CheckingWaitList”, checkT ime,RN), if phase == “StartingInfusion”;
= (“MonitoringPatients”, nextT ime,RN), if phase == “CheckingWaitList”∧ numPatients >
0∧ (WaitList.isEmpty() == true||(WaitList.isEmpty() == false∧ inadT imeCap() ==
true));
= (“StoppingInfusion”, infStopT ime,RN), if phase == “MonitoringPatients”;
= (“CheckingWaitList”, checkT ime,RN), if phase == “StoppingInfusion”;
= (“UpdateTRANSD”, updateT ime,RN), if phase == “CheckingWaitList”∧ WaitList.−
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isEmpty() == true∧ numPatients == 0∧ stopInf == true;
= (“Available”, openT ime,RN), if phase == “UpdateTRANSD”∧ openT ime > 0;
= (“Home”, homeT ime,RN), if phase == “UpdateTRANSD”∧ openT ime <= 0 where
homeTime is the time until the clinic opens on the next business day;
= (“Home”, homeT ime,RN), if phase == “Available”.
Confluence Function:
δcon((s, ta(s), x) = δext(δ(s), 0, x).
Output Function:
λ(phase, σ,RN)
= (“out NurseTask, NurseTask), if phase == “StoppingInfusion”, where NurseTask is the
message sent to CHARGENURSE;
= (“out PatientDepart, PatientChair), if phase == “StoppingInfusion”, where PatientChair
is the message sent to TRANSD;
= (“out PatientSeated, PatientChair), if phase == “GettingPatient”, where PatientChair
is the message sent to WAITROOM;
= (“out DrugOrder, DrugOrder), if phase == “OrderingDrug”, where DrugOrder is the
message sent to PHARM;
= (“out NurseTime, NurseT ime), if phase == “UpdateTRANSD”, where NurseT ime is the
message sent to TRANSD;
= (“out Wait3Time,Wait3Time), if phase == “StartingInfusion”, where Wait3Time is the
message sent to TRANSD.
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A.2 DEVS-CHEMO Scheduling Algorithms
This appendix section specifies the steps for three scheduling algorithms: ASAP, Collective,
and Nurse. All three algorithms build upon the Individual algorithm stated in section 3.3.3. The
left arrow ← is used to denote assignment, & denotes the “and” operator, ! denotes the “not”
operator, and == denotes the “equality” operator.
A.2.1 ASAP Algorithm
The ASAP algorithm only schedules chairs. The code for the Individual algorithm is modi-
fied by removing lines (10), (13)-(27), and (30)-(33). Then the following lines are modified as follows:
28. slots[i]← s; chairs[i]← j;
29. chairFound← true; j ← C;
42. return treatDays[], slots[], chairs[];
A.2.2 Collective Algorithm
The Collective algorithm only schedules chairs, but the nurse assignment is checked among all
nurses. The code for the Individual algorithm is modified by removing lines (13)-(15) and (23)-(26).
The following two methods are introduced:
• TotalStart(Nd, s, d): returns true if there is a nurse available among the Nd nurses on duty
who can start a new patient during slot s on day d, else returns false;
• TotalAcuity(Nd, s, d, acuity, numSlots): returns true if all nurses on duty Nd can handle the
additional load of acuity starting in slot s on day d for numSlots slots, else returns false.
Then the following lines are modified as follows:
17. startCheck ← TotalStart(Nd, s, d);
20. acuityCheck ← TotalAcuity(Nd, s, d, acuity[i], numSlots[i]);
27. if(fail == 0)
28. slots[i]← s; chairs[i]← j;
29. chairFound← true; j ← C;
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42. return treatDays[], slots[], chairs[];
A.2.3 Nurse Algorithm
The Nurse algorithm only schedules nurses. The code for the Individual algorithm is modified
by removing lines (07)-(09), (11)-(12), (14), (25)-(26), (30)-(33). Then the following lines are mod-
ified as follows:
10. for(s← 1; s ≤ S − numSlots[i] + 1; s+ +)
15. for(nurse← 1;nurse ≤ Nd;nurse+ +)
28. slots[i]← s;nurses[i]← nurse;
29. s← S, nurse← Nd;
34. if(!nurseFound)
36. if(nurseFound)
42. return treatDays[], slots[], nurses[];
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A.3 DEVS-CHEMO Experiment Results
Table A.1: Performance Results for Nurse Experiments (1 of 3)
No. of Nurses Performance Measure (units) AVG STDEV 90% CI
5 Total Throughput (appts.) 3092.9 68.8 (3081.6,3104.3)
Chair Utilization (%) 58.30 1.66 (58.02,58.57)
Nurse Utilization (%) 98.84 1.71 (98.56,99.12)
Nurse Overtime+ (min.) 113.37 5.27 (112.50,114.23)
Nurse Overtime+ Count 309.56 14.64 (307.15,311.97)
Nurse Overtime (min.) 63.26 4.58 (62.51,64.01)
Type I Delay (days) 1.31 0.04 (1.31,1.32)
Type II Delay (min.) 29.65 2.14 (29.30,30.00)
Type III Delay (min.) 31.73 0.39 (31.67,31.79)
System Time (min.) 217.65 4.07 (216.98,218.33)
6 Total Throughput (appts.) 3085.3 84.5 (3071.4,3099.2)
Chair Utilization (%) 58.36 1.61 (58.10,58.63)
Nurse Utilization (%) 90.01 1.64 (89.74,90.28)
Nurse Overtime+ (min.) 100.30 5.32 (99.42,101.17)
Nurse Overtime+ Count 304.57 16.20 (301.91,307.23)
Nurse Overtime (min.) 45.90 3.93 (45.26,46.55)
Type I Delay (days) 1.31 0.04 (1.30,1.31)
Type II Delay (min.) 18.64 0.97 (18.48,18.80)
Type III Delay (min.) 32.01 0.38 (31.95,32.07)
System Time (min.) 207.37 3.92 (206.73,208.02)
Nurse Overtime+ excludes zero entries
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Table A.2: Performance Results for Nurse Experiments (2 of 3)
No. of Nurses Performance Measure (units) AVG STDEV 90% CI
7 Total Throughput (appts.) 3090.2 87.9 (3075.7,3104.6)
Chair Utilization (%) 58.42 1.74 (58.14,58.71)
Nurse Utilization (%) 82.98 1.74 (82.69,83.26)
Nurse Overtime+ (min.) 98.82 4.85 (98.03,99.62)
Nurse Overtime+ Count 305.36 17.53 (302.48,308.24)
Nurse Overtime (min.) 38.87 3.29 (38.32,39.41)
Type I Delay (days) 1.31 0.04 (1.30,1.31)
Type II Delay (min.) 15.41 0.66 (15.30,15.52)
Type III Delay (min.) 32.24 0.37 (32.18,32.31)
System Time (min.) 204.06 3.68 (203.46,204.67)
8 Total Throughput (appts.) 3082.6 78.1 (3069.8,3095.4)
Chair Utilization (%) 58.40 1.62 (58.14,58.67)
Nurse Utilization (%) 76.84 1.62 (76.58,77.11)
Nurse Overtime+ (min.) 98.78 5.21 (97.93,99.64)
Nurse Overtime+ Count 305.80 19.34 (302.62,308.98)
Nurse Overtime (min.) 34.04 3.06 (33.54,34.54)
Type I Delay (days) 1.31 0.04 (1.30,1.31)
Type II Delay (min.) 13.81 0.50 (13.73,13.90)
Type III Delay (min.) 32.60 0.35 (32.54,32.66)
System Time (min.) 202.84 3.36 (202.29,203.39)
Nurse Overtime+ excludes zero entries
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Table A.3: Performance Results for Nurse Experiments (3 of 3)
No. of Nurses Performance Measure (units) AVG STDEV 90% CI
9 Total Throughput (appts.) 3098.7 73.6 (3086.6,3110.8)
Chair Utilization (%) 58.84 1.49 (58.60,59.09)
Nurse Utilization (%) 71.48 1.45 (71.24,71.72)
Nurse Overtime+ (min.) 100.00 5.58 (99.08,100.92)
Nurse Overtime+ Count 310.36 16.22 (307.69,313.03)
Nurse Overtime (min.) 31.09 2.67 (30.65,31.53)
Type I Delay (days) 1.31 0.04 (1.31,1.32)
Type II Delay (min.) 13.05 0.51 (12.96,13.13)
Type III Delay (min.) 32.97 0.42 (32.90,33.04)
System Time (min.) 202.50 3.20 (201.98,203.03)
10 Total Throughput (appts.) 3099.77 78.41 (3086.87,3112.67)
Chair Utilization (%) 59.01 1.73 (58.72,59.29)
Nurse Utilization (%) 66.68 1.64 (66.41,66.95)
Nurse Overtime+ (min.) 98.73 5.57 (97.81,99.64)
Nurse Overtime+ Count 311.55 18.51 (308.50,314.60)
Nurse Overtime (min.) 27.72 2.42 (27.33,28.12)
Type I Delay (days) 1.32 0.04 (1.31,1.32)
Type II Delay (min.) 12.49 0.48 (12.41,12.57)
Type III Delay (min.) 33.23 0.38 (33.17,33.29)
System Time (min.) 202.41 3.46 (201.84,202.98)
Nurse Overtime+ excludes zero entries
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APPENDIX B
SIP-CHEMO MODEL
B.1 SIP-CHEMO Experiment Results
Table B.1: Performance Results for Scheduling Algorithms(1 of 3)
Algorithm Performance Measure (units) AVG STDEV 90% CI
ASAP Total Throughput (appts.) 467.5 16.4 (464.8,470.2)
Daily Throughput (appts.) 23.4 0.8 (23.2,23.5)
Chair Utilization (%) 50.24 2.16 (49.88,50.59)
Nurse Utilization (%) 83.68 3.77 (83.06,84.30)
Nurse Overtime+ (min.) 116.96 16.36 (114.27,119.65)
Nurse Overtime+ Count 45.32 4.41 (44.59,46.05)
Nurse Overtime (min.) 46.91 8.45 (45.52,48.30)
Type I Delay (days) 1.36 0.08 (1.34,1.37)
Type II Delay (min.) 28.46 7.81 (27.17,29.74)
Type III Delay (min.) 332.26 0.78 (32.14,32.39)
System Time (min.) 221.39 10.16 (219.71,223.06)
Nurse Overtime+ excludes zero entries
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Table B.2: Performance Results for Scheduling Algorithms (2 of 3)
Algorithm Performance Measure (units) AVG STDEV 90% CI
Individual Total Throughput (appts.) 458.4 14.5 (456.1,460.8)
Daily Throughput (appts.) 22.9 0.7 (22.8,23.0)
Chair Utilization (%) 49.18 1.95 (48.86,49.50)
Nurse Utilization (%) 85.76 3.42 (85.20,86.32)
Nurse Overtime+ (min.) 108.71 11.88 (106.75,110.66)
Nurse Overtime+ Count 47.29 5.06 (46.46,48.12)
Nurse Overtime (min.) 45.19 7.42 (43.97,46.41)
Type I Delay (days) 1.63 0.16 (1.61,1.66)
Type II Delay (min.) 18.69 4.73 (17.91,19.47)
Type III Delay (min.) 32.20 0.75 (32.08,32.33)
System Time (min.) 211.39 8.21 (210.04,212.74)
RN Total Throughput (appts.) 471.8 20.5 (468.4,475.1)
Daily Throughput (appts.) 23.6 1.0 (23.4,23.8)
Chair Utilization (%) 50.28 2.16 (49.92,50.64)
Nurse Utilization (%) 81.37 3.16 (80.85,81.89)
Nurse Overtime+ (min.) 94.96 12.21 (92.95,96.96)
Nurse Overtime+ Count 36.75 4.59 (35.99,37.51)
Nurse Overtime (min.) 30.64 5.83 (29.68,31.60)
Type I Delay (days) 1.55 0.10 (1.53,1.56)
Type II Delay (min.) 16.57 3.87 (15.93,17.21)
Type III Delay (min.) 32.26 0.86 (32.12,32.40)
System Time (min.) 208.02 7.09 (206.85,209.19)
Nurse Overtime+ excludes zero entries
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Table B.3: Performance Results for Scheduling Algorithms (3 of 3)
Algorithm Performance Measure (units) AVG STDEV 90% CI
EE Total Throughput (appts.) 473.4 18.8 (470.3,476.4)
Daily Throughput (appts.) 23.7 0.9 (23.5,23.8)
Chair Utilization (%) 50.48 2.27 (50.10,50.85)
Nurse Utilization (%) 82.67 3.63 (82.07,83.27)
Nurse Overtime+ (min.) 98.33 13.55 (96.10,100.56)
Nurse Overtime+ Count 39.28 5.50 (38.38,40.18)
Nurse Overtime (min.) 34.17 7.47 (32.94,35.40)
Type I Delay (days) 1.54 0.11 (1.52,1.55)
Type II Delay (min.) 16.44 4.28 (15.73,17.14)
Type III Delay (min.) 32.23 0.85 (32.09,32.37)
System Time (min.) 207.97 7.70 (206.71,209.24)
ASD Total Throughput (appts.) 472.1 18.1 (469.2,475.1)
Daily Throughput (appts.) 23.6 0.9 (23.5,23.8)
Chair Utilization (%) 50.49 1.97 (50.17,50.82)
Nurse Utilization (%) 82.46 3.00 (81.97,82.96)
Nurse Overtime+ (min.) 99.64 14.69 (97.22,102.05)
Nurse Overtime+ Count 39.83 5.59 (38.91,40.75)
Nurse Overtime (min.) 34.97 7.04 (33.81,36.12)
Type I Delay (days) 1.54 0.12 (1.52,1.56)
Type II Delay (min.) 16.89 5.31 (16.02,17.77)
Type III Delay (min.) 32.28 0.91 (32.13,32.43)
System Time (min.) 209.00 8.05 (207.68,210.32)
Nurse Overtime+ excludes zero entries
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APPENDIX C
DEVS-SIP-CHEMO MODEL
C.1 DEVS-SIP-CHEMO Experiment Results
Table C.1: Performance Results for EE 5
Experiments Performance Measure (units) AVG STDEV 90% CI
EE 5 Total Throughput (appts.) 467.70 21.02 (456.76,478.64)
Daily Throughput (appts.) 23.38 1.05 (22.84,23.93)
Chair Utilization (%) 48.86 1.94 (47.85,49.87)
Nurse Utilization (%) 71.36 2.56 (70.03,72.69)
Nurse Overtime+ (min.) 19.15 7.19 (15.41,22.89)
Nurse Overtime+ Count 8.90 2.30 (7.70,10.10)
Nurse Overtime (min.) 1.36 0.54 (1.08,1.64)
Type I Delay (days) 1.66 0.09 (1.61,1.71)
Type II Delay (min.) 10.87 1.03 (10.33,11.40)
Type III Delay (min.) 31.85 0.79 (31.44,32.26)
System Time (min.) 198.51 5.62 (195.59,201.44)
Simulation Run Time (sec.) 540.68 47.34 (516.05,565.30)
Nurse Overtime+ excludes zero entries
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Table C.2: Performance Results for ASD 6
Experiments Performance Measure (units) AVG STDEV 90% CI
ASD 6 Total Throughput (appts.) 466.8 17.2 (457.9,475.7)
Daily Throughput (appts.) 23.3 0.9 (22.9,23.8)
Chair Utilization (%) 48.96 1.70 (48.07,49.85)
Nurse Utilization (%) 72.06 2.25 (70.89,73.22)
Nurse Overtime+ (min.) 27.36 8.98 (22.69,32.03)
Nurse Overtime+ Count 8.50 3.35 (6.76,10.24)
Nurse Overtime (min.) 1.76 0.66 (1.42,2.11)
Type I Delay (days) 1.76 0.17 (1.67,1.84)
Type II Delay (min.) 11.65 2.31 (10.45,12.85)
Type III Delay (min.) 32.39 0.56 (32.10,32.68)
System Time (min.) 199.96 3.89 (197.93,201.98)
Simulation Run Time (sec.) 592.76 108.56 (536.29,649.24)
Nurse Overtime+ excludes zero entries
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